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A B S T R A C T
Background
Down’s syndrome occurs when a person has three, rather than two copies of chromosome 21; or the specific area of chromosome 21
implicated in causing Down’s syndrome. It is the commonest congenital cause of mental disability and also leads to numerous metabolic
and structural problems. It can be life-threatening, or lead to considerable ill health, although some individuals have only mild problems
and can lead relatively normal lives. Having a baby with Down’s syndrome is likely to have a significant impact on family life.
Noninvasive screening based on biochemical analysis of maternal serum or urine, or fetal ultrasound measurements, allows estimates
of the risk of a pregnancy being affected and provides information to guide decisions about definitive testing. However, no test can
predict the severity of problems a person with Down’s syndrome will have.
Objectives
The aim of this review was to estimate and compare the accuracy of first trimester serum markers for the detection of Down’s syndrome
in the antenatal period, both as individual markers and as combinations of markers. Accuracy is described by the proportion of fetuses
with Down’s syndrome detected by screening before birth (sensitivity or detection rate) and the proportion of women with a low risk
(normal) screening test result who subsequently had a baby unaffected by Down’s syndrome (specificity).
Search methods
We conducted a sensitive and comprehensive literature search of MEDLINE (1980 to 25 August 2011), Embase (1980 to 25 August
2011), BIOSIS via EDINA (1985 to 25 August 2011), CINAHL via OVID (1982 to 25 August 2011), The Database of Abstracts of
Reviews of Effectiveness (The Cochrane Library 25August 2011),MEDION (25August 2011), TheDatabase of Systematic Reviews and
Meta-Analyses in Laboratory Medicine (25 August 2011), The National Research Register (Archived 2007), Health Services Research
Projects in Progress database (25 August 2011). We did forward citation searching ISI citation indices, Google Scholar and PubMed
‘related articles’. We did not apply a diagnostic test search filter. We also searched reference lists and published review articles.
Selection criteria
We included studies in which all women from a given population had one or more index test(s) compared to a reference standard
(either chromosomal verification or macroscopic postnatal inspection). Both consecutive series and diagnostic case-control study designs
were included. Randomised trials where individuals were randomised to different screening strategies and all verified using a reference
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standard were also eligible for inclusion. Studies in which test strategies were compared head-to-head either in the same women, or
between randomised groups were identified for inclusion in separate comparisons of test strategies. We excluded studies if they included
less than five Down’s syndrome cases, or more than 20% of participants were not followed up.
Data collection and analysis
We extracted data as test positive or test negative results for Down’s and non-Down’s pregnancies allowing estimation of detection
rates (sensitivity) and false positive rates (1-specificity). We performed quality assessment according to QUADAS (Quality Assessment
of Diagnostic Accuracy Studies) criteria. We used hierarchical summary ROC meta-analytical methods or random-effects logistic
regression methods to analyse test performance and compare test accuracy as appropriate. Analyses of studies allowing direct and indirect
comparisons between tests were undertaken.
Main results
We included 56 studies (reported in 68 publications) involving 204,759 pregnancies (including 2113 with Down’s syndrome). Studies
were generally of good quality, although differential verification was common with invasive testing of only high-risk pregnancies. We
evaluated 78 test combinations formed from combinations of 18 different tests, with or without maternal age; ADAM12 (a disintegrin
and metalloprotease), AFP (alpha-fetoprotein), inhibin, PAPP-A (pregnancy-associated plasma protein A, ITA (invasive trophoblast
antigen), free βhCG (beta human chorionic gonadotrophin), PlGF (placental growth factor), SP1 (Schwangerschafts protein 1), total
hCG, progesterone, uE3 (unconjugated oestriol), GHBP (growth hormone binding protein), PGH (placental growth hormone),
hyperglycosylated hCG, ProMBP (proform of eosinophil major basic protein), hPL (human placental lactogen), (free αhCG, and free
ßhCG to AFP ratio. Direct comparisons between two or more tests were made in 27 studies.
Meta-analysis of the nine best performing or frequently evaluated test combinations showed that a test strategy involving maternal
age and a double marker combination of PAPP-A and free ßhCG significantly outperformed the individual markers (with or without
maternal age) detecting about seven out of every 10 Down’s syndrome pregnancies at a 5% false positive rate (FPR). Limited evidence
suggested that marker combinations involving PAPP-A may be more sensitive than those without PAPP-A.
Authors’ conclusions
Tests involving two markers in combination with maternal age, specifically PAPP-A, free βhCG and maternal age are significantly
better than those involving single markers with and without age. They detect seven out of 10 Down’s affected pregnancies for a fixed
5% FPR. The addition of further markers (triple tests) has not been shown to be statistically superior; the studies included are small
with limited power to detect a difference.
The screening blood tests themselves have no adverse effects for the woman, over and above the risks of a routine blood test. However
some women who have a ‘high risk’ screening test result, and are given amniocentesis or chorionic villus sampling (CVS) have a risk of
miscarrying a baby unaffected by Down’s. Parents will need to weigh up this risk when deciding whether or not to have an amniocentesis
or CVS following a ‘high risk’ screening test result.
P L A I N L A N G U A G E S U M M A R Y
Screening tests for Down’s syndrome in first three months of pregnancy
Background
Down’s syndrome (also known as Down’s or Trisomy 21) is an incurable genetic disorder that causes significant physical and mental
health problems, and disabilities. However, there is wide variation in how Down’s affects people. Some individuals are severely affected
whilst others have mild problems and are able to lead relatively normal lives. There is no way of predicting how badly a baby might be
affected.
Expectant parents are given the choice to be tested for Down’s during pregnancy to assist them in making decisions. If a mother is
carrying a baby with Down’s, then there is the decision about whether to terminate or continue with the pregnancy. The information
offers parents the opportunity to plan for life with a Down’s child.
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The most accurate tests for Down’s involve testing fluid from around the baby (amniocentesis) or tissue from the placenta (chorionic
villus sampling (CVS)) for the abnormal chromosomes associated with Down’s. Both these tests involve inserting needles through
the mother’s abdomen and are known to increase the risk of miscarriage. Thus, the tests are not suitable for offering to all pregnant
women. Rather, tests that measure markers in the mother’s blood, urine or on ultrasound scans of the baby are used for screening.
These screening tests are not perfect, they can miss cases of Down’s and also give a ‘high risk’ test result to a number of women whose
babies are not affected by Down’s. Thus, pregnancies identified as ‘high risk’ using these screening tests require further testing using
amniocentesis or CVS to confirm a diagnosis of Down’s.
What we did
The aim of this review was to find out which of the blood screening tests done during the first three months of pregnancy are the most
accurate at predicting the risk of a pregnancy being affected by Down’s. We looked at 18 different blood markers that can be used
alone or in combination, taken before 14 weeks gestation, thus creating 78 screening tests fro Down’s. We found 56 studies, involving
204,759 pregnancies of which 2113 had pregnancies affected by Down’s.
What we found
For the first 14 weeks of pregnancy, the evidence supports the use of the double test of two blood markers; pregnancy-associated plasma
protein A (PAPP-A) and free beta human chorionic gonadotrophin (βhCG), in combination with the mother’s age. This test detects
around seven out of every 10 (68%) pregnancies affected by Down’s. It is common practice to offer amniocentesis or CVS to women
with a high risk test result. About one in 20 women (5%) having this test will have a ‘high risk’ result but most of these women will
not be carrying a baby with Down’s. We found for tests in the first 14 weeks of pregnancy, there is little evidence to support the use of
serum tests made up of more than two blood markers.
Other important information to consider
The blood tests themselves have no adverse effects for the woman, over and above the risks of a routine blood test. However some
women who have a ‘high risk’ screening test result, and are given amniocentesis or CVS have a risk of miscarrying a baby unaffected
by Down’s. Parents will need to weigh up this risk when deciding whether or not to have an amniocentesis or CVS following a ‘high
risk’ screening test result.
B A C K G R O U N D
This is one of a series of reviews on antenatal screening for
Down’s syndrome following a generic protocol (Alldred 2010) -
see Published notes for more details.
Target condition being diagnosed
Down’s syndrome
Down’s syndrome affects approximately one in 800 live-born ba-
bies (Cuckle 1987a). It results from a person having three, rather
than two, copies of chromosome 21, or the specific area of chro-
mosome 21 implicated in causing Down’s syndrome, as a result of
trisomy or translocation. If not all cells are affected, the pattern is
described as ’mosaic’. Down’s syndrome can cause a wide range of
physical and mental problems. It is the commonest cause of men-
tal disability, and is also associated with a number of congenital
malformations, notably affecting the heart. There is also an in-
creased risk of cancers such as leukaemia, and numerous metabolic
problems including diabetes and thyroid disease. Some of these
problemsmay be life-threatening, or lead to considerable ill health,
while some individuals with Down’s syndrome have only mild
problems and can lead a relatively normal life.
There is no cure for Down’s syndrome, and antenatal diagnosis
allows for preparation for the birth and subsequent care of a baby
with Down’s syndrome, or for the offer of a termination of preg-
nancy. Having a baby with Down’s syndrome is likely to have a
significant impact on family and social life, relationships and par-
ents’ work. Special provisions may need to be made for education
and care of the child, as well as accommodating the possibility of
periods of hospitalisation.
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Definitive invasive tests (amniocentesis and chorionic villus sam-
pling (CVS)) exist that allow the diagnosis of Down’s syndrome
before birth, but carry a risk of miscarriage. No test can predict
the severity of problems a person with Down’s syndrome will have.
Noninvasive screening tests based on biochemical analysis of ma-
ternal serum or urine, or fetal ultrasound measurements, allow
an estimate of the risk of a pregnancy being affected and provide
parents with information to enable them to make choices about
definitive testing. Such screening tests are used during the first and
second trimester of pregnancy.
Screening tests for Down’s syndrome
Initially, screening was determined solely by using maternal age to
classify a pregnancy as high or low risk for trisomy 21, as it was
known that older women had a higher chance of carrying a baby
with Down’s syndrome (Penrose 1933).
Further advances in screening were made in the early 1980s, when
Merkatz et al. investigated the possibility that low maternal serum
alpha-fetoprotein (AFP), obtained frommaternal blood in the sec-
ond trimester of pregnancy could be associated with chromoso-
mal abnormalities in the fetus. Their retrospective case-control
study showed a statistically significant relationship between fetal
trisomy, such as Down’s syndrome, and lowered maternal serum
AFP (Merkatz 1984). This was further explored by Cuckle et al in
a larger retrospective trial using data collected as part of a neural
tube defect (NTD) screening project (Cuckle 1984). This work
was followed by calculation of risk estimates using maternal serum
AFP values and maternal age, which ultimately led to the intro-
duction of the two screening parameters in combination (Alfirevic
2004).
In 1987, in a small case-control study of women carrying fe-
tuses with known chromosomal abnormalities, Bogart and col-
leagues investigated maternal serum levels of human chorionic go-
nadotrophin (hCG) as a possible screening tool for chromosomal
abnormalities in the second trimester (Bogart 1987). This fol-
lowed the observations that low hCG levels were associated with
miscarriages, which are commonly associated with fetal chromo-
somal abnormalities. They concluded that high hCG levels were
associated with Down’s syndrome and because hCG levels plateau
at 18 to 24 weeks, that this would be themost appropriate time for
screening. Later work suggested that the ß subunit of hCG was a
more effective marker than total hCG (Macri 1990; Macri 1993).
Second trimester unconjugated oestriol (uE3), produced by the
fetal adrenals and the placenta, was also evaluated as a potential
screening marker. In another retrospective case-control study, uE3
was shown to be lower in Down’s syndrome pregnancies compared
with unaffected pregnancies.Whenused in combinationwithAFP
andmaternal age, it appeared to identifymore pregnancies affected
by Down’s syndrome than AFP and age alone (Canick 1988).
Further work suggested that all three serum markers (AFP, hCG
and uE3) showed even higher detection rates when combined with
maternal age (Wald 1988a; Wald 1988b) and appeared to be a
cost-effective screening strategy (Wald 1992a).
Two other serum markers, produced by the placenta, have been
linked with Down’s syndrome, namely pregnancy associated
plasma protein A or PAPP-A, and first trimester Inhibin A. PAPP-
A has been shown to be reduced in the first trimester of Down’s
syndrome pregnancies, with itsmostmarked reduction in the early
first trimester (Bersinger 1995). Inhibin A is high in the second
trimester in pregnancies affected by Down’s syndrome (Cuckle
1995; Wallace 1995). There are some issues concerning the bio-
logical stability and hence reliability of this marker, and the effect
this will have on individual risk.
Screening and parental choice
Antenatal screening is used for several reasons (Alfirevic 2004), but
the most important is to enable parental choice regarding preg-
nancy management and outcome. Before a woman and her part-
ner opt to have a screening test, they need to be fully informed
about the risks, benefits and possible consequences of such a test.
This includes the choices they may have to face should the re-
sult show that the woman has a high risk of carrying a baby with
Down’s syndrome and implications of both false positive and false
negative screening tests. They need to be informed of the risk of a
miscarriage due to invasive diagnostic testing, and the possibility
that a miscarried fetus may be chromosomally normal. If, follow-
ing invasive diagnostic testing, the fetus is shown to have Down’s
syndrome, further decisions need to be made about continuation
or termination of the pregnancy, the possibility of adoption and
finally, preparation for parenthood. Equally, if a woman has a test
that shows she is at a low risk of carrying a fetus with Down’s
syndrome, it does not necessarily mean that the baby will be born
with a normal chromosomal make up. This possibility can only be
excluded by an invasive diagnostic test (Alfirevic 2003).The deci-
sions that may be faced by expectant parents inevitably engender
a high level of anxiety at all stages of the screening process, and the
outcomes of screening can be associated with considerable physi-
cal and psychological morbidity. No screening test can predict the
severity of problems a person with Down’s syndrome will have.
Index test(s)
This review examined serum screening tests used in the first
trimester of pregnancy (up to 14 weeks’ gestation) comprised
of the following 18 individual markers; a disintegrin and metal-
loprotease 12 (ADAM12), AFP, inhibin, PAPP-A, invasive tro-
phoblast antigen (ITA), free βhCG, placental growth factor
(PlGF), Schwangerschafts protein 1 (SP1), total hCG, proges-
terone, uE3, growth hormone binding protein (GHBP), placen-
tal growth hormone (PGH), hyperglycosylated hCG, proform of
eosinophil major basic protein (ProMBP), human placental lacto-
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gen (hPL), free alpha human chorionic gonadotrophin (αhCG),
and free ßhCG to AFP ratio. These markers can be used individu-
ally, in combination with age, and can also be used in combination
with each other. The risks are calculated by comparing a woman’s
test result for each marker with values for an unaffected popula-
tion, and multiplying this with her age-related risk. Where several
markers are combined, risks are computed using risk equations (of-
ten implemented in commercial software) that take into account
the correlational relationships between the different markers and
marker distributions in affected and unaffected populations.
Alternative test(s)
Down’s syndrome can be detected during pregnancy with inva-
sive diagnostic tests such as amniocentesis or CVS, with or with-
out prior screening. The ability to determine fetal chromosomal
make up (also known as a karyotype) from amniotic fluid sam-
ples was demonstrated in 1966 by Steele and Breg (Steele 1966),
and the first antenatal diagnosis of Down’s syndrome was made
in 1968 (Vaklenti 1968). Amniocentesis is an invasive procedure
that involves taking a small sample of the amniotic fluid (liquor)
surrounding the baby, using a needle which goes through the ab-
dominal wall into the uterus, and is usually performed after 15
weeks’ gestation. CVS involves taking a sample of the placental
tissue using a needle which goes through the abdominal wall and
uterus or a cannula through the cervix. It is usually performed
between 10 and 13 weeks’ gestation. Amniocentesis and CVS are
both methods of obtaining fetal chromosomal material, which are
then used to diagnose Down’s syndrome. Both tests use ultrasound
scans to guide placement of the needle. Amniocentesis carries a
risk of miscarriage in the order of 1%; transabdominal CVS may
carry a similar risk (Alfirevic 2003).
Rationale
This is one of a suite of Cochrane reviews, the aim of which is to
identify all screening tests for Down’s syndrome used in clinical
practice, or evaluated in the research setting, in order to try to
identify the most accurate test(s) available, and to provide clin-
icians, policy-makers and women with robust and balanced evi-
dence on which to base decisions about interpreting test results
and implementing screening policies to triage the use of invasive
diagnostic testing.
There are many different screening tests which are available and
offered which will be the subject of additional Cochrane reviews
(currently in preparation or published (Alldred 2012)), and there
are other reviews looking at this area. Tests to be assessed in
Cochrane reviews include second trimester serum tests; urine tests;
first trimester ultrasound markers; tests that combine serum and
ultrasound markers; and tests that combine markers from the first
trimesterwithmarkers from the second trimester. Second trimester
ultrasound markers have been assessed in a previous systematic
review (Smith-Bindman 2001).
The topic has been split into several different reviews to allow for
greater ease of reading and greater accessibility of data, and also to
allow the reader to focus on separate groups of tests, for example,
first trimester serum tests alone, first trimester serum and ultra-
sound, second trimester serum alone, first and second trimester
serum combinations, with or without ultrasound markers; and
urine markers alone. An overview review will compare the best
tests, focusing on commonly used strategies and the best tests from
each of these categories. This review is written with the global per-
spective in mind, rather than to conform with any specific local or
national policy, as not all tests will be available in all areas where
screening for Down’s syndrome is carried out.
A systematic review of second trimester ultrasound markers in
the detection of Down’s syndrome fetuses was published in 2001
that concluded that nuchal fold thickening may be useful in de-
tecting Down’s syndrome, but that it was not sensitive enough
to use as a screening test. The review concluded that the other
second trimester ultrasound markers did not usefully distinguish
between Down’s syndrome and pregnancies without Down’s syn-
drome (Smith-Bindman 2001). There has yet to be a systematic
review and meta-analysis of the observed data on serum, urine
and first trimester ultrasound markers, in order to draw rigorous
and robust conclusions about the diagnostic accuracy of available
Down’s syndrome screening tests.
O B J E C T I V E S
The aim of this review was to estimate and compare the accuracy
of first trimester serum markers for the detection of Down’s syn-
drome in the antenatal period, both as individual markers and as
combinations of markers. Accuracy is described by the propor-
tion of fetuses with Down’s syndrome detected by screening before
birth (sensitivity or detection rate), and the proportion of women
with a low risk (normal) screening test result who subsequently
had a baby unaffected by Down’s syndrome (specificity).
Investigation of sources of heterogeneity
We planned to investigate whether a uniform screening test is suit-
able for all women, or whether different screening methods are
more applicable to different groups, defined by advanced mater-
nal age, ethnic groups and aspects of the pregnancy and medical
history such as multiple pregnancy, diabetes and family history
of Down’s syndrome. We also considered whether there existed
evidence of overestimation of test accuracy in studies evaluating
risk equations in the derivation sample rather than in a separate
validation sample.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
We included studies in which all women from a given popula-
tion had one or more index test(s) compared to a reference stan-
dard. Both consecutive series and diagnostic case-control study
designs were included. Randomised trials where individuals were
randomised to different screening strategies and all verified using
a reference standard were also eligible for inclusion. Studies in
which test strategies were compared head-to-head, either in the
same women, or between randomised groups were identified for
inclusion in separate comparisons of test strategies. Studies were
excluded if they included less than five Down’s syndrome cases, or
more than 20% of participants were not followed up.
Participants
Pregnant women at less than 14 weeks’ gestation confirmed by
ultrasound, who had not undergone previous testing for Down’s
syndrome in their pregnancy were eligible. Studies were included
if the pregnant women were unselected, or if they represented
groups with increased risk of Down’s syndrome, or difficulty with
conventional screening tests including maternal age greater than
35 years old, multiple pregnancy, diabetes mellitus and family
history of Down’s syndrome.
Index tests
The following 18 index tests were examined; ADAM12, AFP, in-
hibin, PAPP-A, ITA, free βhCG, PlGF, SP1, total hCG, pro-
gesterone, uE3, GHBP, PGH, hyperglycosylated hCG, ProMBP,
hPL, free αhCG, and free ßhCG to AFP ratio, and combinations
of these markers combined with maternal age.
We looked at comparisons of tests used in isolation and in 78
various combinations. These included single (one marker), double
(two markers), triple (three markers), quadruple (four markers)
and quintuple (five markers) tests, some of which were adjusted
for maternal age.
Where tests were used in combination, we looked at the perfor-
mance of test combinations according to predicted probabilities
computed using risk equations and dichotomised into high risk
and low risk.
Target conditions
Down’s syndrome in the fetus due to trisomy, translocation or
mosaicism.
Reference standards
We considered several reference standards, involving chromoso-
mal verification and postnatal macroscopic inspection. Chromo-
somal verification is considered preferential but because of the
risks involved, often not feasible. Where macroscopic inspection
or examination raises a question about the possibility of an indi-
vidual being affected by Down’s syndrome, in clinical practice this
is usually confirmed or refuted by formal karyotyping.
Amniocentesis and CVS are invasive chromosomal verification
tests undertaken during pregnancy. They are highly accurate but
the process carries a 1% miscarriage rate, and therefore they are
only used in pregnancies considered to be high risk of Down’s,
or on the mother’s request. All other types of testing (postnatal
examination, postnatal karyotyping, birth registers and Down’s
syndrome registers) are based on information available at the end
of pregnancy. For the purposes ofmeta-analysis they are considered
equivalent. The greatest concern is not their accuracy, but the
loss of the pregnancy to miscarriage between the timing of serum
testing and the reference standard. Miscarriage with cytogenetic
testing of the fetus is included in the reference standard where
available.
We anticipated that older studies, and studies undertaken in older
women were more likely to have used invasive chromosomal veri-
fication tests in all women. Studies undertaken in younger women
and more recent studies were likely to use differential verification
as they often only used prenatal karyotypic testing on fetuses con-
sidered screen positive or high risk according to the screening test;
the reference standard for most unaffected infants is likely to be
observation of a phenotypically normal baby. Although the ac-
curacy of this combined reference standard is considered high, it
is methodologically a weaker approach because pregnancies that
miscarry between the index test and birth are likely to be lost from
the analysis, andmiscarriage is more likely to occur in Down’s than
normal pregnancies.
Search methods for identification of studies
We used one generic search strategy to identify studies for all
reviews in this series
Electronic searches
We applied a sensitive search strategy to search the follow-
ing databases using the text words and MeSH terms detailed
in Appendix 1, adapting the search strategy for each different
database.
Databases searched included:
• MEDLINE via OVID (1980 to 25 August 2011)
• Embase via Dialog Datastar (1980 to 25 August 2011)
• BIOSIS via EDINA (1985 to 25 August 2011)
• CINAHL via OVID (1982 to 25 August 2011)
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• The Database of Abstracts of Reviews of Effectiveness (25
August 2011)
• MEDION (25 August 2011)
• The Database of Systematic Reviews and Meta-Analyses in
Laboratory Medicine (www.ifcc.org/) (25 August 2011)
• The National Research Register (Archived 2007)
• Health Services Research Projects in Progress database (
HSRPROJ) (25 August 2011)
The search strategy combined three sets of search terms (see
Appendix 1). The first set was made up of named tests, general
terms used for screening/diagnostic tests and statistical terms.Note
that the statistical terms were used to increase sensitivity and were
not used as a methodological filter to increase specificity. The sec-
ond set was made up of terms that encompass Down’s syndrome
and the third set made up of terms to limit the testing to pregnant
women. All termswithin each set were combinedwith the Boolean
operator OR and then the three sets were combined using AND.
The terms used were a combination of subject headings and free
text terms. The search strategy was adapted to suit each database
searched.
We attempted to identify cumulative papers which reported data
from the same data set, and contacted authors to obtain clarifi-
cation of the overlap between data presented in these papers, in
order to prevent data from the same women being analysed more
than once.
Searching other resources
In addition, we examined references cited in studies identified as
being potentially relevant, and those cited by previous reviews.
We contacted authors of studies where further information was
required.
We carried out forward citation searching of relevant items, us-
ing the search strategy in ISI citation indices, Google scholar and
Pubmed ‘related articles’.
We did not apply language restrictions to the search.
Data collection and analysis
Selection of studies
Two review authors screened the titles and abstracts (where avail-
able) of all studies identified by the search strategy. We obtained
full-text versions of studies identified as being potentially relevant
and two review authors independently assessed these for inclusion,
using a study eligibility screening pro forma according to the pre-
specified inclusion criteria. Any disagreement between the two re-
view authors was settled by consensus, or where necessary, by a
third party.
Data extraction and management
A data extraction formwas developed and piloted using a subset of
20 identified studies. Two review authors independently extracted
data, andwhere disagreement or uncertainty existed, a third review
author validated the information extracted.
Data on each marker were extracted as binary test positive/test
negative results for Down’s and non-Down’s pregnancies, with a
high-risk result-as defined by each individual study-being regarded
as test positive (suggestive or diagnostic of Down’s syndrome),
and a low-risk result being regarded as test negative (suggestive
of absence of Down’s syndrome). Where results were reported at
several thresholds, we extracted data at each threshold.
We made a note of those in special groups that posed either in-
creased risk of Down’s syndrome or difficulty with conventional
screening tests, including maternal age greater than 35 years old,
multiple pregnancy, diabetesmellitus and family history ofDown’s
syndrome.
Assessment of methodological quality
We used a modified version of the QUADAS (Quality Assessment
of Diagnostic Accuracy Studies) tool (Whiting 2003), a quality
assessment tool for use in systematic reviews of diagnostic accuracy
studies, to assess the methodological quality of included studies.
We anticipated that a key methodological issue would be the po-
tential for bias arising from the differential use of invasive testing
and follow-up for the reference standard according to index test
results, bias arising due to higher loss to miscarriage if false nega-
tives than true negatives. We chose to code this issue as originating
from differential verification in the QUADAS tool: we are aware
that it could also be coded under delay in obtaining the reference
standard, and reporting ofwithdrawals.We omitted theQUADAS
item assessing quality according to length of time between index
and reference tests, as Down’s syndrome is either present or absent
rather than a condition that evolves and resolves, and disregarding
the differential reference standard issue, thus any length of delay is
acceptable. Two review authors assessed each included study sep-
arately. Any disagreement between the two authors was settled by
consensus, or where necessary, by a third party. Each item in the
QUADAS tool was be marked as ‘yes’, ‘no’ or ‘unclear’, and scores
are presented graphically and in tables. We did not use a summary
quality score. See Appendix 3 for QUADAS questionnaire.
Statistical analysis and data synthesis
We initially examined each test or test strategy at each of the com-
mon risk thresholds used to define test positivity by plotting esti-
mates of sensitivity and specificity from each study on forest plots
and in receiver operating characteristic (ROC) space. Test strate-
gies were selected for further investigation if they were evaluated
in four or more studies or, if there were two or three studies, but
the individual study results indicated performance likely to be su-
perior to a sensitivity of 70% and specificity of 90%.
7First trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Estimation of average sensitivity and specificity
The analysis for each test strategy was undertaken first restricting
to studies that reported a common threshold to estimate average
sensitivity and specificity for each test at each threshold. Although
data on all thresholds were extracted, we present only key common
thresholds from the literature, close to risks of 1:384, 1:250 and
the 5% false positive rate (FPR), unless other thresholds weremore
commonly reported. Where combinations of tests were used in a
risk score we extracted the result for the test combination using
the risk score and not the individual components that made up
the test.
We undertook meta-analyses using hierarchical summary ROC
(HSROC) models, which included estimation of random-effects
in accuracy and threshold parameterswhen therewere four ormore
studies. Where there were fewer than four studies and the studies
reported test performance at a common threshold, we computed
average sensitivity and specificity values by using univariate fixed-
effect or random-effects logistic regression models to average logit
sensitivity and logit specificity separately because of insufficient
number of studies to reliably estimate all the parameters in the
HSROC model. It is common in this field for studies to report
sensitivity for a fixed specificity (usually a 5% FPR). This removes
the requirement to account for the correlation between sensitivity
and specificity across studies by using a bivariate meta-analytical
method since all specificities are the same value. Thus, at a fixed
specificity value, logit sensitivities were pooled using a univariate
random-effects logistic regression model. This model was further
simplified to a fixed-effect model when there were only two or
three studies and heterogeneity was not observed on the SROC
plot. All analyseswere undertakenusing theNLMIXEDprocedure
in SAS (version 9.2; SAS Institute, Cary, NC) and the xtmelogit
command in Stata version 11.2 (Stata-Corp, College Station, TX,
USA).
Comparisons between tests
Wemade comparisons between tests, first by utilising all available
studies, selecting one threshold from each study to estimate a sum-
mary ROC curve without restricting to a common threshold, and
second, by making pair-wise comparisons using studies that com-
pared tests in the samemothers (direct head-to-head comparison).
The threshold was chosen for each study according to the follow-
ing order of preference a) the risk threshold closest to 1 in 250; b)
a multiples of the median (MoM) or presence/absence threshold;
c) the performance closest to a 5% FPR or 95th percentile. The
5% FPR was chosen as a cut-off point as this is the cut-off most
commonly reported in the literature.
For the analysis that included data from all studies, we compared
test strategies in a single HSROC model, including two indicator
terms for each test to allow for differences in accuracy and thresh-
old. There was no indication of differing SROC curve shape be-
tween tests and so a single SROC shape parameter was included
in the model, such that the fitted SROC curves did not cross. The
initial meta-analyses of individual test strategies indicated there
were differences in the variability of the accuracy parameter such
that the assumption of equal variances may not be justifiable. We
attempted to fit a model with separate variance terms for each test
strategy for the accuracy parameter but the model did not con-
verge.We therefore restricted the meta-analysis that compared the
accuracy of the different test strategies to only studies that used a
5% FPR threshold so that we could fit a univariate random effects
logistic regression model that allowed for a separate variance term
for the random-effects of logit sensitivity for each test. Using non-
linear combinations of the parameter estimates from this model,
we derived ratios of sensitivities for each pair of tests included in
the model and obtained their corresponding 95% confidence in-
terval (CI) by using the delta method. We used likelihood ratio
tests to assess the statistical significance of differences in sensitivity
between tests.
For direct comparisons between each pair of tests at the 5% FPR
threshold, we used a separate model for each pair-wise compari-
son and pooled logit sensitivities using a univariate random-effects
model. As studies rarely reported data cross-classified by both tests
for Down’s and normal pregnancies, the analytical method did not
take full account of the pairing of test results, but the restriction
to direct head-to-head comparisons should have removed the po-
tential confounding of test comparisons with other features of the
studies. The strength of evidence for differences in performance of
test strategies relied on evidence from both the direct and indirect
comparisons.
Investigations of heterogeneity
We planned to undertake investigations of heterogeneity if there
were 10 or more studies available for a test. We planned to in-
vestigate the effect of a covariate by adding covariate terms to the
HSROC model to assess differences in accuracy and threshold.
Sensitivity analyses
Mothers with pregnancies identified as high risk for Down’s syn-
drome by serum testing are often offered immediate definitive
testing by amniocentesis, whereas those considered low risk are
assessed for Down’s syndrome by inspection at birth. Such delayed
and differential verification will introduce bias most likely through
there being greater loss to miscarriage in the Down’s syndrome
pregnancies that were not detected by the serum testing (the false
negative diagnoses). Testing and detection of miscarriages is im-
practical in many situations, and no clear data are available on the
magnitude of these miscarriage rates.
To account for the possible bias introduced by such a mechanism,
we planned to perform sensitivity analyses by increasing the per-
centage of false negatives in studies where delayed verification in
test negatives occurred (Mol 1999). We planned to incrementally
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increase the percentage from 10% to 50%, the final value repre-
senting a scenario where a third or more Down’s pregnancies than
normal pregnancies were likely to miscarry, thought to be higher
than the likely value. We intended to conduct the sensitivity anal-
yses on the analysis investigating the effect of maternal age on test
sensitivity.
R E S U L T S
Results of the search
The search for the whole suite of reviews identified a total of
15,394 papers, once the results from each bibliographic database
were combined and duplicates were removed. After screening out
obviously inappropriate papers based on their title and abstract,
1145 papers remained and we obtained full-text copies for formal
assessment of eligibility. From these, a total of 269 papers were
deemed eligible and were included in the suite of reviews. We
included a total of 56 studies (reported in 68 publications) in
this review of first trimester serum screening, involving 204,759
pregnancies, of which 2113 were Down’s syndrome pregnancies.
A total of 78 different test strategies or combinations, at one or
more thresholds, were evaluated in the 56 studies. These tests were
produced from combinations of 18 different serum tests with and
without maternal age; ADAM12, AFP, inhibin, PAPP-A, ITA,
free βhCG, PlGF, SP1, total hCG, progesterone, uE3, GHBP,
PGH, hyperglycosylated hCG,ProMBP, hPL, freeαhCG, and free
ßhCG to AFP ratio. Strategies evaluated included three quintuple
tests, three quadruple tests, 12 triple tests, 27 double tests and
15 single tests in combination with maternal age, and three triple
tests, five double tests and 10 single tests without maternal age.
The following combinations evaluated included four ormore stud-
ies.
Double tests with maternal age
1. Free ßhCG, AFP and maternal age (five studies; 5160
women including 174 Down’s syndrome pregnancies)
2. Free ßhCG, PAPP-A and maternal age (31 studies; 158,878
women including 1430 Down’s syndrome pregnancies)
Single tests with maternal age
1. Free ßhCG and maternal age (nine studies; 16,656 women
including 549 Down’s syndrome pregnancies)
2. PAPP-A and maternal age(six studies; 13,742 women
including 409 Down’s syndrome pregnancies)
Single tests without maternal age
1. Free ßhCG (four studies; 4280 women including 390
Down’s syndrome pregnancies)
2. PAPP-A (six studies; 25,510 women including 430 Down’s
syndrome pregnancies)
Of the remaining test combinations, seven were evaluated in three
studies, 17 were evaluated in two studies and the remainder were
evaluated in single studies only.
Methodological quality of included studies
We judged the methodological quality of the studies to be high
in most categories (Figure 1). Due to the nature of testing for
Down’s syndrome screening and the potential side effects of inva-
sive testing, differential verification is almost universal in the gen-
eral screening population, as most women whose screening test
result is defined as low risk will have their screening test verified
at birth, rather than by invasive diagnosis in the antenatal period.
Additionally, it was not always possible to ascertain from the in-
cluded studies whether or not the results of index tests and refer-
ence standards were blinded. It would be difficult to blind clini-
cians performing invasive diagnostic tests (reference standards) to
the index test result, unless all women received the same reference
standard, which would not be appropriate in most scenarios. Any
biases secondary to a lack of clinician blinding are likely to be
minimal.
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Figure 1. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
Where details of completeness of follow-up were poorly reported,
most studies seemed to assume 100% follow-up. However, there
will inevitably be losses to follow-up due to women moving out
of area, for example. Studies sometimes accounted for these and
it is unlikely that there were enough losses to follow-up to have
introduced significant bias. There was likely under-ascertainment
of miscarriage, and very few papers accounted for miscarriage, or
performed tissue karyotyping in pregnancies resulting in miscar-
riage. Some studies attempted to adjust for predicted miscarriage
rate and the incidence of Down’s syndrome in this specific pop-
ulation, but most did not. We have not attempted to adjust for
expected miscarriage rate in this review. There is a higher natural
miscarriage rate in the first trimester, however this will be uniform
across studies and therefore unlikely to introduce significant bias.
Some studies that provided estimates of risk using multivariable
equations used the same data set to evaluate performance of the
risk equation as was used to derive the equation. This is often
thought to lead to over-estimation of test performance.
Findings
The findings of the 21 most common and/or best performing test
strategies are given in Summary of findings 1. The remaining 57
strategies are briefly summarised in Summary of findings 2. The
test strategies evaluated by four or more studies are detailed below.
1) Free ßhCG, PAPP-A and maternal age (double
test)
Results for this double test were derived from 31 studies (Biagiotti
1998; Brambati 1994; Christiansen 2005; Christiansen 2007a;
Christiansen 2009; Christiansen 2010; Cowans 2010; Crossley
2002a; De Graaf 1999a; Forest 1997; Gyselaers 2005; Haddow
1998; Kagan 2009; Kozlowski 2007 GC; Kozlowski 2007 PC;
Krantz 2000; Muller 2003a; Niemimaa 2001a; O’Leary 2006;
Orlandi 1997; Sahota 2010; Schaelike 2009; Scott 2004; Spencer
1999a; Torring 2010; Tsukerman 1999; Valinen 2007; Wald
2003a;Wapner 2003;Wojdemann 2005; Zaragoza 2009), and in-
cluded 158,878 women in whom 1430 pregnancies were known
to be affected byDown’s syndrome. Seven studies contributed over
10,000 pregnancies each to the data (Crossley 2002a; Gyselaers
2005; Kagan 2009; Krantz 2000; O’Leary 2006; Sahota 2010;
Schaelike 2009). Studies presented data for cut-points of 5% FPR
(Biagiotti 1998; Brambati 1994; Cowans 2010; De Graaf 1999a;
Forest 1997; Haddow 1998; Kagan 2009; Sahota 2010; Spencer
1999a;Sahota 2010; Torring 2010; Tsukerman 1999; Wald
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2003a; Wapner 2003; Zaragoza 2009), 1:250 risk (Christiansen
2005; Christiansen 2007a; Christiansen 2009; Christiansen 2010;
Crossley 2002a; Kagan 2009; Muller 2003a; Niemimaa 2001a;
Torring 2010; Valinen 2007; Wojdemann 2005), and 1:300 risk
(Kozlowski 2007 GC; Kozlowski 2007 PC; Schaelike 2009). At a
cut-point of 5% FPR (17 studies), the sensitivity wa s estimated as
68% (95% confidence interval (CI) 65 to 71) and the specificity at
95% (95%CI 95 to 95). At a cut-point of 1:250 FPR (11 studies),
the sensitivity was estimated as 73% (95% CI 67 to 79) and the
specificity as 93% (95% CI 91 to 94).
2) Free ßhCG, AFP and maternal age (double test)
Results for this double test were derived from five studies (Benattar
1999; Biagiotti 1995; Forest 1995; Tsukerman 1999; Wald
2003a), and included 5160women inwhom174pregnancies were
known to be affected by Down’s syndrome. Two contributed over
1000 pregnancies each to the data (Benattar 1999; Tsukerman
1999. Studies presented data for cut-points of 5% FPR (Biagiotti
1995; Tsukerman 1999; Wald 2003a), 1:250 risk (Benattar 1999)
and 1:384 risk (Forest 1995). At a cut-point of 5% FPR (three
studies), the sensitivity was estimated as 49% (95% CI 39 to 60)
and the specificity as 95% (95% CI 94 to 96).
3) PAPP-A and maternal age (single test)
Results for this single test were derived from six studies (Biagiotti
1998; Brambati 1993; Forest 1997; Krantz 2000; Spencer 1999a;
Wald 2003a), and included 13,742women inwhom409pregnan-
cies were known to be affected by Down’s syndrome. Krantz 2000
was the largest study, contributing over 10,000 pregnancies to the
data. Studies presented data for cut-points of 5% FPR (Biagiotti
1998; Brambati 1993; Forest 1997; Spencer 1999a; Wald 2003a)
and 1:105 risk (Krantz 2000). At a cut-point of 5% FPR (five
studies), the sensitivity was estimated as 55% (95% CI 46 to 63)
and the specificity as 95% (95% CI 94 to 96).
4) Free ßhCG and maternal age (single test)
Results for this single test were derived from nine studies (Biagiotti
1995; Biagiotti 1998; Brambati 1994; Forest 1995; Forest 1997;
Krantz 2000; Noble 1995; Spencer 1999a; Wald 2003a), and in-
cluded 16,656 women in whom 549 pregnancies were known to
be affected by Down’s syndrome. Krantz 2000 contributed over
10,000 pregnancies to the data. Studies presented data for cut-
points of 5%FPR (Biagiotti 1995; Biagiotti 1998; Brambati 1994;
Forest 1997, Noble 1995; Spencer 1999a; Wald 2003a), 1:384
risk (Forest 1995) and 1:105 risk (Krantz 2000). At a cut-point
of 5% FPR (seven studies), the sensitivity was estimated as 42%
(95% CI 36 to 48) and the specificity as 95% (95% CI 94 to 96).
5) PAPP-A alone (single test without maternal age)
Results for this single test were derived from six studies (Brambati
1993; Brameld 2008; Brizot 1994; Casals 1996; Spencer 1999a;
Wald 2003a), and included 25,510 women in whom 430 preg-
nancies were known to be affected by Down’s syndrome. Brameld
2008 was the largest study contributing over 20,000 pregnan-
cies to the data. Studies presented data for cut-points of 5% FPR
(Brambati 1993; Brizot 1994; Casals 1996; Spencer 1999a; Wald
2003a) and ≤ 5th percentile (Brameld 2008). At a cut-point of
5% FPR (four studies), the sensitivity was estimated as 52% (95%
CI 39 to 65) and the specificity as 95% (95% CI 94 to 96).
6) Free ßhCG alone (single test without maternal age)
Results for this single test were derived from four studies (Casals
1996; Noble 1997; Spencer 1999a; Wald 2003a), and included
4280 women in whom 390 pregnancies were known to be affected
by Down’s syndrome. Studies were all of a similar size. Studies
presented data at a 5% FPR. At this cut-point, the sensitivity was
estimated as 25% (95% CI 18 to 34) and the specificity as 95%
(95% CI 94 to 96).
7) Other test combinations
Of the 73 test combinations evaluated in three or fewer studies,
several test combinations demonstrated estimated sensitivities of
more than 70% and estimated specificities of more than 90%.
Twelve of these were evaluated in single studies (Summary of
findings 2), however, three test combinations were evaluated in
two or more studies.
1. A triple test ofPAPP-A, free ßhCG, AFP and maternal
age was evaluated in three studies (Muller 2003a; Tsukerman
1999; Wald 2003a), had an estimated sensitivity of 74% (95%
CI 65 to 81) at a cut-point of 5% FPR.
2. A triple test of ADAM 12, PAPP-A, free ßhCG and
maternal age was evaluated in three studies (Christiansen 2010;
Torring 2010; Valinen 2009), had an estimated sensitivity of
74% (95% CI 63 to 83) at a cut-point of 5% FPR.
3. A triple test of PlGF, PAPP-A, free ßhCG and maternal
age was evaluated in two studies (Cowans 2010; Zaragoza 2009),
had an estimated sensitivity of 76% (95% CI 69 to 82) at a cut-
point of 5% FPR.
Comparative analysis of the nine selected test
strategies
We chose to estimate detection rates at a 5%FPR, in commonwith
much of the literature. Figure 2 shows point estimates of detection
rates for a 5% FPR based on all available data for all nine test com-
binations described above, and the confidence intervals at a fixed
5% FPR. For example, the plot shows that for the double test with
a marker combination of free βhCG, AFP and maternal age, the
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estimated detection rate at a 5% FPR was 49% (95% CI 39 to 60)
based on data from three studies with 157 affected cases and 2992
total participants. The test combinations in Figure 2 are ordered
according to decreasing detection rates. The single test strategies
with and without maternal age (PAPP-A alone; free βhCG alone,
PAPP-A and maternal age, and free βhCG and maternal age) have
the worst performance, whereas, the triple test strategies (ADAM
12, PAPP-A, free βhCG and maternal age; PAPP-A, free βhCG,
AFP and maternal age) have the highest performance. In between
lie the double tests (free βhCG, PAPP-A and maternal age; free
βhCG, AFP and maternal age). However, it should be noted that
the confidence intervals on these estimates are wide and overlap
for the lower performing five strategies, suggesting that any of the
differences observed may be explicable by chance.
Figure 2. Detection rates (sensitivity) at a 5% false positive rate for the nine selected test strategies. Each
circle represents the summary sensitivity for a test strategy and the size of each circle is proportional to the
number of Down’s cases. The estimates are shown with 95% confidence intervals. The test strategies are
ordered on the plot according to decreasing detection rate. The number of studies, cases and women included
for each test strategy are shown on the horizontal axis.A = Age, PlGF, PAPP-A and free ßhCG; B = Age, PAPP-
A, free ßhCG and AFP; C = Age, ADAM 12, PAPP-A and free ßhCG; D = Age, PAPP-A and free ßhCG ; E =
Age, PAPP-A; F = PAPP-A; G = Age, free ßhCG and AFP ; H = Age, free ßhCG; I = Free ßhCG
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Table 1 shows pair-wise direct comparisons (head-to-head) where
studies were available. Such comparisons are regarded as providing
the strongest evidence as they compare tests within pregnancies
and are thus unconfounded. The table shows the ratios of sen-
sitivities with 95% CIs and P values (P < 0.05 being considered
a statistically significant difference) for each test comparison, the
number of studies (K) for which data were available. The table
shows that the sensitivity of the single test combinations (PAPP-
A alone, free βhCG alone, PAPP-A and maternal age, and free
βhCG and maternal age) tended to be significantly worse (P <
0.05) than the double and triple tests where data are available. The
double test comprised of PAPP-A, free βhCG and maternal age
appears to have significantly better (P = 0.004) test accuracy than
the double test comprised of free βhCG, AFP and maternal age.
Otherwise, there was no strong evidence of significant improve-
ments in sensitivity with the addition of a third marker. However,
most comparisons in this table are based on only single studies
and are unlikely to be powered to detect differences in detection
rates.
Table 2 shows the same comparisons made using all available data
(as used to create Figure 2). Results are in agreement with the di-
rect comparisons, and in addition, showed that the triple test com-
prised of PlGF, PAPP-A, free ßhCG and maternal age is signifi-
cantly better (P = 0.024) than the double test comprised of PAPP-
A, free βhCG and maternal age. However, these comparisons are
potentially confounded by differences between the studies, and
are based on small numbers of studies.
Investigation of heterogeneity and sensitivity analyses
The key characteristics of the 56 included studies is summarised
in Table 3 with further details available in the Characteristics of
included studies table. Only one test combination- PAPP-A, free
ßhCG and maternal age (17 studies) was evaluated by 10 or more
studies but there were no data for investigation of the effect of
maternal age or any other potential source of heterogeneity. The
planned sensitivity analyses were also not possible.
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Summary of findings
Review Question What is the accuracy of serum-based markers for Down’s syndrome screening in the first trimester?
Population Pregnant women at less than 14 weeks’ gestation confirmed by ultrasound, who had not undergone previous testing for Down’s syndrome. Most studies were
undertaken in women identified to be high risk based on maternal age
Settings All settings
Numbers of studies, preg-
nancies and Down’s syn-
drome cases
56 studies (68 publications) involving 204,759 pregnancies of which 2113 were Down’s syndrome pregnancies
Index tests 18 serum markers (ADAM12, AFP, inhibin, PAPP-A, ITA, free βhCG, PlGF, SP1, total hCG, progesterone, uE3, GHBP, PGH, hyperglycosylated hCG, ProMBP,
hPL, free αhCG, and free ßhCG to AFP ratio) singly or in combination with or without maternal age
Reference standards Chromosomal verification (amniocentesis and CVS undertaken during pregnancy, and postnatal karyotyping) and postnatal macroscopic inspection
Study limitations 35 studies used selective chromosomal verification during pregnancy, and were at risk of under-ascertainment of Down’s syndrome cases due loss of the
pregnancy to miscarriage between the serum test and the reference standard
Tests with at least 70% sensitivity and at least 95% specificity
Test strategy Studies Women (cases) Sensitivity (95% CI) Specificity (95% CI) Test*
Test strategies (with or without maternal age) evaluated by a single study
Without maternal age
Double tests
PAPP-A and AFP 1 96 (16) 81 (54 to 96) 95 (88 to 99)
PAPP-A and ITA 1 344 (24) 71 (49 to 87) 95 (92 to 97)
Triple tests
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PAPP-A, free ßhCG and ITA 1 344 (24) 75 (53 to 90) 95 (92 to 97)
PlGF, PAPP-A and free ßhCG 1 699 (90) 72 (62 to 81) 95 (93 to 97)
With maternal age
Double tests
Free ßhCG and SP1 1 60 (14) 71 (42 to 92) 96 (85 to 99)
PAPP-A and Hyperglycosy-
lated hCG
1 10775 (23) 74 (52 to 90) 95 (95 to 95)
Triple tests
PAPP-A, free ßhCG and In-
hibin
1 1110 (85) 74 (63 to 83) 95 (94 to 96)
PAPP-A, SP1 and ProMBP 1 192 (15) 73 (45 to 92) 95 (91 to 98)
hPL, PAPP-A and free ßhCG
(1:250 risk)
1 183 (47) 77 (62 to 88) 95 (90 to 98)
Quadruple tests
GHBP, PGH, PAPP-A and free
ßhCG (1:250 risk)
1 335 (74) 76 (64 to 85) 95 (91 to 97)
Quintuple tests
PAPP-A, free ßhCG, AFP, uE3
and Inhibin
1 1110 (85) 78 (67 to 86) 95 (94 to 96)
PAPP-A, total hCG, AFP, uE3
and Inhibin
1 1110 (85) 73 (62 to 82) 95 (94 to 96)
Test strategies (with or without maternal age) evaluated by at least two studies1
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Free ßhCG 4 4280 (390) 25 (18 to 34) 95 (94 to 96) P <0.001
PAPP-A 4 2837 (325) 52 (39 to 65) 95 (94 to 96)
Age, free ßhCG 7 5893 (460) 42 (36 to 48) 95 (94 to 96)
Age, PAPP-A 5 3491 (359) 55 (46 to 63) 95 (94 to 96)
Age, free ßhCG and AFP 3 2992 (157) 49 (39 to 60) 95 (94 to 96)
Age, PAPP-A and free ßhCG 17 49827 (1037) 68 (65 to 71) 95 (95 to 95)
Age, PAPP-A, free ßhCG and
AFP
2 2705 (116) 74 (65 to 81) 95 (94 to 96)
Age, ADAM 12, PAPP-A and
free ßhCG
2 1222 (74) 74 (63 to 83) 95 (94 to 96)
Age, PlGF, PAPP-A and free
ßhCG
2 1144 (160) 76 (69 to 82) 95 (93 to 96)
*Likelihood ratio test for the difference in sensitivity between the nine test strategies that were formally compared in a single meta-
analytic model.
ADAM12: a disintegrin and metalloprotease; AFP: alpha-fetoprotein; αhCG: alpha human chorionic gonadotrophin; ßhCG: beta human
chorionic gonadotrophin; CI: confidence interval; CVS: chorionic villus sampling; GHBP: growth hormone binding protein; hCG: human
chorionic gonadotrophin; hPL: human placental lactogen; ITA: invasive trophoblast antigen; PAPP-A: pregnancy-associated plasma
protein A; PGH: placental growth hormone; PIGF: placental growth factor; PROMBP: proform of eosinophil major basic protein; SPI:
Schwangerschafts protein 1; uE3: unconjugated oestriol
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Test strategy Studies Women (cases) Sensitivity (95% CI) Specificity (95% CI) Threshold
Without maternal age
Single tests
AFP 2 2248 (104) 10 (4 to 21) 95 5% FPR
ADAM 12 1 579 (17) 41 (18 to 67) 95 (93 to 97) 5% FPR
Free ßhCG to AFP ratio 1 476 (9) 11 (0 to 48) 98 (96 to 99) 0.25 MoM
Inhibin 3 2098 (184) 19 (4 to 58) 95 5% FPR
PlGF 1 699 (90) 28 (19 to 38) 95 (93 to 97) 5% FPR
Total hCG 3 2098 (184) 19 (4 to 58) 95 5% FPR
SP1 3 1080 (53) 32 (1 to 96) 95 5% FPR
uE3 1 1110 (85) 13 (7 to 22) 95 (94 to 96) 5% FPR
Double tests
Free ßhCG and AFP 1 1138 (19) 16 (3 to 40) 95 (94 to 96) 5% FPR
Free ßhCG and Inhibin 1 876 (76) 30 (20 to 42) 95 (93 to 96) 5% FPR
PAPP-A and free ßhCG 2 795 (106) 64 (50 to 76) 95 5% FPR
Triple tests
Total hCG, free αhCG and pro-
gesterone
1 129 (17) 53 (28 to 77) 96 (90 to 99) 0.34 MoM
With maternal age1
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Single tests
ADAM 12 2 703 (46) 67 (46 to 83) 91 (87 to 94) 1:400 risk
AFP 2 1397 (126) 33 (23 to 46) 95 5% FPR
Free αhCG 1 512 (12) 25 (5 to 57) 89 (86 to 91) 1:384 risk
GHBP 1 335 (74) 27 (17 to 39) 95 (91 to 97) 1:250 risk
hPL 1 183 (47) 45 (30 to 60) 93 (88 to 97) 1:250 risk
Inhibin 1 1110 (85) 32 (22 to 43) 95 (94 to 96) 5% FPR
ITA 1 278 (54) 48 (34 to 62) 95 (91 to 98) 5% FPR
PGH 1 335 (74) 41 (29 to 53) 94 (91 to 97) 1:250 risk
PlGF 1 699 (90) 43 (33 to 54) 95 (93 to 97) 5% FPR
ProMBP 1 181 (25) 36 (18 to 57) 94 (89 to 97) 1:250 risk
SP1 2 804 (29) 38 (22 to 56) 95 5% FPR
Total hCG 1 512 (12) 33 (10 to 65) 94 (92 to 96) 1:384 risk
uE3 1 512 (12) 33 (10 to 65) 86 (83 to 89) 1:384 risk
Double tests
ADAM 12 and PAPP-A 1 691 (46) 61 (45 to 75) 95 (93 to 97) 5% FPR
AFP and free αhCG 1 512 (12) 33 (10 to 65) 87 (83 to 89) 1:384 risk
AFP and total hCG 1 512 (12) 33 (10 to 65) 93 (90 to 95) 1:384 risk
1
8
F
irst
trim
e
ste
r
se
ru
m
te
sts
fo
r
D
o
w
n
’s
sy
n
d
ro
m
e
sc
re
e
n
in
g
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
5
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
AFP and uE3 1 512 (12) 42 (15 to 72) 87 (84 to 90) 1:384 risk
Free ßhCG and free αhCG 1 512 (12) 42 (15 to 72) 94 (91 to 96) 1:384 risk
Free ßhCG and Inhibin 1 1110 (85) 44 (33 to 55) 95 (94 to 96) 5% FPR
Free ßhCG and total hCG 1 512 (12) 25 (5 to 57) 93 (90 to 95) 1:384 risk
Free ßhCG and uE3 1 287 (41) 61 (45 to 76) 95 (92 to 97) 5% FPR
GHBP and free ßhCG 1 335 (74) 61 (49 to 72) 92 (88 to 95) 1:250 risk
GHBP and PAPP-A 1 335 (74) 66 (54 to 77) 93 (89 to 96) 1:250 risk
GHBP and PGH 1 335 (74) 47 (36 to 59) 93 (90 to 96) 1:250 risk
hPL and free ßhCG 1 183 (47) 68 (53 to 81) 94 (89 to 97) 1:250 risk
hPL and PAPP-A 1 183 (47) 55 (40 to 70) 94 (89 to 97) 1:250 risk
PAPP-A and AFP 2 2705 (116) 63 (50 to 74) 95 5% FPR
PAPP-A and Inhibin 1 1110 (85) 68 (57 to 78) 95 (94 to 96) 5% FPR
PAPP-A and ITA 2 622 (78) 62 (46 to 75) 95 5% FPR
PGH and free ßhCG 1 335 (74) 64 (52 to 74) 93 (89 to 96) 1:250 risk
PGH and PAPP-A 1 335 (74) 65 (53 to 76) 93 (89 to 96) 1:250 risk
Total hCG and free αhCG 1 512 (12) 42 (15 to 72) 92 (89 to 94) 1:384 risk
Total hCG and Inhibin 1 1110 (85) 34 (24 to 45) 95 (94 to 96) 5% FPR
Total hCG and PAPP-A 2 4327 (133) 66 (54 to 76) 95 5% FPR
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Total hCG and uE3 1 512 (12) 42 (15 to 72) 92 (89 to 94) 1:384 risk
uE3 and free αhCG 1 512 (12) 33 (10 to 65) 89 (86 to 91) 1:384 risk
Triple tests
AFP, free αhCG and uE3 1 512 (12) 58 (28 to 85) 82 (79 to 85) 1:384 risk
Free ßhCG, AFP and uE3 1 287 (41) 66 (49 to 80) 95 (92 to 97) 5% FPR
GHBP, PAPP-A and free ßhCG 1 335 (74) 76 (64 to 85) 94 (91 to 97) 1:250 risk
PAPP-A, total hCG and Inhibin 1 1110 (85) 69 (58 to 79) 95 (94 to 96) 5% FPR
PGH, PAPP-A and free ßhCG 1 335 (74) 76 (64 to 85) 94 (91 to 97) 1:250 risk
Total hCG, AFP and uE3 1 512 (12) 42 (15 to 72) 91 (88 to 94) 1:384 risk
Quadruple tests
Free ßhCG, total hCG, AFP and
uE3
1 512 (12) 50 (21 to 79) 92 (89 to 94) 1:384 risk
Total hCG, AFP, uE3 and free
αhCG
1 512 (12) 50 (21 to 79) 90 (87 to 92) 1:384 risk
Quintuple tests
Free ßhCG, total hCG, AFP,
uE3 and free αhCG
1 512 (12) 33 (10 to 65) 90 (87 to 92) 1:384 risk
AFP: alpha-fetoprotein; αhCG: alpha human chorionic gonadotrophin; ßhCG: beta human chorionic gonadotrophin; CI: confidence
interval; FPR: false positive rate; GHBP: growth hormone binding protein; hCG: human chorionic gonadotrophin; hPL: human placental
lactogen; ITA: invasive trophoblast antigen; PAPP-A: pregnancy-associated plasma protein A; PGH: placental growth hormone; PIGF:
placental growth factor; PROMBP: proform of eosinophil major basic protein; SPI: Schwangerschafts protein 1; uE3: unconjugated
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D I S C U S S I O N
Summary of main results
The systematic review found a large number of studies evaluating
first trimester Down’s syndrome serum screening tests, including
studies evaluating the commonly used double test. Few studies
were available to evaluate the performance of test strategies in-
volving newer markers, such as ADAM 12, and few studies pro-
vided unconfounded comparisons of test strategies by applying
and comparing several strategies using the same serum sample, the
majority of studies only evaluating a single test combination. A
summary of results for the nine most common and best perform-
ing strategies is given in Summary of findings 1, briefer details for
the remaining strategies are given in Summary of findings 2.
Three key findings were noted.
1. The double test comprised of PAPP-A, free βhCG and
maternal age appears to have significantly better (P < 0.05) test
accuracy than the double test comprised of free βhCG, AFP and
maternal age, and the single tests (both the markers alone and in
combination with maternal age). This test detects around seven
out of every 10 Down’s affected pregnancies for a fixed 5% FPR.
By comparison, the double test comprised of free βhCG, AFP
and maternal age, and single tests alone and in combination with
maternal age detects between two and five out of every 10
Down’s affected pregnancies for a fixed 5% FPR.
2. Whilst the triple test combinations show the highest
detection rates, they were not shown to be statistically superior to
the double test comprised of PAPP-A, free βhCG and maternal
age. Whilst some significant differences between these categories
of tests were noted in the indirect comparisons, the potential for
confounding is of concern. Estimates suggest that triple test
combinations may detect between seven and eight out of every
10 Down’s syndrome pregnancies at a 5% FPR, however these
estimates are based on data from two or three studies evaluating
small numbers of women. It is difficult to make strong
recommendations on the use of triple tests, as we cannot rule out
possible differences due to the limited power there is to detect a
difference.
3. The evidence for higher numbers of markers shows similar
detection rates to double and triple markers, but are based on
data from one study only, therefore further evaluation of these
tests is required. Furthermore, there are other combinations of
double markers that show similar detection rates to standard
double markers commonly used in clinical practice, which may
warrant further study.
Strengths and weaknesses of the review
This review is the first comprehensive review of first trimester
serum screening. We examined papers from around the world,
covering a wide cross-section of women in varying populations.
We contacted authors to verify data where necessary to give as
complete a picture as possible, while trying to avoid replication of
data.
There were a number of factors that made meta-analysis of the
data difficult, which we tried to adapt for, in order to allow for
comparability of data presented in different studies.
1. There were many different cut-points used to define
pregnancies as high or low risk for Down’s syndrome. This
means that direct comparison is more difficult than if all studies
used the same cut-point to dichotomise their populations. This
is less of an issue for first trimester serum screening, compared to
second trimester serum screening, as the majority of authors
chose a cut-point of 5% FPR.
2. There were many different risk equations and software
applications in use for combination of multiple markers, which
were often not described in the papers. This means that risks
may be calculated by different formulae and they may not be
directly comparable for this reason. It is possible that this is
responsible for unexplained heterogeneity in results.
3. Different laboratories and clinics run different assays and
use different machines and methods. This may influence raw
results and subsequent risk calculations. Many laboratories have
a quality assessment or audit trail, however, this may not
necessarily be standard across the board. For example, how many
assays are run, how often medians are calculated and adjusted for
a given population and how quickly samples are tested from
initially being taken.
4. Few papers made direct comparisons between tests, making
it difficult to detect if a real difference exists between tests (i.e.
how different tests perform in the same population). There were
differences in populations, with assay medians being affected, for
example, by race. It is not certain whether it is appropriate to
make comparisons between populations which are inherently
different.
5. We were unable to perform the investigations of
heterogeneity that we had originally intended to because the data
simply were not available. The vast majority of papers looking at
pregnancies conceived by IVF, affected by diabetes, multiple
gestation or a family history of Down’s syndrome involved
unaffected pregnancies only.
In addition, the search for this review was last updated in August
2011, and it is possible that new studies may have been published
which have not been included. Since the search was completed
we have kept a watching brief on outputs and are not aware of
any studies with substantial sample sizes which could substantially
affect the findings.
Applicability of findings to the review question
Potentially, when planning screening policy or a clinical screening
programme, clinicians and policy makers need to make decisions
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about a finite number of tests or type of tests that can be offered.
These policies are often driven by both the needs of a specific pop-
ulation and by financial resources. Economic analysis was consid-
ered to be outside of the scope of this review. Many of the tests
examined as part of this review are already commercially available
and in use in the clinical setting. The studies were carried out on
populations of typical pregnant women and therefore, the results
should be considered comparable with most pregnant populations
encountered in every day clinical practice.
We were unable to extract information about harms of testing, in-
formation about miscarriage rates and uptake of definitive testing
as the data were not available the majority of the time. Whilst it
is unlikely that major differences between the tests evaluated here
exist in terms of direct harms of testing, as they are all based on
a single blood sample, differences in accuracy may lead to differ-
ences in the use of definitive testing and its consequent adverse
outcomes.
In some countries with a defined screening policy (i.e. the UK),
first trimester screening plays a major role, although usually in
combination with first trimester ultrasound scanning. In others
however, theremay only be a limited range of tests ormarkers avail-
able, often second trimester markers, rather than first trimester
markers. The results of this review should be interpreted and ap-
plied in the context of test availability and local restrictions, pop-
ulations or policies.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The evidence supports the use of the first trimester double test
comprised of PAPP-A, free βhCG and maternal age, there is little
evidence to recommend the use of first trimester serum tests with
three or moremarkers, however the data available on these tests are
limited, and based on generally small populations of women. We
would not recommend that these tests be introduced into wider
clinical practice without careful consideration of cost.
The review has shown that tests involving two or three markers in
combination with maternal age are significantly better than those
involving one marker. We would therefore recommend that one
marker tests are not used for Down’s syndrome screening. The
choice of multiple markers will depend on the availability of cer-
tain assays in local laboratories. On the basis of this review we
would recommend the combination of PAPP-A, free βhCG and
maternal age, as it significantly outperforms free βhCG, AFP and
maternal age, and is widely available. The data for other test com-
binations limits our ability to make any other recommendations
about specific test combinations. Alternative screening methods
should also be considered (i.e. use of ultrasound markers in the
first trimester) when making policy decisions, and are the subject
of other reviews in this suite.
The screening blood tests themselves have no adverse effects for the
woman, over and above the risks of a routine blood test. However
some women who have a ‘high risk’ screening test result, and are
given amniocentesis or CVS have a risk of miscarrying a baby
unaffected by Down’s. Parents will need to weigh up this risk
when deciding whether or not to have an amniocentesis or CVS
following a ‘high risk’ screening test result.
Implications for research
Further evaluations of test combinations involving three or more
markers are required to determine whether their apparent advan-
tages are not chance findings.
Future studies should ensure that adequate sample sizes are re-
cruited, and take opportunities to make comparisons of test per-
formance testing several alternative test combinations on the same
serum samples. Such direct comparison removes issues of con-
founding when making test comparisons, and allows a clear focus
on testing the incremental benefit of increasingly complex and
expensive testing strategies. The reporting of studies of test accu-
racy can be improved and more closely adhere to the standards
for the reporting of diagnostic accuracy studies (STARD) guide-
line. Three key aspects of this are 1) formally testing the statistical
significance of differences in test performance in direct compar-
isons and estimating incremental changes in detection rates (to-
gether with confidence intervals), 2) clearly reporting the number
of mothers studied and their results, and 3) reporting the numbers
of womenwho are lost to follow-up.Many authors reported results
of extrapolating findings to age-standardised national cohorts to
demonstrate the performance of the test, and failed to report the
actual numbers studied and evaluated.
For the purposes of meta-analysis and to allow for comparisons
to be made between different tests and combinations, we would
recommend the publication of consensus standard algorithms for
estimating risk, and reporting of test performance at a standard set
of thresholds. This would be difficult to achieve and implement,
but an attempt at consensus should be made.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Baviera 2010
Clinical features and settings Routine screening.
Participants 579 participants: 17 cases and 562 controls matched for gestational age
Italy - single centre.
December 2006-May 2009.
Pregnant women.
Mean maternal age 35.3 years (cases) and 30.4 years (controls)
Singleton pregnancies.
7-10 and 14-17 weeks’ gestation.
Study design Case- control study.
Target condition and reference standard(s) Down’s syndrome: 17 cases (14 identified by amniocentesis, 3 from follow-up to birth)
Reference standards: amniocentesis or follow-up to birth.
Index and comparator tests Frozen serum samples tested for:
First trimester and second trimester ADAM12s (time resolvedfluorescence immunoassay,
DELFIA assay kit, Perkin Elmer Life and Analytical Sciences)
First trimester PAPP-A (details not reported).
Second trimester AFP, uE3 and hCG (details not reported).
Follow-up Details of follow-up not reported.
Aim of study To demonstrate the potential value of repeated measures of ADAM12s for the screening
of Down’s syndrome
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results.
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Baviera 2010 (Continued)
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Benattar 1999
Clinical features and settings Routine screening.
Participants 1656 participants.
France - single centre.
January to December 1995.
Singleton pregnancies.
Pregnant women.
Mean age 32 years (16-46 years).
Enrolled before 13 weeks’ gestation.
Study design Prospective cohort.
Target condition and reference standard(s) Down’s syndrome: 5 cases.
Reference standards: amniocentesis due to maternal age > 38 years (6.1% or women)
. Karyotyping encouraged for women with positive result on 1 or more index test. No
details of reference standard for index test negative women
Index and comparator tests Maternal age.
NT at 12-14 weeks (Toshiba SSA 270), cut-point 1/250.
First trimester (12-14 weeks) serum AFP and free ßhCG (Elsa AFP and Elsa free ßhCG;
Cis-Bio International)
Second trimester (15-18 weeks) serum AFP and total hCG (AFP-2T and hCG-60;
Ortho-Clinical Diagnostics)
Follow-up Details of follow-up not stated. Unclear whether women were followed up to birth
Aim of study To evaluate the sequential combination of ultrasound screening for fetal aneuploidy at
11-14 weeks with maternal biochemistry at 12-14 and 15-18 weeks of gestation
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Benattar 1999 (Continued)
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard.
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements.
Withdrawals explained?
All tests
Yes 12 patients were lost to follow-up due to miscarriages.
Biagiotti 1995
Clinical features and settings High-risk referral for invasive testing.
Participants 287 participants: 41 cases and 246 controls matched for maternal and gestational age,
and duration of sample storage (from cohort of 4452 participants undergoing invasive
testing)
Italy - single centre.
Dates not specified.
Pregnant women.
Singleton pregnancies.
8-12 weeks’ gestation.
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Biagiotti 1995 (Continued)
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 41 cases.
Reference standards: amniocentesis or CVS.
Index and comparator tests Maternal age.
Frozen samples tested for:
First trimester AFP - AFP-M-K S Kit.
First trimester uE3 - Amersham Amerlex M.
First trimester Intact hCG - Hybritech tandem.
First trimester free ßhCG - ELSA Free beta hCG CIS.
Follow-up 100% karyotyping.
Aim of study Evaluate first trimester maternal serum AFP, uE3 and hCG to assess the efficacy of
different combinations of these markers on a screening test for Down’s syndrome in the
first trimester
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes Karyotyping.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
Yes All women had invasive testing.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results
Index test results blinded?
All tests
Yes Index test interpretedwithout knowledge of ref-
erence standard results (lab analysis blinded)
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
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Biagiotti 1995 (Continued)
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements.
Withdrawals explained?
All tests
No No details of withdrawals given.
Biagiotti 1998
Clinical features and settings High-risk referral for invasive testing.
Participants 232 participants: 32 cases and 200 randomly selected controls (selected from series of
3731 women)
Italy - single centre.
July 1993 to December 1996.
Pregnant women.
Singleton pregnancies.
10 to 13 weeks’ gestation.
Study design Retrospective case-control study.
Target condition and reference standard(s) Down’s syndrome: 32 cases.
Reference standards: amniocentesis or CVS.
Index and comparator tests Maternal age.
First trimester NT (in longitudinal section of the fetus with caliper measurements to the
nearest 0.1 mm)
First trimester serumPAPP-A (Amerlex-MPAPP-A IRMA, Ortho-Clinical Diagnostics)
First trimester serum free ßhCG (Elsa9free B-hCG CIS).
Follow-up 100% karyotyping.
Aim of study To evaluate the potential effectiveness of maternal serum PAPP-A and free beta hCG in
combination with NT measurement in the first trimester of pregnancy
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes Karyotyping.
Partial verification avoided?
All tests
Yes All women received a reference standard.
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Biagiotti 1998 (Continued)
Differential verification avoided?
All tests
Yes All women had the same reference standard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge
of index test results
Index test results blinded?
All tests
Yes Index test interpretedwithout knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements
Withdrawals explained?
All tests
Unclear No details of withdrawals given.
Brambati 1993
Clinical features and settings HIgh-risk referral for invasive testing.
Participants 522 participants.
Italy.
Dates not specified.
Pregnant women.
Median age 38 years (20-47 years).
Singleton pregnancies.
6-11 weeks’ gestation.
Study design Retrospective cohort.
Target condition and reference standard(s) Down’s syndrome: 14 cases.
Reference standard: CVS.
Index and comparator tests Maternal age.
Frozen blood sample tested for:
FIrst trimester serum PAPP-A (radio-immunoassay).
Follow-up 100% karyotyping.
47 women who miscarried prior to CVS were excluded from the study
Aim of study To assess the relationship between maternal serum PAPP-A in the first trimester and the
outcome of pregnancy by karyotype
62First trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Brambati 1993 (Continued)
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes CVS.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
Yes All women had the same reference standard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results
Index test results blinded?
All tests
Unclear Unclear if all index tests interpreted without
knowledge of reference standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninter-
pretable measurements.
Withdrawals explained?
All tests
No No details of withdrawals given.
Brambati 1994
Clinical features and settings HIgh-risk referral for invasive testing.
Participants 102 participants: 13 case and 89 randomly selected controls matched for gestational age
Italy.
Dates not specified.
Pregnant women.
8-12 weeks’ gestation.
Study design Case-control study.
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Brambati 1994 (Continued)
Target condition and reference standard(s) Down’s syndrome: 13 cases.
Reference standard: CVS.
Index and comparator tests Maternal age.
Frozen serum samples tested for:
FIrst trimester PAPP-A (radioimmunoassay, as described in Sinosich 1982)
First trimester free ßhCG (radioimmunoassay, CIS, UK).
Follow-up 100% karyotyping.
Aim of study To report the results for the combined measurement of serum PAPP-A and free-ßhCG
in women attending for prenatal diagnosis
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes CVS.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
Yes All women had the same reference standard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of
reference standard results (biochemical testing
conducted blind to karyotype results)
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninter-
pretable measurements
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Brambati 1994 (Continued)
Withdrawals explained?
All tests
No No details of withdrawals given.
Brameld 2008
Clinical features and settings Routine screening.
Participants 22,280 participants with complete screening results and outcome data
August 2001-October 2003.
Australia - State-wide screening programme evaluation.
Pregnant women.
Median maternal age 31 years (range 14-47 years), 20% ≥ 35 years
Singleton pregnancies.
10-14 weeks’ gestation.
Study design Retrospective cohort.
Target condition and reference standard(s) Down’s syndrome: 60 cases.
Reference standards: karyotyping or follow-up to birth.
Index and comparator tests Maternal age.
First trimester PAPP-A, free ßhCG and NT (details not reported)
Risk cut-point 1:300.
Follow-up Data on outcome from the Western Australia Midwives data collection, Birth Defects
Registry and hospital morbidity and mortality data
Aim of study To identify first trimester indicators of adverse pregnancy outcomes
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results.
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Brameld 2008 (Continued)
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Brizot 1994
Clinical features and settings High-risk referral for invasive testing.
Participants 393 participants: 45 cases of Down’s syndrome and 348 controls matched for crown
rump length, maternal age and storage time
UK.
Dates not specified.
Pregnant women.
Median age 38 years (22-45 years).
Singleton pregnancies.
10-13 weeks’ gestation.
Study design Retrospective case-control study.
Target condition and reference standard(s) Down’s syndrome: 45 cases.
Reference standard: fetal karyotyping.
Index and comparator tests Maternal age.
Frozen serum samples tested for:
First Trimester PAPP-A (Double sandwich time resolved immunofluorometric assay with
chelated europium as a label. Antibody to PAPPA binding Ig was polyclonal rabbit IgG
in stabilised solution)
Follow-up 100% karyotyping
Aim of study To determine if the risk for fetal trisomies during the first trimester of pregnancy can be
derived by combining data from maternal serum PAPP-A and fetal NT thickness
Notes Cases were pre-selected for increased NT thickness.
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Brizot 1994 (Continued)
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes Karyotyping.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
Yes All women had the same reference standard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of
reference standard results (biochemical testing
conducted blind to karyotype results)
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice.
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements.
Withdrawals explained?
All tests
No No details of withdrawals given.
Casals 1996
Clinical features and settings High-risk referral for invasive testing.
Participants 1138 participants.
Spain.
1990-1993.
Pregnant women.
94.4% of women aged > 35 years.
Singleton pregnancies.
10-13 weeks’ gestation.
Study design Retrospective case-control study.
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Casals 1996 (Continued)
Target condition and reference standard(s) Down’s syndrome: 19 cases.
Reference standard: CVS.
Index and comparator tests Maternal age.
Frozen serum samples tested for:
First trimester serum free ßhCG (IMx microparticle enzyme immunoassay technology)
(19 case and > 80 control samples)
First trimester serum AFP (Stratus fluorometric enzyme immunoassay) (19 case and >
80 control samples)
First trimester serum PAPP-A (radioimmunoassay) (only for 16 case and 80 control
samples)
Follow-up 100% karyotyping.
Aim of study To examine the value of ßhCG, AFP and PAPP-A in biochemical screening for Down’s
syndrome in 19 women carrying Down’s syndrome versus normal pregnancies
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes CVS.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
Yes All women had the same reference standard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results
Index test results blinded?
All tests
Unclear Unclear if all index test interpreted without
knowledge of reference standard results (PAPP-
A testing conducted blind to CVS results but
presence of blinding is not stated for free ßhCG
and AFP)
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Casals 1996 (Continued)
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice.
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements.
Withdrawals explained?
All tests
No No details of withdrawals given.
Christiansen 1999
Clinical features and settings High-risk referral for invasive testing.
Participants 181 participants (for first trimester serum samples): 25 cases and 156 controls matched
for length of storage
Denmark.
Dates not specified.
Pregnant women.
5-20 weeks’ gestation.
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 25 cases.
Reference standard: karyotyping.
Index and comparator tests Maternal age.
Frozen serum samples tested for:
First and second trimester ProMBP (2 site immunoradiometric assay samples reduced
and alkylated and added to microtitre wells coated with monoclonal antibody J13 6B6)
Follow-up 100% karyotyping.
Aim of study To examine whether the maternal serum concentration of ProMBP was influenced by
the presence of a Down’s syndrome fetus. To evaluate its potential as a screening marker
for Down’s syndrome in the first and second trimester of pregnancy. To examine the
performance characteristics of a serum screening programme using ProMBP in combi-
nation with age as risk markers
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
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Christiansen 1999 (Continued)
Acceptable reference standard?
All tests
Yes Karyotyping.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
Yes All women had the same reference standard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results
Index test results blinded?
All tests
Unclear Unclear if index tests interpreted without
knowledge of reference standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice.
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements.
Withdrawals explained?
All tests
No No details of withdrawals given.
Christiansen 2004
Clinical features and settings Routine screening.
Participants 334 participants: 156 cases, 546 control samples (348 control women, 198 of these were
sampled from the same women in first and second trimesters)
Denmark.
Dates not specified.
Pregnant women.
Singleton pregnancies.
4-20 weeks’ gestation.
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 156 cases.
Reference standard: CVS (for 120 of cases of Down’s) or follow-up to birth (for 36 of
cases of Down’s)
Index and comparator tests Maternal age.
Frozen serum samples tested for:
First/second trimester hCG and AFP (AutoDELFIA analytical system)
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Christiansen 2004 (Continued)
First/second trimester PAPP-A and SP1 (in-house sandwich immunoassays)
First/second trimester ProMBP (2 site immunoradiometric assay (IRMA))
First/second trimester free ßhCG and some AFP (dual label kit)
Follow-up The Danish Cytogenetic Central Registry was routinely used to ascertain that none of
the controls were pregnancies with a chromosomally diseased fetus
Aim of study To evaluate 6 markers of fetal Down’s syndrome pregnancies (includes first trimester
markers)
Notes Unclear criteria for the selection of controls.
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowledge of index test
results
Index test results blinded?
All tests
Unclear Unclear if index tests interpretedwithout knowledge of reference
standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice.
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements.
Withdrawals explained?
All tests
No No details of withdrawals given.
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Christiansen 2005
Clinical features and settings Screening programmes for syphilis and Down’s syndrome.
Participants 108 participants: 27 cases of Down’s syndrome and 81 controls
Denmark - Statens Serum Institute.
Dates not specified.
5-11 weeks’ gestation.
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 27 cases (18 diagnosed in 2nd trimester, 9 at birth)
Reference standard: karyotyping.
Index and comparator tests Maternal age.
First trimester (week 11-14) NT.
Frozen samples tested for:
First trimester (week 5-11) 1T Inhibin A (dimer assay kit MCA 950KZZ, Serotec)
First trimester (week 5-11) ßhCG (available for some samples)
First trimester (week 5-11) PAPP-A (available for some samples) (combined PAPP-A
and B-hCG TrIFMA assay)
Risk cut-points of 1:100, 1:250 and 1:400.
Performance assessed with SPlus algorithm.
Follow-up All diagnosis were verified by karyotyping.
Aim of study To investigate whether first trimester Inhibin A can be used in the first trimester for
Down’s syndrome screening
Notes Identified through the Danish central cytogenetic registry as part of quality assurance
programme
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant pop-
ulation.
Acceptable reference standard?
All tests
Yes Karyotyping.
Partial verification avoided?
All tests
Yes All women had a reference standard.
Differential verification avoided?
All tests
Yes All women had the same reference stan-
dard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the
index test.
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Christiansen 2005 (Continued)
Reference standard results blinded?
All tests
No Reference standard interpreted with
knowledge of NT results.
Index test results blinded?
All tests
Unclear Unclear if all index tests interpreted with-
out knowledge of reference standard results
Relevant clinical information?
All tests
Yes Information available as would be in stan-
dard clinical practice.
Uninterpretable results reported?
All tests
No No details given for test failures/uninter-
pretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Christiansen 2007a
Clinical features and settings Routine screening.
Participants 183 participants: 47 cases and 136 controls matched for gestational age
Dates not reported.
Denmark - Statens Serum Institute.
Pregnant women.
Singleton pregnancies.
Median age cases 37.7 years (24-48 years) and controls 36.4 years (22-44 years)
8-14 weeks’ gestation.
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 47 cases.
Reference standards: karyotyping or follow-up to birth.
Index and comparator tests Maternal age.
Fresh serum samples tested for:
First trimester PAPP-A and free βhCG (AutoDelfia, PerkinElmer, Turku or Kryptor,
Brahms)
Frozen serum samples tested for:
First trimester human placental lactogen (hPL) (hPLELISA, enzyme immunoassay (EIA)
-1283, DRG Instruments GmBH)
Follow-up Cross-referencing with the Danish Cytogenetic Central Registry
Aim of study To examine the potential of human placental lactogen as a first trimester maternal serum
screening marker for fetal Down’s syndrome
Notes
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Christiansen 2007a (Continued)
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of some index
test results
Index test results blinded?
All tests
Unclear Unclear if all index tests interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Christiansen 2009
Clinical features and settings Routine screening.
Participants 335 participants: 74 cases and 261 controls matched for length of sample storage and
maternal age
Denmark - screening programme.
Dates not reported.
Pregnant women.
Singleton pregnancies.
Median maternal age cases 37.5 years and controls 36.4 years
8-13 weeks’ gestation.
Study design Case-control study.
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Christiansen 2009 (Continued)
Target condition and reference standard(s) Down’s syndrome: 74 cases.
Reference standards: karyotyping or follow-up to birth.
Index and comparator tests Maternal age.
First trimester NT (details not reported).
Fresh serum samples tested for:
First trimester PAPP-A and free ßhCG (AutoDelfia, PerkinElmer, Turku or Kryptor,
Brahms)
Frozen serum samples tested for:
First trimester placental growth hormone (PGH) (double monoclonal ELISA, DSL-10-
19 200, Diagnostic Systems Laboratory Inc)
First trimester growth hormone binding protein (GHBP) (Enzyme-amplified ELISA,
DSL-10-48 100, Diagnostic Systems Laboratory Inc)
Follow-up Cross-referencing with the Danish Cytogenetic Central Registry
Aim of study To examine the potential of placental growth hormone and growth hormone binding
protein as maternal serum screening markers for Down’s syndrome
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of some index
test results
Index test results blinded?
All tests
Unclear Unclear if all index tests interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
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Christiansen 2009 (Continued)
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Christiansen 2010
Clinical features and settings Routine screening.
Participants 531 participants: 28 cases and 503 controls.
Denmark - screening programme.
Dates not specified.
Pregnant women.
Singleton pregnancies.
Median age cases 36 years (range 25-44 years) and controls 29 years (range 17-45 years)
8-14 weeks’ gestation.
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 28 cases.
Reference standards: karyotyping or follow-up to birth.
Index and comparator tests Maternal age.
First trimester NT (details not reported).
First trimester PAPP-A and free ßhCG (details not reported).
First trimester ADAM12s (AutoDELFIA/Delfia ADAM12 Research kit 4025-0010,
PerkinElmer Life and Analytical Sciences, on the 1235 AutoDELFIA automatic im-
munoassay system)
Follow-up Cross-referencing with the Danish Cytogenetic Central Registry
Aim of study To examine the efficiency of a second generation assay for ADAM12
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Yes All women received a reference standard.
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Christiansen 2010 (Continued)
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of some index
test results
Index test results blinded?
All tests
Unclear Unclear if all index tests interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Cowans 2010
Clinical features and settings Routine screening.
Participants 445 participants: 70 cases and 375 controls matched for storage time and gestational age
January 2007-October 2008.
UK.
Pregnant women.
Singleton pregnancies.
Mean maternal age cases 37.0 years (IQR 32.9-40.5 years) and controls 32.4 years (IQR
29.0-35.9 years)
11-13 weeks’ gestation.
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 70 cases.
Reference standards: karyotyping or follow-up to birth.
Index and comparator tests Maternal age.
First trimester NT (FMF certified sonographers).
Fresh serum samples tested for:
First trimester PAPP-A and free ßhCG (Kryptor analyser, Brahms)
Frozen serum samples tested for:
First trimester placental growth factor (PlGF) (Solid-phase, two-site fluoroimmuno-
metric research assay (4083-0010) on 6000 DELFIA Xpress random access platform,
PerkinElmer)
Modelled on UK 2002 population data.
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Cowans 2010 (Continued)
Follow-up Karyotype and results for pregnancy outcome were received from cytogenetics laborato-
ries and maternity units where deliveries took place
Aim of study To examine placental growth factor levels in first trimester maternal serum in trisomy 21
pregnancies and to investigate the potential value of PlGF in a first trimester screening
test
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of some index
test results
Index test results blinded?
All tests
Unclear Unclear if all index tests interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
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Crandall 1993
Clinical features and settings High-risk referral for invasive testing.
Participants 893 participants.
USA - 3 centres.
Dates not specified.
Pregnant women, 90% > 35 years.
11-15 weeks’ gestation.
Study design Retrospective cohort.
Target condition and reference standard(s) Down’s syndrome: 11 cases.
Reference standard: amniocentesis.
Index and comparator tests Maternal age.
Frozen samples tested for:
First trimester serum AFP (Tandem E kit).
First trimester serum uE3 (Amerlex M).
First trimester serum hCG (Hybritech tandem E kit).
Follow-up 100% karyotyping.
Aim of study To investigate whether hCG is a useful predictor of Down’s syndrome between 11 and
15 weeks’ gestation
Notes Unclear criteria for the selection of controls.
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes Amniocentesis.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
Yes All women had the same reference standard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results
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Crandall 1993 (Continued)
Index test results blinded?
All tests
Unclear Unclear if index tests interpreted without
knowledge of reference standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
Yes 33 samples excluded because out of the date
range or insufficient sample volume or infor-
mation
Withdrawals explained?
All tests
No No details of withdrawals given.
Crossley 2002a
Clinical features and settings Routine screening.
Participants 17,229 participants.
UK - 15 centres.
Dates not specified.
Pregnant women with median age 29.9 years, 15.4% ≥ 35 years.
10-14 weeks’ gestation.
Study design Prospective cohort study.
Target condition and reference standard(s) Down’s syndrome: 45 cases.
Reference standards: CVS offered where women had high NT measurements, amnio-
centesis or follow-up to birth
Index and comparator tests Maternal age.
NT (FMF method) in 73% of patients.
Clotted blood samples tested for:
Free ßhCG and PAPP-A (Kryptor analyser) in 98.4% of patients
Follow-up Reported that the outcome of all pregnancies was followed up
Aim of study To evaluate the use of ultrasound measurements of fetal NT obtained in a routine
antenatal clinic setting in combination with appropriate biochemical markers as a first
trimester screening test for Down’s syndrome
Notes
Table of Methodological Quality
Item Authors’ judgement Description
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Crossley 2002a (Continued)
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population .
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes Report average success rate of NT (72.9%).
Withdrawals explained?
All tests
Yes Numbers of patients not undergoing NT and biochemical test-
ing given
De Graaf 1999a
Clinical features and settings High-risk referral for invasive testing.
Participants 292 participants (207 participants before 14 weeks’ gestation): 37 cases and 255 controls
matched for maternal age (within 2 years), gestational age (within 2 weeks) and duration
of sample storage (within 2 months)
The Netherlands - single centre.
1994-1997.
Pregnant women.
9-15 weeks’ gestation (in a few cases, blood samples for serum testing taken at 15-19
weeks)
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 37 cases (30 affected pregnancies in women with serum testing en-
rolled before 14 weeks’ gestation)
Reference standards: CVS or amniocentesis.
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De Graaf 1999a (Continued)
Index and comparator tests Maternal age.
First trimester NT (FMF methods) with cut off > 3 mm.
Frozen serum samples tested for:
First trimester free ßhCG and AFP (DELFIA dual labelled time resolved fluorescent
assay)
First trimester serum PAPP-A (DELFIA research assay (CR61-105))
First trimester serum AFP.
Follow-up 100% karyotyping.
Aim of study To determine the expected detection rate and false positive rate for Down’s syndrome
achievable by early pregnancy screening with combined measurements of serum PAPP-
A, free beta hCG and fetal NT, with the addition of AFP
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes Karyotyping.
Partial verification avoided?
All tests
Yes All women had a reference standard.
Differential verification avoided?
All tests
Yes All women had the same reference standard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge
of some index test results
Index test results blinded?
All tests
Unclear Unclear if all index tests interpreted without
knowledge of reference standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice.
Uninterpretable results reported?
All tests
Yes Failed to measure NT in 11 control women.
Withdrawals explained?
All tests
No No details of withdrawals given.
82First trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Forest 1995
Clinical features and settings Routine screening.
Participants 1023 participants (512 first trimester participants).
Canada - 6 centres.
June 1989-October 1993.
Pregnant women.
23 cases of Down’s syndrome (12 in of women recruited first trimester and 11 in second
trimester)
1000 control samples (100 for each gestational week from 9-18) matched to the age of
the original cohort in which Down’s cases were detected (n = 14,612)
Mean maternal age 29.1 (SD 4.7) years, 10.7% aged ≥ 35 years
Singleton pregnancies.
9-13 (first trimester) and 14-18 (second trimester) weeks’ gestation
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 12 cases (first trimester).
Reference standards: follow-up to birth.
Index and comparator tests Maternal age.
Frozen serum samples tested for:
First trimester AFP and total hCG (Enzymum-Test enzyme immunoassay analyser, ES-
300 analyser)
First trimester uE3 (ultra sensitive radioimmunometric assay)
First trimester free αhCG and free ßhCG (radioimmunometric assays)
3 different models used for risk calculation (Wald, Spencer and Ryall)
Follow-up Review of maternal and neonatal charts in each centre.
Aim of study Evaluate the impact of risk estimation parameters for screening for Down’s syndrome
during the first and second trimesters of pregnancy
Notes 3 different models used for risk calculation (Wald, Spencer and Ryall)
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Follow-up to birth.
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard.
Differential verification avoided?
All tests
Unclear Unclear if women received different reference standards.
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Forest 1995 (Continued)
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowledge of index test
results
Index test results blinded?
All tests
Unclear Unclear if index tests interpretedwithout knowledge of reference
standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Forest 1997
Clinical features and settings Routine screening.
Participants 518 participants.
Canada - 6 centres.
June 1989-January 1995.
Pregnant women.
18 cases of Down’s syndrome.
500 control samples (representative of the cohort from which they were taken: n = 10,
160)
100 for each gestational week from 9-13 weeks.
Mean maternal age 27.9 years, 10.7% aged ≥ 35 years.
Singleton pregnancies.
9-13 weeks’ gestation at enrolment.
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 18 cases.
Reference standards: follow-up to birth.
Index and comparator tests Maternal age.
Frozen serum samples tested for:
First trimester PAPP-A (fluorescence-linked immunosorbent assay)
First trimester free ßhCG (radioimmunometric assay, Bioclone Australia)
Risk cut-point 1:384.
Follow-up Review of maternal and neonatal charts in each centre and consulting the database of
the local cytogenetic laboratories
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Forest 1997 (Continued)
Aim of study To confirm the usefulness of free ßhCG and AFP as first trimester screening markers in
a prospective study
Notes Exclusion of cases of babies that died before 20 weeks’ gestation. Unclear criteria (apart
from age) for the selection of controls
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Follow-up to birth.
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard.
Differential verification avoided?
All tests
Unclear Unclear if women received different reference standards.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowledge of index test
results
Index test results blinded?
All tests
Unclear Unclear if index tests interpretedwithout knowledge of reference
standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice.
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Gyselaers 2005
Clinical features and settings Routine screening.
Participants 13,267 participants (13,207 participant received both NT test and serum testing)
Belgium - multicentre study (35 centres).
First Jan 2004-First April 2004 (data added to previous database from before 2003)
Pregnant women.
Singleton pregnancies.
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Gyselaers 2005 (Continued)
Study design Prospective cohort.
Target condition and reference standard(s) Down’s syndrome: 26 cases.
Reference standards: amniocentesis, CVS and postnatal karyotyping
Index and comparator tests Maternal age.
First trimester serum PAPP-A (ELISA 2397, DRG International Inc)
First trimester serum free ßhCG (free ßhCG IRMA K1P1001, BioSource Europe SA)
Second trimester PAPP-A and free ßhCG.
First trimester NT.
Risk cut-points of 1:200 and 1:300.
Follow-up Follow-up to birth reported by mail by obstetricians. Non-responding obstetricians con-
tacted personally to obtain missing data. Cases of miscarriages (n = 49) and other fetal
chromosomal abnormalities excluded from the study. Unclear if other patients were lost
to follow-up
Aim of study To evaluate the performance of a first trimester fetal aneuploidy screening programme
Notes Women with miscarriages or cases of other chromosomal defects were excluded from the
study. 9 live births of babies with Down’s syndrome
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
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Gyselaers 2005 (Continued)
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice.
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements.
Withdrawals explained?
All tests
Yes Numbers of women excluded due to miscarriage or other chro-
mosomal defects and numbers not undergoing NT and bio-
chemical testing reported
Haddow 1998
Clinical features and settings High-risk referral for invasive testing.
Participants 3217 participants.
USA - 16 prenatal diagnostic centres.
June 1994 to November 1996.
Pregnant women aged 15-51 years (median 37 years).
Singleton pregnancies.
9-14 weeks’ gestation.
Study design Prospective cohort study.
Target condition and reference standard(s) Down’s syndrome: 48 cases.
Reference standards: amniocentesis or CVS.
Index and comparator tests Maternal age.
Fresh serum sample tested for:
First trimester serum hCG (hCG MAIA clone assay).
First trimester serum PAPP-A (enzyme-linked immunosorbent assay, Dako)
First trimester free ßhCG and AFP - Fluoroimmunoassay (DELFIA hAFP/Free beta
hCG dual kit)
First trimester uE3 (Ultrasensitive uE3 kit).
Follow-up 100% karyotyping.
Aim of study To further examine the efficacy of serum and ultrasound screening for Down’s syndrome
in the first trimester and the possible advantages and disadvantages of screening at this
time rather than in the second trimester
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
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Haddow 1998 (Continued)
Acceptable reference standard?
All tests
Yes Karyotyping.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
Yes All women had the same reference standard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge
of index test results
Index test results blinded?
All tests
Yes Index test interpretedwithout knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements.
Withdrawals explained?
All tests
No No details of withdrawals given.
Kagan 2009
Clinical features and settings Routine screening.
Participants 56,954 participants with available outcome data.
UK - multicentre study.
July 1999 - April 2007.
Pregnant women.
Singleton pregnancies.
Mean maternal age 35.4 years (14.1-52.2 years).
11-13 weeks’ gestation.
Study design Prospective cohort.
Target condition and reference standard(s) Down’s syndrome: 395 cases.
Reference standards: karyotyping or follow-up to birth.
Index and comparator tests Maternal age.
First trimester NT.
First trimester fetal heart rate (pulsed-wave Doppler).
First trimester nasal bone (FMF certified sonographers).
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Kagan 2009 (Continued)
First trimester ductus venous flow (FMF certified sonographers)
First trimester flow across tricuspid valve (FMF certified sonographers)
First trimester PAPP-A and free ßhCG (Kryptor, Brahms AG or Delfia Express, Perkin
Elmer)
Multiple publications with different test evaluations.
Follow-up Karyotype results and details of pregnancy outcome were added to databases as they
became available. Women without complete screening and outcome data (n = 3053, 5.
1%) were excluded from the study
Aim of study To examine the performance of first-trimester screening for trisomies 21, 18 and 13 by
maternal age, fetal NT thickness, fetal heart rate and maternal serum free ß-hCG and
PAPP-A
Other objectives in related publications.
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
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Kagan 2009 (Continued)
Withdrawals explained?
All tests
No No details of withdrawals given.
Kornman 1998
Clinical features and settings High-risk referral for invasive testing.
Participants The Netherlands - antenatal diagnosis unit.
October 1990-February 1994.
Pregnant women.
15 cases of Down’s syndrome.
97 control samples (matched on gestational age, sample storage time and maternal age)
Singleton pregnancies.
8-12 weeks’ gestation.
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 15 cases.
Reference standard: CVS.
Index and comparator tests Maternal age.
Frozen serum samples tested for:
First trimester serum SP1 (modified commercial radioimmunoassay, RIA-gnost SP1))
Follow-up 100% karyotyping.
Aim of study To compare SP1 levels in Down’s syndrome versus normal pregnancies
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes CVS.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
Yes All women received the same reference stan-
dard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
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Kornman 1998 (Continued)
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results
Index test results blinded?
All tests
Unclear Unclear if index test interpretedwithout knowl-
edge of reference standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Kozlowski 2007 GC
Clinical features and settings Routine referral.
Participants 6906 participants with complete outcome data.
Germany - gynaecologists practices.
January 2000-December 2003.
Pregnant women.
Median maternal age 32 years (15-48 years), 26.4% ≥ 35 years
11-14 weeks’ gestation.
Study design Cohort study.
Target condition and reference standard(s) Down’s syndrome: 19 cases.
Reference standard: karyotyping or follow-up to birth.
Index and comparator tests Maternal age.
First trimester NT (FMF certified gynaecologists).
First trimester free ßhCG and PAPP-A (Kryptor analyser, Brahms)
Risk cut-point 1:300.
Follow-up Data on pregnancy outcome were obtained by contacting the patient or their general
gynaecologist. Women without complete outcome data (36%) were excluded from the
study
Aim of study To evaluate and compare the screening performance for fetal trisomy 21 in the first
trimester of pregnancy in general gynaecologists practices and specialised centres for
prenatal care in Germany
Notes
Table of Methodological Quality
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Kozlowski 2007 GC (Continued)
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
Yes 146 women (including 11 with Down’s syndrome) excluded as
results could not be assigned to gynaecologists or prenatal centre
group.
Kozlowski 2007 PC
Clinical features and settings Routine referral.
Participants 3862 participants with complete outcome data.
Germany - tertiary level prenatal centres.
January 2000-December 2003.
Pregnant women.
Median maternal age 34 years (14-46 years), 43.2% ≥ 35 years
11-14 weeks’ gestation.
Study design Cohort study.
Target condition and reference standard(s) Down’s syndrome: 26 cases.
Reference standard: karyotyping or follow-up to birth.
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Kozlowski 2007 PC (Continued)
Index and comparator tests Maternal age.
First trimester NT (FMF certified sonographers).
First trimester free ßhCG and PAPP-A (Kryptor analyser, Brahms)
Risk cut-point 1:300.
Follow-up Data on pregnancy outcome were obtained by contacting the patient or their general
gynaecologist. Women without complete outcome data (8%) were excluded from the
study
Aim of study To evaluate and compare the screening performance for fetal trisomy 21 in the first
trimester of pregnancy in general gynaecologists practices and specialised centres for
prenatal care in Germany
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
Yes 146 women (including 11 with Down’s syndrome) excluded as
results could not be assigned to gynaecologists or prenatal centre
group.
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Krantz 2000
Clinical features and settings Routine screening.
Participants 10,251 participants.
USA.
September 1995 to June 1998.
Pregnant women.
Singleton pregnancies.
Maternal age 34.7% ≥ 35 years.
No diabetes.
9-13 weeks’ gestation.
Study design Prospective cohort..
Target condition and reference standard(s) Down’s syndrome: 50 cases (33 had undergone biochemical testing)
Reference standard: not reported.
Index and comparator tests Maternal age.
Dried blood samples tested for:
First trimester NT in 5809 patients (FMF methods).
First trimester free ßhCG and PAPP-A in 10,251 patients (enzyme-linked immunosor-
bent assay procedures)
Follow-up No details of follow-up reported.
Aim of study To assess the effectiveness of free ßhCG, PAPP-A and NT for first-trimester screening
for Down’s syndrome and trisomy 18
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Unclear Unclear reference standard.
Partial verification avoided?
All tests
Unclear Unclear if all patients had a reference standard.
Differential verification avoided?
All tests
Unclear Unclear if choice of reference depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
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Krantz 2000 (Continued)
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements.
Withdrawals explained?
All tests
No No details of withdrawals given.
Kratzer 1991
Clinical features and settings High-risk referral for invasive testing.
Participants 141 participants.
USA.
Dates not stated.
Pregnant women.
Controls matched for maternal age.
Singleton pregnancies.
9-12 weeks’ gestation.
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 17 cases
Reference standard: CVS
Index and comparator tests Frozen serum samples tested for:
First trimester hCG and free ßhCG (double antibody radio-immunoassay)
First trimester free αhCG (radio-immunoassay, monoclonal antibody, Biomerica Inc)
First trimester progesterone (radio-immunoassay).
Follow-up 100% karyotyping.
Aim of study To present evidence on the value of first trimester serum assays as an early, non-invasive
screen for aneuploidy
Notes
Table of Methodological Quality
Item Authors’ judgement Description
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Kratzer 1991 (Continued)
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes CVS.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
Yes All women received the same reference stan-
dard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results
Index test results blinded?
All tests
Yes Index tests interpreted without knowledge of
reference standard results (index tests con-
ducted blind to outcome)
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice.
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Laigaard 2003
Clinical features and settings Routine screening.
Participants 172 participants (18 cases of Down’s syndrome and 154 controls)
Denmark - University hosp1T ITAl.
Dates not specified.
Pregnant women.
Singleton pregnancies.
8-13 weeks’ gestation.
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 18 cases.
Reference standards: karyotyping, unclear reference standard for controls
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Laigaard 2003 (Continued)
Index and comparator tests Frozen serum tested for:
First trimester ADAM12 (ELISA, 6E6 and 8F8 antibodies).
Follow-up No details of follow-up reported.
Aim of study To determine whether ADAM12 concentration is a useful indicator of fetal health
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Unclear Unclear reference standard in controls.
Partial verification avoided?
All tests
Unclear Unclear if all women had a reference standard.
Differential verification avoided?
All tests
No Different reference standards used.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowledge of index test
results
Index test results blinded?
All tests
Unclear Unclear if index test interpreted without knowledge of reference
standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
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Macintosh 1993
Clinical features and settings High-risk referral for invasive testing.
Participants 692 participants.
UK and Italy.
Dates not specified.
Pregnant women.
Median maternal age 38 years (27-40 years).
Singleton pregnancies.
6-12 weeks’ gestation.
Study design Retrospective cohort study.
Target condition and reference standard(s) Down’s syndrome: 14 cases.
Reference standard: CVS.
Index and comparator tests Maternal age.
Frozen serum tested for:
First trimester serum SP1 (Radioimmunoassay).
Follow-up 100% karyotyping.
Aim of study To examine the relationship between first trimester maternal serum SP1 and the kary-
otype of the pregnancy and to quantify its potential use as a screening test
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes CVS.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
Yes All women received the same reference stan-
dard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results
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Macintosh 1993 (Continued)
Index test results blinded?
All tests
Unclear Unclear if index test interpretedwithout knowl-
edge of reference standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice.
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements.
Withdrawals explained?
All tests
No No details of withdrawals given.
Muller 2003a
Clinical features and settings Routine screening.
Participants 5694 pregnant women who had first trimester NT and biochemical testing
France - 9 centres serving 12 maternity units.
January 1998-June 2001.
Singleton pregnancies.
Maternal age not reported.
11-13 weeks’ gestation.
Study design Retrospective cohort study.
Target condition and reference standard(s) Down’s syndrome: 26 cases.
Reference standards: invasive testing (offered to women with high NT measurement) or
follow-up to birth
Index and comparator tests Maternal age.
First trimesterNT in 98%of patients (methods not specified. 60 sonographers - 2 trained
by FMF, who trained 30 in turn. 8 externally trained in France. 20 were self-taught.
Machines not specified)
Frozen serum tested for:
First trimester PAPP-A (99% of patients), free ßhCG 99% of patients and AFP (93%
of patients) (time-resolved fluorescent assay, Perkin-Elmer Life sciences)
Risk cut-point 1:250.
Follow-up Data from the French national screening programme used for follow-up at birth. 211
women (3.7%) who did not return after NT or were found to be > 14 weeks were
excluded. It is unclear how many patients had follow-up to birth
Aim of study Prospective study of NT and retrospective evaluation of serum (in same patient popu-
lation) to evaluate whether or not to move the national French Down’s screening pro-
gramme to a first trimester programme
Notes FMF methods - some self-taught sonographers.
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Muller 2003a (Continued)
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard.
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice .
Uninterpretable results reported?
All tests
Yes Women with NT too small to measure assumed to have NT of
< 0.5 mm
Withdrawals explained?
All tests
Yes Women failing to return or who more than 14 weeks’ pregnant
were excluded (214)
Nebiolo 1990
Clinical features and settings High-risk referral for invasive testing.
Participants 492 participants.
Italy.
Dates not specified.
Pregnant women, approximately 75% were aged ≥ 35 years.
Singleton pregnancies.
8-12 weeks’ gestation.
Study design Retrospective cohort study.
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Nebiolo 1990 (Continued)
Target condition and reference standard(s) Down’s syndrome: 9 cases.
Reference standard: CVS.
Index and comparator tests Frozen serum tested for:
First trimester serumAFPandbeta/alpha hCGratio (simultaneous sandwichmonoclonal
based radioimmunoassay)
Follow-up 100% karyotyping.
Aim of study To determine the efficacy of combined maternal serum AFP and hCG screening in
detecting chromosome defects in the first trimester of pregnancy
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes CVS.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
Yes All women received the same reference stan-
dard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results
Index test results blinded?
All tests
Yes Index test interpretedwithout knowledge of ref-
erence standard results (biochemical tests con-
ducted blind to pregnancy outcome)
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice.
Uninterpretable results reported?
All tests
Yes Samples from 48 patients were either no longer
available or had been stored at 4oC and were
discarded.
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Nebiolo 1990 (Continued)
Withdrawals explained?
All tests
No No details of withdrawals given.
Niemimaa 2001a
Clinical features and settings Routine screening.
Participants 2515 participants.
Finland - primary care centres and maternity clinics of hospitals
During 1999.
Pregnant women, 17.5% ≥ 35 years.
10-13 weeks’ gestation.
Study design Prospective cohort.
Target condition and reference standard(s) Down’s syndrome: 8 cases.
Reference standards: invasive testing (patients considered high risk based on NT screen-
ing) or follow-up to birth
Index and comparator tests Maternal age.
First trimester NT (≥ 3 mm) (64% of women) (method not described)
Fresh serum tested for:
First trimester free ßhCG and PAPP-A (Wallac analytes and 1st trimester risk calculation
programme Maternal weight correction)
Risk cut-point 1:250.
Follow-up Follow-up data from maternity clinics and the National Research and Development
Centre for Welfare and Health. Test negative patients followed up by contacting all
maternity clinics and the National Research and Development Centre for Welfare and
Health. Unclear if follow-up information was obtained in all cases
Aim of study To evaluate efficacy of combining first trimester maternal serum and fetal NT measure-
ment in screening for Down’s syndrome in Finland
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard.
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Niemimaa 2001a (Continued)
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements.
Withdrawals explained?
All tests
No No details of withdrawals given.
Noble 1995
Clinical features and settings Routine screening in a high-risk population.
Participants 2529 participants.
UK.
October 1994 to April 1995.
Singleton pregnancies.
Pregnant women.
Median maternal age 34 years (15-47 years), 47% ≥ 35 years.
10-14 weeks’ gestation.
Study design Prospective cohort.
Target condition and reference standard(s) Down’s syndrome: 61 cases.
Reference standards: karyotyping performed (27% of women) due to increased NT
(14%), advanced maternal age (10%), previous chromosomally abnormal child (0.5%)
or parental anxiety (2%).Ultrasound examination at 20weeks (65%of patients). Follow-
up to birth (9% of women)
Index and comparator tests Maternal age.
First trimester NT (methods not stated).
Fresh serum (or serum frozen over a weekend) tested for:
First trimester free ßhCG (immunoradiometric assay, CIS).
Follow-up Pregnancy outcome obtained from maternity units or the patients themselves. Follow-
up information only appears to have been obtained in 9% of cases (second trimester
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Noble 1995 (Continued)
ultrasound used as reference standard for other women)
Aim of study To measure the contribution of maternal serum free ßhCG in a screening programme
for fetal trisomy 21 based on fetal NT in the first trimester of pregnancy
Notes No proper results, data are presented for this study.
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant pop-
ulation.
Acceptable reference standard?
All tests
No Invasive testing, ultrasound at 20 weeks or
follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference
standard.
Differential verification avoided?
All tests
No Choice of reference standard depended on
index test results.
Incorporation avoided?
All tests
Yes Reference standard was independent of the
index test.
Reference standard results blinded?
All tests
No Reference standard interpreted with
knowledge of index test results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge
of reference standard results
Relevant clinical information?
All tests
Yes Information available as would be in stan-
dard clinical practice.
Uninterpretable results reported?
All tests
No No details given for test failures/uninter-
pretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Noble 1997
Clinical features and settings Routine screening, women self-referred for first trimester NT
Participants 876 participants.
UK - Research Centre for Fetal Medicine.
Dates not stated.
104First trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Noble 1997 (Continued)
76 cases of Down’s syndrome.
800 controls matched for maternal and gestational age.
Pregnant women.
Median maternal age 34 years (15-47 years).
Singleton pregnancies.
10-14 weeks’ gestation.
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 76 cases.
Reference standards: CVS, follow-up to birth not reported.
Index and comparator tests Maternal age.
Frozem serum tested for:
First trimester serum Inhibin A (ELISA).
Fresh serum (or serum stored over weekend) tested for:
First trimester serum free ßhCG (immunoradiometric assay, CIS France)
Follow-up Details of methods of follow-up not reported.
Aim of study To determine the relationship between maternal serum first trimester Inhibin A and
free ßhCG concentrations in chromosomally normal pregnancies and to compare 2
biochemical markers for their sensitivity in identifying trisomy 21 pregnancies
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant pop-
ulation.
Acceptable reference standard?
All tests
Unclear Unclear what the reference standard was.
Partial verification avoided?
All tests
Unclear Unclear if all women had a reference stan-
dard.
Differential verification avoided?
All tests
Unclear Unclear if the reference standard differed
between women.
Incorporation avoided?
All tests
Yes Reference standard was independent of the
index test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without
knowledge of index test results
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Noble 1997 (Continued)
Index test results blinded?
All tests
Yes Index test interpreted without knowledge
of reference standard results (biochemical
tests conducted blind to pregnancy out-
come).
Relevant clinical information?
All tests
Yes Information available as would be in stan-
dard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninter-
pretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
O’Leary 2006
Clinical features and settings Routine screening.
Participants 22,340 participants.
Australia - 13 ultrasound practices.
August 2001 to October 2003.
Singleton pregnancies.
Pregnant women aged 14-47 years (median 31 years), 20% ≥ 35 years
11-13 weeks’ gestation.
Study design Prospective cohort.
Target condition and reference standard(s) Down’s syndrome: 60 cases.
Reference standards: CVS or amniocentesis (women assessed to be high risk on screening)
, or follow-up to birth
Index and comparator tests Maternal age.
First trimester NT (FMF methods).
First trimester free ßhCG and PAPP-A (machine not stated).
All study participants underwent all tests.
Risk cut-point 1:300.
Follow-up Follow-up data obtained by review of the Midwives Notification System and the Birth
Defects Registry. 415 patients (1.8%) excluded due to no follow-up data. Patients with
multiple pregnancies or incomplete screens (n = 3946) were also excluded from the study
Aim of study To assess fetal outcomes for pregnancies identified at increase risk for Down’s syndrome
by first trimester combined ultrasound examination and maternal serum biochemistry
Notes Appears likely that patients with miscarriages and terminations excluded
Table of Methodological Quality
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O’Leary 2006 (Continued)
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
Unclear Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements.
Withdrawals explained?
All tests
Yes Details given of patients excluded due to incomplete screening
data or loss to follow-up
Orlandi 1997
Clinical features and settings Routine screening of general- and high-risk women.
Participants 2,010 participants (744 in subgroup undergoing NT testing).
Italy.
Dates not reported.
Recruited through private physician or genetic counselling program for women of ad-
vanced maternal age
Pregnant women aged 15-46 years, 35% > 35 years.
Singleton pregnancies.
9-13 weeks’ gestation.
Study design Cohort.
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Orlandi 1997 (Continued)
Target condition and reference standard(s) Down’s syndrome: 11 cases (7 in subgroup with NT testing).
Reference standards: not reported.
Index and comparator tests Maternal age.
First trimester NT (37% of patients) (FMF methods, Toshiba SSA 250A or Acuson XP
10)
First trimester free ßhCGandPAPP-A (all patients) (dried blood samples, enzyme-linked
immunosorbent assays)
Risk cut-point 1:380.
Follow-up Not reported.
Aim of study To evaluate first trimester combined screening for Down’s syndrome
Notes Unclear as to what reference standard (if any) was used. All cases of Down’s syndrome
identified had been picked up by screening
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant pop-
ulation.
Acceptable reference standard?
All tests
Unclear Reference standard not reported.
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference
standard.
Differential verification avoided?
All tests
Unclear Unclear if the choice of reference standard
depended on screening results
Incorporation avoided?
All tests
Yes Reference standard was independent of the
index test.
Reference standard results blinded?
All tests
No Reference standard interpreted with
knowledge of index test results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge
of reference standard results
Relevant clinical information?
All tests
Yes Information available as would be in stan-
dard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninter-
pretable measurements
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Orlandi 1997 (Continued)
Withdrawals explained?
All tests
Yes Details given of women undergoing NT
but not biochemical testing
Palomaki 2007
Clinical features and settings Routine screening.
Participants 10,775 participants.
Canada - General Hospital.
October 2003-November 2004.
Pregnant women.
Mean maternal age 32.3 years (SD 4.6 years).
10-13 weeks’ gestation.
Study design Prospective cohort.
Target condition and reference standard(s) Down’s syndrome: 23 cases.
Reference standards: karyotyping or follow-up to birth.
Index and comparator tests Maternal age.
First trimester NT (encouraged to only accept measurements from sonographers with
FMF certification)
First trimester PAPP-A (AutoDELFIA, PerkinElmer).
First trimester hyperglycosylated-hCG (Nichols Advantage Specialty system, Nochols
Institute Diagnosics)
Follow-up From electronic record searches of local patient and cytogenetic records and case finding
of local and regional birth records
Aim of study To validate Down’s syndrome screening protocols that include hyperglycosylated-hCG
measurements
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard.
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Palomaki 2007 (Continued)
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Qin 1997
Clinical features and settings Routine screening.
Participants 702 participants.
Copenhagen.
Dates not specified.
Pregnant women.
156 cases of Down’s syndrome (25 in weeks 3-9 and 131 in weeks 10-20 gestation)
546 controls (260 in weeks 3-9 and 286 in weeks 10-20 gestation)
5-20 weeks’ gestation.
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 25 cases (3-9 weeks’ gestation).
Reference standards: CVS, amniocentesis, karyotyping at birth, unclear reference stan-
dard for controls
Index and comparator tests Frozen serum tested for:
First trimester schwangerschaftsprotein 1 (SP1) (non-competitive time-resolved im-
munofluorometric assay, A131, DAKO A/S))
Follow-up No details of follow-up reported.
Aim of study To assess the potential of the maternal concentration of schwangerschaftsprotein 1 as a
marker for Down’s syndrome pregnancies
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Qin 1997 (Continued)
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Unclear Unclear if all women received reference standard.
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowledge of index test
results
Index test results blinded?
All tests
Unclear Unclear if index test interpreted without knowledge of reference
standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Sahota 2010
Clinical features and settings Routine screening.
Participants 10,854 pregnancies with complete outcome data.
China - University Hospital.
January 2005-May 2008.
Pregnant women.
Singleton pregnancies.
Median maternal age 33.1 years, 30.1% of women aged ≥ 35 years
10-13 weeks’ gestation.
Study design Retrospective cohort.
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Sahota 2010 (Continued)
Target condition and reference standard(s) Down’s syndrome: 32 cases.
Reference standards: karyotyping or follow-up to birth.
Index and comparator tests Maternal age.
First trimester NT (FMF accredited sonographers, HDI 5000, Philips Medical System)
First trimester PAPP-A and free ßhCG (kryptor analyser, Brahms Diagnostica GmbH)
Follow-up Fetal karyotypes were entered into a database when information was available. Data on
pregnancy outcomes were obtained from either a local maternity database (for those who
delivered in the unit) or via telephone calls to patients
Aim of study To assess the relative performance of a multi-stage first trimester screening protocol for
fetal Down’s syndrome
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
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Schaelike 2009
Clinical features and settings Routine screening.
Participants 10,668 participants with complete outcome data.
Germany - Private centre.
Pregnant women.
November 2000-December 2006.
Singleton pregnancies.
Maternal age ≥ 35 years in 31.0% of women.
11-13 weeks’ gestation.
Study design Prospective cohort.
Target condition and reference standard(s) Down’s syndrome: 59 cases.
Reference standards: karyotyping or follow-up to birth.
Index and comparator tests Maternal age.
First trimester NT (FMF certified physicians).
First trimester PAPP-A and free ßhCG (Kryptor analyser, Brahms GmbH)
Cut-point 1:300.
Follow-up Information provided by either obstetric departments or obstetricians. Results obtained
from CVS and amniocentesis, as well as karyotypes from aborted fetal tissue or postnatal
investigations. 3.9% of women were lost to follow-up and were excluded from the study
Aim of study To assess the performance of a combined first trimester screening concept for trisomies
21, 18 and 13 applied to a low- and high-risk patient sample in a specialised private
centre for prenatal medicine.
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
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Schaelike 2009 (Continued)
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Scott 2004
Clinical features and settings Routine screening.
Participants 2053 participants.
Australia - Private practice (Sydney Ultrasound for Women).
July 2000 to May 2002.
Pregnant women 15-44 years (median 32 years).
Singleton pregnancies.
11-14 weeks’ gestation.
Study design Prospective cohort study.
Target condition and reference standard(s) Down’s syndrome: 5 cases.
Reference standards: invasive testing or follow-up to birth.
Index and comparator tests Maternal age.
First trimester NT (FMF methods, sagittal plane, ATL 5000; Philips)
First trimester free ßhCG and PAPP-A (kryptor analyser, Brahms Diagnostics)
All participants had all tests.
Risk cut-point 1:300.
Follow-up Data obtained from referring doctors or patients via letter, phone or completed feedback
form given at the time of consultation. Only cases of known outcome included in the
study. 68 (1.3%) lost to follow-up, largely due to miscarriage (n = 20) and loss to follow-
up (n = 40)
Aim of study To report the sensitivity of combined first trimester biochemistry and ultrasound screen-
ing for Down’s syndrome in an Australian private practice specialising in obstetric ultra-
sound
Notes Only women having biochemical testing before NT were included in the study. This was
done to avoid bias from women declining biochemical testing following negative NT
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Scott 2004 (Continued)
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice.
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
Yes No details of withdrawals given.
Spencer 1999a
Clinical features and settings Women referred for invasive testing or self-referred for screening
Participants 1156 participants.
UK - Fetal medicine research centre.
Dates not specified.
210 cases of Down’s syndrome, maternal age 19-46 (median 38 years)
946 controlsmatched for gestational andmaternal age,maternal age 15-47 years (median
age 36 years)
10-14 weeks’ gestation.
Study design Case-control study.
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Spencer 1999a (Continued)
Target condition and reference standard(s) Down’s syndrome: 210 cases.
Reference standards: invasive testing (high-risk women) or follow-up to birth
Index and comparator tests Maternal age.
First trimester NT (methods not reported).
First trimester free ßhCGandPAPP-A (Kryptor analyser, time resolved amplified cryptate
emission (TRACE))
Follow-up Details of methods for follow-up to birth not reported.
Aim of study To examine the potential impact of combining maternal age with fetal NT thickness and
maternal serum free ßhCG and PAPP-A in screening for trisomy 21 at 10-14 weeks of
gestation
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as
done in practice.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
No Choice of reference standard depended on
index test results.
Incorporation avoided?
All tests
Yes Reference standard was independent of the
index test.
Reference standard results blinded?
All tests
No Reference standard interpreted with
knowledge of index test results
Index test results blinded?
All tests
Unclear Unclear if all index tests interpreted with-
out knowledge of reference standard results
Relevant clinical information?
All tests
Yes Information available as would be in stan-
dard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninter-
pretable measurements.
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Spencer 1999a (Continued)
Withdrawals explained?
All tests
No No details of withdrawals given.
Spencer 2002a
Clinical features and settings Routine screening.
Participants 278 participants.
UK - Single hosp1T ITAl study (OSCAR screening program).
Samples collected since 1998.
54 cases of Down’s syndrome, maternal age 20-44 years, median 36 years
224 controls (no details of selection), maternal age16-41 years, median 30 years
11-13 weeks’ gestation..
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 54 cases.
Reference standards: no description given.
Index and comparator tests Maternal age.
First trimester NT (FMF methods).
First trimester free ßhCG, PAPP-A and ThCG (Kryptor Analyser (TRACE) and auto-
mated immunofluorescent assays)
All women underwent all tests.
Follow-up Methods for follow-up to birth not reported.
Aim of study To assess serum hyperglycosylated hCG for use in the first trimester of pregnancy as a
marker of Down’s syndrome
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth (Nicolaides ref (OSCAR)).
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results.
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Spencer 2002a (Continued)
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Unclear Unclear of all index tests interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice.
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Torring 2010
Clinical features and settings Routine screening.
Participants 691 participants: 46 cases and 645 controls.
Denmark - nationwide screening programme.
Dates not reported.
Pregnant women.
Singleton pregnancies.
Mean maternal age cases 35 years, controls 31 years.
8-11 weeks’ gestation.
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 46 cases.
Reference standards: karyotyping or follow-up to birth.
Index and comparator tests Maternal age.
First trimester NT (11-13 weeks’ gestation) (FMF certified sonographers)
Fresh serum tested for:
First trimester PAPP-A and free ßhCG (8-11 weeks’ gestation) (Kryptor analyser,
Brahms)
Frozen serum tested for:
First trimester ADAM12s (8-11 weeks’ gestation) (Kyptor analyser, assay by Cezanne
SAS, TRACE technology)
Follow-up Details not reported.
Aim of study To determine whether ADAM12s is a useful serum marker for fetal trisomy 21 using
the mixture model
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Torring 2010 (Continued)
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of some index
test results
Index test results blinded?
All tests
Unclear Unclear if all index tests interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Tsukerman 1999
Clinical features and settings Routine screening.
Participants 1595 participants.
Belarus.
Started January 1996.
Pregnant women.
1,564 controls matched for gestational age and duration of storage
8-13 weeks’ gestation.
Study design Case-control study.
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Tsukerman 1999 (Continued)
Target condition and reference standard(s) Down’s syndrome: 31 cases.
Reference standards: karyotyping, karyotyping at birth, follow-up to birth not reported
Index and comparator tests Frozen or fresh serum tested for:
First trimester free ßhCG, AFP and PAPP-A (DELFIA, EG&G Wallac Oy)
Follow-up No details of follow-up reported.
Aim of study To report results of a large population study looking at AFP, free ßhCG and PAPP-A in
the first trimester of pregnancy among women having routine ultrasound dating as part
of NT assessment
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard.
Differential verification avoided?
All tests
No Women received different reference standards.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of some index
test results
Index test results blinded?
All tests
Unclear Unclear if all index tests interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice.
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements.
Withdrawals explained?
All tests
No No details of withdrawals given.
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Valinen 2007
Clinical features and settings Routine screening
Participants 7534 participants.
Finland - screening programme.
2002-2004.
Pregnant women.
Singleton pregnancies.
Mean maternal age 29.6 years, 18.6% ≥ 35 years.
10-12 weeks’ gestation.
Study design Retrospective cohort.
Target condition and reference standard(s) Down’s syndrome: 30 cases (24 underwent NT as well as biochemical testing)
Reference standards: karyotyping or follow-up to birth.
Index and comparator tests Maternal age.
First trimester NT (trained nurses, midwives and doctors) (4765 women)
First trimester PAPP-A and free ßhCG (details not reported) (7534 women)
Cut-point 1:250.
Follow-up Contacted chromosome laboratory at the department of clinical genetics in the Oulu
university clinic and the Finish Register of Congenital Malformation and the National
Research and Development Centre for Welfare and Health
Aim of study To compare the efficacy of both separate and combined maternal serum testing and
fetal NT measurement in the first trimester screening for Down’s syndrome in northern
Finland
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard.
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
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Valinen 2007 (Continued)
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Valinen 2009
Clinical features and settings Routine screening.
Participants 279 participants: 53 cases and 226 controls matched for maternal and gestational age
and sample storage time
Finland - screening programme.
May 2002-December 2007.
Pregnant women.
Maternal age not reported.
9-13 weeks’ gestation.
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 53 cases (in 5 cases, NT not measured).
Reference standards: karyotyping or follow-up to birth.
Index and comparator tests Maternal age.
Fresh serum tested for:
First trimester PAPP-A and free ßhCG (details not reported).
Frozen serum tested for:
First trimester ADAM12 (DELFIA/AutoDELFIA ADAM12 research kit, PerkinElmer
Wallac)
Cut-point 1:250.
Follow-up Details not reported.
Aim of study To investigate whether incorporating the measurement of ADAM12 in the risk calcula-
tion program LifeCycle can improve Down’s syndrome screening in the first trimester
Notes
Table of Methodological Quality
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Valinen 2009 (Continued)
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Unclear Unclear if all index tests interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Van Lith 1992
Clinical features and settings High-risk referral for invasive testing.
Participants 1372 participants (24 cases and 1348 controls, criteria for matching not reported)
The Netherlands - 6 prenatal diagnostic centres.
Dates not stated.
Pregnant women.
Less than 13 weeks’ gestation.
Study design Case-control study (changed from cohort).
Target condition and reference standard(s) Down’s syndrome: 24 cases.
Reference standard: CVS.
Index and comparator tests Frozen serum rested for:
Total hCG (IMx hCG assay, Abbott).
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Van Lith 1992 (Continued)
Follow-up 100% karyotyping.
Aim of study To assess the value ofMS-hCG in the first trimester of pregnancy in screening for Down’s
syndrome
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes CVS.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
Yes All women received the same reference stan-
dard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results
Index test results blinded?
All tests
Yes Index test interpretedwithout knowledge of ref-
erence standard results (biochemical measure-
ment conducted blind to pregnancy outcome)
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
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Wald 2003a
Clinical features and settings Routine screening.
Participants 606 participants.
UK and Austria - multicentre trial.
September 1996 to April 2000.
Pregnant women: 101 cases, 505 controls matched for gestation, duration of storage and
centre
9-13 and 14-20 weeks’ gestation.
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 101 cases.
Reference standards: invasive testing (following second trimester screening) or follow-
up to birth
Index and comparator tests First trimesterNT (midsagittal section, optimal magnification of thickness of translucent
space between inner skin surface and fascia covering cervical spine (white black interface
(outer) - black white interface (inner), 41 models of ultrasound machine, 20 minutes
allotted scanning time)
First and second trimester serum AFP, hCG, uE3, PAPP-A, free ßhCG (time resolved
fluoroimmunoassay, AutoDELFIA)
First and second trimester inhibin A (Sandwich enzyme linked immunosorbent assay,
Oxford bioinnovation)
First and second trimester urinary beta core fragment, total hCG, ITA and free ßhCG
(ITA and beta core fragment, Quest diagnostics USA)
Follow-up Follow-up by: 1) Staff at local hospitals completed a study outcome form at, or just
after delivery, 2) Study records of CVS, amniocentesis or karyotype at birth linked to
information from cytogenic laboratories, 3) Study records linked to records of cases
of Down’s syndrome from the National Down’s Syndrome Cytogenetic Register, 4)
Information obtained from local obstetrical outcome records, 5) Forms sent to all women
with a request to return details of the outcome of their pregnancy, 6) individual searches
in respect of women whose outcomes of pregnancy had not been obtained by any of the
previous methods. 96% birth/karyotype full outcome documentation obtained
Aim of study To identify the most effective, safe and cost-effective strategy for antenatal screening for
Down’s syndrome using NT, maternal serum and urine markers in the first and second
trimesters of pregnancy and maternal age in various combinations
Notes Performance of screening assessed at 17 weeks’ gestation. Study tried to be non-interven-
tional in the first trimester - second trimester testing was aimed to be used as the basis
for any referral for invasive testing
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
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Wald 2003a (Continued)
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard.
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Unclear Unclear if all index tests interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes Rates of NT failure on average 9%. pre-10 weeks’ gestation, >
33% failure rate, declined to 7% at 12 weeks
Withdrawals explained?
All tests
No No details of withdrawals given.
Wallace 1995
Clinical features and settings Routine screening.
Participants 112 participants.
UK.
Dates not stated.
Pregnant women.
23 cases (maternal age 22-44 years, mean 32 years).
89 controls matched for gestational age and duration of sample storage (maternal age
19-38 years, mean 28 years)
11-13 weeks’ gestation.
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 23 cases.
Reference standard: not reported.
Index and comparator tests Frozen serum tested for dimeric first trimester Inhibin A (enzyme-linked two-site im-
munoassay)
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Wallace 1995 (Continued)
Follow-up Methods of follow-up not reported.
Aim of study To evaluate dimeric first trimester inhibin A as a possible first trimester screening marker
for Down’s syndrome screening
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Unclear Unclear reference standard.
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard.
Differential verification avoided?
All tests
Unclear Unclear if the reference standard differed between women.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowledge of index test
results
Index test results blinded?
All tests
Unclear Unclear if index test interpreted without knowledge of reference
standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements.
Withdrawals explained?
All tests
No No details of withdrawals given.
Wapner 2003
Clinical features and settings Routine screening.
Participants 8216 participants.
USA - multicentre study (12 prenatal diagnostic centres).
Dates not specified.
Singleton pregnancies.
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Wapner 2003 (Continued)
Pregnant women with mean age 35 years (SD 4.6), 50% ≥ 35 years
11 to 14 weeks’ gestation.
Study design Prospective cohort.
Target condition and reference standard(s) Down’s syndrome: 61 cases.
Reference standards: invasive testing, miscarriage with cytogenetic testing, follow-up to
birth
Index and comparator tests Maternal age.
First trimester NT (FMF methods).
Dried blood samples tested for:
First trimester free ßhCG and PAPP-A (dried blood samples, enzyme-linked immunoad-
sorbent assay as previously described)
Risk cut-point 1:270.
Follow-up Follow-up to birth by directly following up women and reviewing delivery records. An
effort was also made to obtain information on terminated or miscarried pregnancies.
196 (2.3%) of patients without follow-up information were excluded
Aim of study To evaluate the use of combined first trimester markers for aneuploidy in clinical practice
Notes 16 live Down’s syndrome births.
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
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Wapner 2003 (Continued)
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
Yes No details of withdrawals given.
Weinans 2005
Clinical features and settings High-risk referral for invasive testing.
Participants 344 participants.
The Netherlands - antenatal diagnosis unit.
1999-2002.
Pregnant women with mean age 38 years (SD 2.7 years) for cases and 37 years (SD 3.0)
for controls
24 cases, 320 controls matched for maternal and gestational age and length of storage
Singleton pregnancies.
9 to 11 weeks’ gestation.
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 24 cases.
Reference standard; CVS.
Index and comparator tests Maternal age.
Frozen serum samples tested for:
First trimester serum free ßhCG and PAPP-A (fluoroimmunoassay, Auto Delfia, Perkin
Elmer)
First trimester maternal serum ITA (immunochemiluminometric assay, Nichols Advan-
tage platform)
Follow-up 100% karyotyping.
Aim of study To investigate Down’s syndrome screening performance of serum ITA before 12 weeks’
gestation and compare it with performance of PAPP-A and free ßhCG in the same sample
set
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
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Weinans 2005 (Continued)
Acceptable reference standard?
All tests
Yes CVS.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
Yes All women received the same reference stan-
dard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results
Index test results blinded?
All tests
Unclear Unclear if index tests interpreted without
knowledge of reference standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements.
Withdrawals explained?
All tests
No No details of withdrawals given.
Wojdemann 2005
Clinical features and settings Referrals for screening.
Participants 8622 participants (6441 with serum screening).
Denmark - 3 obstetrics departments.
March 1998 to June 2001
Pregnant women with mean age 29 years, 10.8% ≥ 35 years.
Singleton pregnancies.
11 to 14 weeks’ gestation.
Study design Prospective cohort.
Target condition and reference standard(s) Down’s syndrome: 12 cases.
Reference standards: invasive testing (in cases of increased risk) or follow-up to birth
Index and comparator tests Maternal age.
First trimester NT (all patients) (FMF methods, Logic 700 MR machine)
First trimester free ßhCG (AFP/ßhCG Auto Delfia kit) and PAPP-A (In-house ELISA
(Sandwich)) in 6,441 patients (75%)
Risk cut-point 1:250.
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Wojdemann 2005 (Continued)
Follow-up Cross-checking with all the chromosome laboratories in Denmark. Follow-up in 96.2%
of pregnancies through patients records
Aim of study To determine the performance of screening for Down’s syndrome and other major chro-
mosomal abnormalities using NT, free ßhCG and PAPP-A in a prospective study of a
non-selected population
Notes Uptake of screening was 73% (9941 accepted out of 13,621 offered screening)
Women with miscarriages excluded from the study.
3 live Down’s syndrome births.
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard.
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpretedwithout knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes NT could not be measured in 2.5% of cases.
Withdrawals explained?
All tests
No No details of withdrawals given.
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Zaragoza 2009
Clinical features and settings Routine screening.
Participants 699 participants: 90 cases and 609 controls matched for length of storage
UK - single centre.
Dates not reported.
Pregnant women.
Singleton pregnancies.
Median maternal age cases 37.9 years (19.1-46.5 years), controls 32.7 years (16.1-45.2
years)
11-13 weeks’ gestation.
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 90 cases.
Reference standards: karyotyping or follow-up to birth.
Index and comparator tests Maternal age.
Fresh samples tested for:
First trimester PAPP-A and free ßhCG (Delfia Express system, PerkinElmer, Waltham)
Frozen samples tested for:
First trimester PlGF (ELISA, Quantikine human PlGF immunoassay, R&D systems
Europe Ltd)
Follow-up Karyotype results and details on pregnancy outcome were added to database as soon as
they became available
Aim of study To investigate the potential value of maternal serum placental growth factor (PlGF) in
first trimester screening from trisomy 21 and other major chromosomal abnormalities
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
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Zaragoza 2009 (Continued)
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Unclear Unclear if all index tests interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
AFP: alpha-fetoprotein
αhCG: alpha human chorionic gonadotrophin
ßhCG: beta human chorionic gonadotrophin
CVS: chorionic villus sampling
ELISA: enxyme-linked immunosorbent assay
FMF: Fetal Medicine Foundation
GHBP: growth hormone binding protein
hCG: human chorionic gonadotrophin
ITA: invasive trophoblast antigen
IQR: interquartile range
NT: nuchal translucency
PAPP-A: Pregnancy-associated plasma protein A
PGH: placental growth hormone
PIGF: placental growth factor
PROMBP: proform of eosinophil major basic protein
SD: standard deviation
SP 1: Schwangerschafts protein 1
uE3: unconjugated oestriol
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abbas 1995 Unable to extract useful data.
Abdul-Hamid 2004 No Down’s syndrome pregnancies.
Abraha 1999 Unable to extract useful data.
Abu-Rustum 2010 Not Down’s syndrome specific.
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Achiron 2010 Study only includes cases of Down’s syndrome.
Adekunle 1999 Unable to extract useful information.
Agaard-Tillery 2010 Results presented in another study.
Aitken 1993 Unable to extract useful data.
Aitken 1996a Fewer than 80% of pregnancies had gestational age confirmed by USS
Aitken 1996b Fewer than 80% of pregnancies had gestational age confirmed by USS
Ajayi 2011 No diagnostic data.
Akbas 2001 Less than 5 Down’s syndrome pregnancies.
Alexioy 2009 Study only includes test positives.
Allingham-Hawkins 2011 Quantitative fluorescent polymerase chain reaction study.
American College 2009 Discussion article.
Antona 1998 Likely fewer than 80% of pregnancies dated by USS.
Antsaklis 1999 Women screened at greater than 24 weeks’ gestation.
Anuwutnavin 2009 Second trimester ultrasound.
Ashwood 1987 Unable to extract useful data.
Asrani 2005 Review article.
Audibert 2001 Unable to ascertain whether part of screening population in Rozenberg et al. No response from
authors, therefore excluded to reduce risk of data replication
Axt-Fleidner 2006 Unable to extract useful data.
Azuma 2002 Unable to extract useful data.
Baghagho 2004 Unable to obtain paper.
Bahado-Singh 1995 USS markers greater than 14 weeks’ gestation.
Bahado-Singh 1996 USS markers greater than 14 weeks’ gestation.
Bahado-Singh 1999 USS markers greater than 14 weeks’ gestation.
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Bahado-Singh 2002 USS markers greater than 14 weeks’ gestation.
Bahado-Singh 2003 Review article.
Ball 2007 Data from the FASTER trial.
Bar-Hava 2001 No Down’s pregnancies in study population.
Barkai 1996 No Down’s pregnancies in study population.
Barnabei 1995 No Down’s pregnancies in study population.
Bartels 1988 Unable to extract useful data.
Bartels 1993 No Down’s pregnancies in study population.
Barth 1991 Second trimester ultrasound study.
Bas-Budecka 2007 No diagnostic data.
Baviera 2004 Unclear method of confirmation of gestational age.
Bazzett 1998 Male versus female fetuses.
Beke 2008 Results are not specific to Down’s syndrome.
Bellver 2005 No Down’s syndrome pregnancies in study.
Benn 1995 Less than 80% follow-up.
Benn 1996 Less than 80% follow-up.
Benn 1997 No Down’s pregnancies in study population.
Benn 1998 Less than 80% follow-up.
Benn 2001 Statistical modelling (computer simulation).
Benn 2002 Modelled data.
Benn 2003a Less than 80% of pregnancies dated by USS.
Benn 2003b Editorial.
Benn 2005a No Down’s pregnancies included.
Benn 2005b Mathematical model.
135First trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Benn 2007 No follow-up information.
Berry 1995 Less than 80% of pregnancies USS dated.
Berry 1997 Less than 80% of pregnancies USS dated.
Bersinger 1994 Gestational age not USS estimated.
Bersinger 2000 Unable to extract useful data.
Bersinger 2001 No Down’s syndrome pregnancies in study population.
Bersinger 2003 Unable to extract useful data.
Bersinger 2004 No Down’s syndrome pregnancies in study population.
Bersinger 2005 No Down’s syndrome pregnancies in study population.
Bestwick 2008 All healthy pregnancies.
Biggio 2004 Cost-effectiveness analysis.
Bilardo 2011 Not a proper sample - most had elevated NT.
Bindra 2002 Review article.
Blundell 1999 Unable to extract useful data.
Boormans 2010 Study of testing on amniocentesis samples.
Boots 1989 Population risk factor calculations.
Bornstein 2009a No diagnostic data.
Bornstein 2009b No diagnostic data.
Bornstein 2010 No diagnostic data.
Borowski 2007 No diagnostic data.
Borrell 2007 No follow-up data.
Borruto 2002 Unable to extract useful data.
Bottalico 2009 Second trimester ultrasound.
Boue 1990 Review article.
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Bradley 1994 Screen negative population gestations not confirmed by ultrasound
Braithwaite 1996 Review article.
Brambati 1995 USS screening inclusive of women greater than 14 weeks’ gestation
Brambati 1996 Review article.
Brizot 1995a Unable to extract useful data.
Brizot 1995b Unable to extract useful data.
Brizzi 1989 Second trimester ultrasound.
Brock 1990 Unable to extract useful data.
Calda 2010 No data for false positive rates.
Campogrande 2001 Unable to extract useful data.
Canick 1988 Unable to extract useful data.
Canick 1995 Unable to extract useful data.
Canini 2002 No Down’s syndrome pregnancies in study population.
Cans 1998 Second trimester ultrasound.
Carreras 1991 Second trimester ultrasound.
Caughey 2007 No diagnostic data.
Cebesoy 2008 No diagnostic data.
Chelli 2008 No follow-up for false negatives.
Chen 1999 Review article.
Chen 2002 No Down’s syndrome pregnancies in study population.
Chen 2004 Less than 5 Down’s cases in study population.
Chen 2005 Unable to extract useful data.
Chen 2008 No diagnostic data.
Cheng 1993 Likely that fewer than 80% of gestational age confirmed by USS
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Cheng 1999 Case series. No Down’s syndrome pregnancies in study population
Cheng 2004a No Down’s syndrome pregnancies in study population.
Cheng 2004b No Down’s syndrome pregnancies in study population.
Chitayat 2002 Less than 5 Down’s cases in study population.
Chiu 2011 Study of maternal DNA testing.
Cho 2009 Study of testing amniotic fluid.
Chou 2009 Not possible to calculate specificity.
Christiansen 2002 Unable to extract useful data.
Christiansen 2007b Unable to extract useful data.
Christiansen 2008 No diagnostic data.
Chung 2000 Less than 5 Down’s syndrome pregnancies in study population.
CNGOF 1996 Unable to obtain translation.
Cole 1996 Review article.
Comas 2001 USS at greater than 14 weeks.
Comas 2002a USS at greater than 14 weeks.
Comas 2002b USS at greater than 14 weeks.
Comstock 2006 Unable to extract useful data.
Conde 1998 Review article.
Cowans 2011 No diagnostic data.
Crossley 1991 Less than 80% of pregnancies had gestational age confirmation by ultrasound
Crossley 1993 Less than 80% of pregnancies had gestational age confirmation by ultrasound
Crossley 1996 No Down’s syndrome pregnancies in study population.
Crossley 2002b Adjustment factors for smokers.
Cuckle 1984 Gestational age not confirmed by USS.
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Cuckle 1987a Gestational age not confirmed by USS.
Cuckle 1987b No gestational age limits given.
Cuckle 1990 Paper presenting adjustment factors.
Cuckle 1996 Data modelled on 4 meta-analysed studies.
Cuckle 1999a Unable to extract useful data.
Cuckle 1999b Review article.
Cullen 1990 Abnormal scans only in study population.
Cusick 2004 Less than 5 Down’s syndrome pregnancies in study population.
Cusick 2007 Second trimester ultrasound.
D’Ottavio 1997 Second trimester USS.
Dancoine 2001 No Down’s syndrome pregnancies in study population.
Dane 2008 Not specific to Down’s syndrome.
De Biasio 2000 Unable to extract useful information.
De Biasio, 1999 Unable to ascertain whether overlapping populations between several papers - attempted to contact
author with no response
De Biasio, 2001 Unable to ascertain whether overlapping populations between several papers - attempted to contact
author with no response
De Graaf 1991 Unable to extract useful data.
De Graaf 1999b Modelled data.
Del Carmen Saucedo 2009 No follow-up information.
DeVore 2001 Second trimester ultrasound.
Dhaifalah 2007a Unable to obtain translation.
Dhaifalah 2007b Unable to obtain translation.
Dhallan 2007 DNA testing of blood samples from parents.
Dickerson 1994 Comment.
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Dimaio 1987 Gestational age by USS only in screen-positive population.
Doran 1986 Ultrasound confirmation of gestational age performed in screen positive women only
Dreux 2008 No information for specificity.
Drugan 1996a Second trimester ultrasound.
Drugan 1996b Unable to extract useful data.
Drysdale 2002 Fewer than 5 Down’s syndrome pregnancies in population.
Dugoff 2008 Not specific to Down’s syndrome.
Ebell 1999 Review article.
Economides 1998 Unable to extract useful data.
Erickson 2004 No Down’s syndrome pregnancies in population.
Evans 1996 No Down’s syndrome pregnancies in population.
Evans 2007 Data previously presented in another study.
Falcon 2005 Unable to extract useful data.
Falcon 2006 Unable to extract useful data.
Ford 1998 Audit.
Frishman 1997 No Down’s syndrome pregnancies in population.
Fukada 2000 Unable to extract useful data.
Gaudry 2009 Study of karyotyping.
Gebb 2009 Study only examines screen positives.
Geerts 2008 Study only examines abnormal fetuses.
Geipel 2010 Second trimester ultrasound.
Gekas 2009 Diagnostic data from other studies.
Gekas 2011a Diagnostic data from other studies.
Gekas 2011b Diagnostic parameters from other studies.
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Gerovassili 2007 No diagnostic data.
Ghidini 1998 Comparison of male versus female fetuses.
Goetzinger 2010 Second trimester ultrasound.
Goldie 1995 Fewer than 80% of study population and gestational age confirmed by USS
Gollo 2008 Only one case of Down’s syndrome.
Gonçalves 2004 Greater than 14 weeks USS screening.
Goodburn 1994 Likely that fewer than 80% of pregnancies had gestational age estimated by USS
Gorduza 2007 Study of FISH technique.
Grace 2010 Second trimester ultrasound.
Grati 2010 No diagnostic data.
Gray 2009 Second trimester ultrasound.
Gregor 2007 Unable to obtain translation.
Gregor 2009 Unable to obtain translation.
Grether 2009 Systematic review and guidelines.
Grozdea 2002 Unable to extract useful data.
Guo 2010 Study of fetal samples.
Gyselaers 2004a Less than 80% follow-up.
Gyselaers 2004b Less than 80% follow-up.
Gyselaers 2006a Unaffected pregnancies only.
Gyselaers 2006b Unable to extract useful data.
Hackshaw 1995 No Down’s syndrome pregnancies in population.
Hackshaw 2001 No Down’s syndrome pregnancies in population
Haddow 1992 Less than 80% of pregnancies had gestational age confirmed by ultrasound scan
Hadzsiev 2007 Study of FISH technique.
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Hafner 1995 Less than 5 Down’s pregnancies in study population.
Hallahan 1998 Gestational age greater than 24 weeks.
Han 2008 Study of findings on amniocentesis.
Harper 2010 Second trimester ultrasound.
Harrison 2006 Less than 80% of pregnancies had gestational age confirmed by ultrasound scan
Harry 2006 Editorial.
Hayashi 1995 Unable to extract useful data.
Hayashi 1996 Less than 5 Down’s pregnancies in study population.
Heikkila 1997 Fewer than 80% of pregnancies had gestational age confirmed by USS
Heinig 2007 No Down’s syndrome data.
Heinonen 1996 No Down’s syndrome pregnancies in population.
Herman 2000 No Down’s syndrome pregnancies in study population.
Herman 2003 Correlation between markers, not evaluation of screening tests
Herrou 1992 Unable to extract useful data.
Hershey 1985 Gestation unclear.
Hershey 1986 Gestation based on LMP.
Hewitt 1993 Unable to extract useful data.
Hills 2010 Study of testing on CVS and amniocentesis samples.
Ho 2010 Study of FISH diagnosis.
Hogdall 1992 Unclear method of determination of gestational age. Unable to extract useful data
Hong Kong Practitioner CME.
Hoogendoorn 2008 Diagnostic data from other studies used.
Howe 2000 Second trimester ultrasound scans.
Hsiao 1991 Unable to obtain translation.
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Hsieh 1999 No Down’s syndrome pregnancies in study population.
Hsu 1997 Adjustment factors.
Hsu 1998 No Down’s syndrome pregnancies in study population.
Hsu 1999 No Down’s pregnancies.
Hu 2007 Same data as Liu 2010.
Huang 2003 No Down’s syndrome pregnancies in study population.
Huang 2007a Not possible to obtain detection rate.
Huang 2007b No diagnostic data.
Huggon 2004 Study of cardiac function in pregnancies with normal and abnormal NT results
Hui 2003 No Down’s syndrome pregnancies in population.
Hui 2005 No Down’s syndrome pregnancies in population.
Hultén 2004 Editorial/commentary.
Hung 2003 Modelling.
Hung 2008 Second trimester ultrasound.
Hurley 1993 Unable to extract useful data.
Huttly 2004 No Down’s syndrome pregnancies in population.
Hwa 2004 Less than 5 Down’s pregnancies in population.
Iles 1996 Review.
Ind 1994 Unable to extract useful data.
Ivorra-Deleuze 2010 No diagnostic data.
Jakobsen 2011 Not Down’s syndrome specific.
Jean-Pierre 2005 Review article.
Johnson 1991 Gestational age estimated by USS in fewer than 80% of cases.
Johnson 1993 Normal pregnancies only.
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Jorgensen 1999 Gestation greater than 14 weeks for USS.
Jorgez 2007 Study of DNA testing on maternal blood.
Josefsson 1998 No Down’s syndrome pregnancies in study population.
Jou 2001 Less than 5 Down’s syndrome pregnancies in study population.
Jung 2007 Second trimester ultrasound.
Kagan 2006 Screen positive pregnancies only.
Kagan 2007 No diagnostic data.
Kagan 2008 Not Down’s syndrome detection.
Kalelioglu 2007 Second trimester ultrasound.
Kautzmann 1995 Fewer than 80% pregnancies had gestational age estimated by USS
Kazerouni 2009 Not possible to obtain complete diagnostic data.
Keith 1992 Summary article.
Kelekci 2004 Less than 5 Down’s syndrome pregnancies in population.
Kellner 1995a Less than 5 Down’s syndrome pregnancies in population.
Kellner 1995b Less than 80% follow-up.Unable to ascertain proportion of population with gestational age confirmed
by USS
Kellner 1997 Assumption of normal karyotype without reference standard in significant proportion of control
pregnancies
Kirkegaard 2008 False positive rate only calculated for subset of the cohort
Kjaergaard 2008 Unable to obtain translation.
Knight 1990 Review article.
Knight 2001 Validation of a specific assay.
Knight 2005 Less than 80% of pregnancies had gestational age confirmed by ultrasound scan
Koos 2006 Review article.
Kornman 1996 Less than 5 Down’s syndrome pregnancies in population.
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Kornman 1997 Unable to extract useful information.
Kotaska 2007 No new data.
Kramer 1998 No Down’s syndrome pregnancies in study population.
Krantz 1996 Modelled data.
Krantz 2005 Adjustment factor.
Krantz 2007 Uses data from other published studies.
Kulch 1993 No Down’s cases in population.
Lai 1998 Modelled population.
Lai 2003 No Down’s syndrome pregnancies in study population.
Laigaard 2006a Unable to extract useful data.
Laigaard 2006b Simulation.
Lam 1997 Unable to extract useful data.
Lam 1998 Fewer than 80% pregnancies had gestational age estimated by USS
Lam 1999a No Down’s syndrome pregnancies in population.
Lam 1999b Unable to extract useful data.
Lam 2000 Study of women’s decisions about screening.
Lam 2001 Male versus female fetuses.
Lambert-Messerlian 1996 Fewer than 80% of pregnancies USS dated.
Lambert-Messerlian 1998 Unable to extract useful data.
Lauria 2007 No diagnostic data.
Lehavi 2005 Down’s syndrome pregnancies only.
Leung 2006 Unable to separate twins from singletons therefore unable to extract useful data
Leymarie 1993 Appears to be a review article (French).
Li 1998 Unable to obtain translation.
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Li 1999 Unable to obtain translation.
Li 2010 No diagnostic data.
Liao 1997 Unable to obtain translation.
Liao 2001 Unable to extract useful data.
Lim 2002 Second trimester ultrasound.
Lippman 1987 Editorial.
Liu 2003 Unable to obtain translation.
Liu 2010 Not possible to separate out data for cases of Down’s syndrome
Lo 2010 Pooled test results.
Lustig 1988 Gestational age by LMP only.
Luthgens 2008 False positive rate and detection rate obtained from different cohorts
MacDonald 1991 Fewer than 80% of gestational ages estimated by USS.
Macintosh 1994 Unable to extract useful data.
Macintosh 1997 Unable to extract useful data.
MacRae 2010 Pooled test results.
Macri 1994 Likely fewer than 80% evaluated for gestational age by ultrasound examination
Macri 1996 Likely fewer than 80% evaluated for gestational age by ultrasound examination
Malone 1998 Review article.
Malone 2003 Review article.
Mandryka-Stankewycz 2009 No diagnostic data.
Mangione 2001 Abnormal screening results only.
Markov 2008 Unable to obtain paper.
Maymon 2001a No Down’s syndrome pregnancies in study population.
Maymon 2001b No normal test results included therefore unable to extract meaningful data
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Maymon 2002 No Down’s syndrome pregnancies in study population.
Maymon 2004 No Down’s syndrome pregnancies in study population.
Maymon 2005 Modelled data.
McDuffie 1996 USS dating on screen positive women only.
Meier 2002 Observed versus expected cases of Down’s syndrome in a population
Merkatz 1984 Gestational age not confirmed by ultrasound scan.
Merz 2005 Editorial.
Merz 2008 Data available for only combined ultrasound marker (nuchal translucency) and serum tests
Metzenbauer 2001 Normal pregnancies only.
Metzenbauer 2002 Unable to extract useful data.
Mikic 1999 No Down’s syndrome pregnancies in study population.
Miller 1991 Unable to extract useful data.
Milunsky 1989 Fewer than 80% gestational age estimated by USS.
Milunsky 1996 Fewer than 80% gestational age estimated by USS.
Minobe 2002 Gestational age greater than specified limits.
Miron 2008 No diagnostic data.
Miron 2009 No diagnostic data.
Miron 2010 No diagnostic data.
Miyamura 1999 Unable to extract useful data.
Moghadam 1998 Unable to extract useful data.
Monni 2000 Less than 5 Down’s syndrome pregnancies.
Monni 2002 Review article.
Mooney 1994 Greater than 24 weeks’ gestation.
Muhcu 2008 No diagnostic data.
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Muller 1994 No Down’s syndrome pregnancies in study population.
Muller 1996 Unable to extract useful data.
Muller 1999 Unable to extract useful data.
Muller 2002a Gestational age greater than 24 weeks.
Muller 2002b Unable to extract meaningful data - unable to separate double- and triple-test data
Muller 2003b No Down’s syndrome pregnancies in study population.
Murta 2002 Unable to extract useful data.
Musone 2000 Unable to extract useful data.
Musto 1986 Fewer than 80% USS dated.
Myrick 1990 Unable to extract useful data.
Naidoo 2008 Not specific Down’s syndrome results.
Nau 2009a No diagnostic data.
Nau 2009b No diagnostic data.
Neveux 1996a No Down’s syndrome pregnancies in population.
Neveux 1996b Unable to extract useful data.
Ng 2004 Unable to extract useful data.
Nicolaides 1992 Study of outcomes of abnormal NT results.
Nicolaides 2000 Review article.
Nicolaides 2004 Review article.
Nicolaides 2005a Unable to obtain translation - appears to be a review article
Nicolaides 2005b Unable to obtain translation - appears to be a review article
Nicolaides 2005c Unable to obtain translation - appears to be a review article
Nicolaides 2005d Unable to obtain translation - appears to be a review article
Nicolaides 2005e Unable to obtain translation - appears to be a review article
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Nicolaides 2005f Review article.
Niemimaa 2001b No Down’s pregnancies in study population.
Niemimaa 2002 No Down’s syndrome pregnancies in population.
Niemimaa 2003 No Down’s syndrome pregnancies in population.
Noble 1997a Unable to extract useful data.
Norgaard 1990 Less than 80% of gestational ages confirmed by USS.
Norton 1992 Unable to extract useful data.
Novakov-Mikic 2007 Out of first trimester screening time frame.
O’Brien 1997a No Down’s syndrome pregnancies in population.
O’Brien 1997b No Down’s syndrome pregnancies in population.
Odibo 2004 Gestational age of greater than 14 weeks in USS population.
Odibo 2007 Second trimester ultrasound.
Odibo 2008 Second trimester ultrasound.
Odibo 2009 No results presented.
Offerdal 2008 Second trimester ultrasound.
Ognibene 1999 Unable to extract useful data.
Oh 2007 No diagnostic data.
Olajide 1989 Unable to extract useful data.
Onda 1996 Unable to extract useful data.
Onda 1998 Unable to extract useful data.
Onda 2000 Less than 80% follow-up.
Orlandi 2002 No Down’s syndrome pregnancies in study population.
Ozkaya 2010 Only healthy pregnancies.
Paladini 2007 No diagnostic data.
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Palka 1998 Twin data used in calculation of the median.
Palomaki 1989 Fewer than 80% USS dated.
Palomaki 1993 No Down’s syndrome pregnancies in population.
Palomaki 1994 No Down’s syndrome pregnancies in population.
Palomaki 1996 Meta-analysis.
Palomaki 2005 Unable to extract meaningful data.
Panburana 2001 Less than 5 Down’s syndrome pregnancies in population.
Pandya 1994 Study of outcomes of abnormal nuchal translucency results.
Pandya 1995 Review article.
Papadopoulou 2008 No diagnostic data.
Parra-Cordero 2007 Second trimester ultrasound.
Paterlini-Brechot 2007 Editorial, no new data.
Paul 2001 Unable to extract useful data.
Peralta 2005 Unable to extract useful data.
Perenc 1998 No Down’s syndrome pregnancies in study population.
Perheentupa 2002 No Down’s syndrome pregnancies in population.
Perona 1998 Smokers versus non smokers.
Persico 2008 Second trimester ultrasound.
Petervari 2000 Unable to extract useful data.
Petrocik 1989 Likely fewer than 80% USS dated.
Phillips 1992 Gestational age confirmed by USS in less than 80% of population
Phillips 1993 Gestational age confirmed by USS in less than 80% of population
Pihl 2008 Only 2 cases of Down’s syndrome.
Pinette 2003 Women screened prior to recruitment.
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Platt 2004 Unable to extract useful data.
Podobnik 1995 Abnormal results only.
Poon 2009 No diagnostic data.
Prefumo 2002 Comparison of prevalence and prediction.
Prefumo 2004 Comparison of a marker in women of different ethnic origins.
Price 1998 Unable to extract useful data.
Páez 2004 Unable to obtain translation.
Raty 2000 No Down’s syndrome pregnancies in population.
Rembouskos 2004 Unable to extract useful data.
Ren 1992 Review article.
Renier 1998 Method of ascertainment of gestational age unclear. Twin gestations included in general population
Resta 1990 Second trimester USS.
Reynders 1997 Fewer than 5 Down’s cases.
Reynolds 1989 Explanation of mathematical techniques.
Reynolds 1999 Unable to extract useful data.
Reynolds 2008 Not full diagnostic data.
Ribbert 1996 No Down’s syndrome pregnancies in study population.
Rice 2005 Down’s syndrome pregnancies excluded from study.
Rich 1991 Unable to extract useful data.
Roberts 1995 No Down’s syndrome pregnancies in study population.
Robertson 1991 Editorial.
Rode 2003 No Down’s pregnancies.
Ronge 2006 Editorial - summary of FASTER results.
Rose 1995 Review article.
151First trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Ross 1997 Review article.
Rotmensch 1996 Unable to extract useful data.
Rotmensch 1999 No Down’s syndrome pregnancies in study population.
Rozenberg 2006 USS greater than 14 weeks’ gestation.
Rudnicka 2002 No Down’s syndrome pregnancies in population.
Ryall 1992 Unable to determine method of confirmation of gestational age
Ryall 2001 High-risk results only included (i.e. no screen-negative group for comparison)
Räty 2002 No Down’s pregnancies in population.
Sabriá 2002 Unable to ascertain how numbers calculated and from which populations
Sacchini 2003 Unable to extract useful data.
Sahota 2009 No diagnostic data.
Sahota 2010a Included in Sahota 2010.
Salazar 2007 Unable to obtain paper.
Salazar 2008 Only one case of Down’s syndrome.
Saller 1997 Down’s syndrome secondary to Robertsonian translocation only. No controls
Salomon 2001 No Down’s syndrome pregnancies in population.
Salonen 1997 Fewer than 80% had gestational age estimated by USS.
Saltvedt 2005 Gestation greater than 14 weeks for nuchal scanning.
Saridogan 1996 Down’s syndrome and Edward’s syndrome affected pregnancies only
Savoldelli 1993 Unable to extract useful data.
Schielen 2009 Full study information not given.
Schiott 2006 Unable to extract useful data.
Schmidt 2007a Not specific to Down’s syndrome.
Schmidt 2007b No separate Down’s syndrome data.
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Schmidt 2007c No diagnostic data.
Schmidt 2008a Not specific to Down’s syndrome.
Schmidt 2008b Not specific to Down’s syndrome.
Schmidt 2008c Not specific to Down’s syndrome.
Schmidt 2010 No follow-up data for test negatives.
Schuchter 1998 No Down’s pregnancies in study population.
Scott 1995 Less than 5 Down’s syndrome pregnancies in study population.
Seeds 1990 Review article.
Seki 1995 No Down’s syndrome pregnancies in study population.
Shenhav 2003 No Down’s syndrome pregnancies.
Shintaku 1989 Unable to extract useful data.
Shulman 2003 No Down’s syndrome pregnancies in population.
Sieroszewski 2008 No Down’s syndrome specific information for specificity.
Simon-Bouy 1999 Review article.
Simpson 1986 Gestational age confirmed by USS in less than 80% of population
Smith 1990 Analysis of screen-positive results.
Smith 1996 Review/meta-analysis.
Smith 1999 Unable to extract useful data.
Smith-Bindman 2001 Meta-analysis of second trimester ultrasound markers.
Smith-Bindman 2003 Population study, not examining DTA.
Snijders 1995 Study of prevalence, not screening.
Snijders 1999 Study of prevalence, not screening.
Soergel 2006 Less than 80% follow-up.
Sokol 1998 Observation of Down’s prevalence stratified by age.
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Sonek 2003 Editorial.
Sonek 2007 Second trimester ultrasound.
Sood 2010 No diagnostic data.
Sooklim 2010 Second trimester ultrasound.
Spencer 1985 Fewer than 80% USS dated.
Spencer 1991a Likely fewer than 80% USS dated.
Spencer 1991b Unable to extract useful data.
Spencer 1992 Unable to extract useful data.
Spencer 1993a Fewer than 80% USS dated.
Spencer 1993b No Down’s pregnancies in study population.
Spencer 1993c Unable to extract useful data.
Spencer 1993d Fewer than 80% of pregnancies had gestational age confirmed by USS
Spencer 1993e Unable to extract useful data.
Spencer 1995 No Down’s pregnancies in population.
Spencer 1996 Fewer than 80% of pregnancies had gestational age confirmed by USS
Spencer 1997 Statistical modelling, aneuploid pregnancies only in study population
Spencer 1998a No Down’s pregnancies in population.
Spencer 1998b Unable to extract useful data.
Spencer 1999b Review.
Spencer 1999c Statistical methods paper.
Spencer 2000a Examination of median shifts rather than an evaluation of screening
Spencer 2000b No Down’s syndrome pregnancies in population.
Spencer 2000c No Down’s syndrome pregnancies in population.
Spencer 2000d No Down’s cases.
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Spencer 2000e Male versus female fetuses.
Spencer 2000f No Down’s cases in population.
Spencer 2000g No Down’s pregnancies in population.
Spencer 2000h No Down’s pregnancies in population.
Spencer 2000i Comparison of fetal sex.
Spencer 2001a No Down’s syndrome pregnancies in population.
Spencer 2001b Unable to extract useful data.
Spencer 2001c Unable to extract useful data.
Spencer 2001d Unable to extract useful data.
Spencer 2001e No Down’s syndrome pregnancies in population.
Spencer 2002b No Down’s pregnancies.
Spencer 2002c Risk validation study.
Spencer 2002d No Down’s syndrome pregnancies in population.
Spencer 2002e Demonstration of median changes with time, rather than evaluation of screening
Spencer 2003a No Down’s pregnancies in population.
Spencer 2003b No Down’s pregnancies in population.
Spencer 2003c Calculation of weight correction factor.
Spencer 2003d Fewer than 5 Down’s syndrome pregnancies.
Spencer 2004 Calculation of smoking correction factor.
Spencer 2005a No Down’s pregnancies.
Spencer 2005b No Down’s pregnancies.
Spencer 2005c Comparison of 2 different assays - not actual screening evaluation
Spencer 2008 Unable to extract appropriate data for unaffected pregnancies
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Spong 1999 Comparison of male and female fetuses.
Staboulidou 2009 No diagnostic data.
Stevens 1998 Literature review.
Stoll 1992 Review article.
Stressig 2011 Second trimester ultrasound.
Su 2002 Unable to extract useful data.
Suchet 1995 Review article.
Suchy 1990 Unable to ascertain method of confirmation of gestational age
Summers 2003a Only 55% gestational ages estimated by USS.
Summers 2003b No Down’s syndrome pregnancies in study population.
Suntharasaj 2005 Examination of inter-observer variation in NT scanning.
Susman 2010 No diagnostic data.
Sutton 2004 Unable to extract useful data.
Suzuki 1998 Unable to extract useful data.
Tabor 1987 Gestational age not confirmed by USS.
Tanski 1999 Information on screen positive pregnancies only.
Thilaganathan 1998 No Down’s syndrome pregnancies in study population.
Thilaganathan 1999 Editorial.
Tislaric 2002 No Down’s syndrome pregnancies in population.
Torok 1997 Unable to extract useful data.
Torring 2009 Not possible to obtain full diagnostic data.
Trninic-Pjevic 2007 Unable to obtain translation.
Tsai 2001 Less than 5 Down’s syndrome pregnancies in study population.
Valerio 1996 Fewer than 80% pregnancies had gestational age estimated by USS
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(Continued)
Van Blerk 1992 Unable to extract useful data.
Van Dyke 2007 Not possible to obtain full diagnostic data.
Van Heesch, 2006 No Down’s syndrome pregnancies in study population. Software comparison study
Van Lith 1991 Unable to extract useful data.
Van Lith 1993 Unable to extract useful data.
Van Lith 1994 Unable to extract useful data.
Veress 1986 Unable to extract useful data.
Veress 1988 Unable to extract useful data.
Vergani 2008 Second trimester ultrasound.
Vintzileos 2003 Second trimester USS.
Wald 1988a Less than 80% had gestational age confirmed by ultrasound.
Wald 1988b Gestational age not confirmed by USS.
Wald 1991 No Down’s pregnancies in study.
Wald 1992a Less than 80% had gestational age confirmed by ultrasound.
Wald 1992b No Down’s pregnancies in study.
Wald 1992c No Down’s pregnancies in study.
Wald 1993 No USS dating.
Wald 1994 No Down’s syndrome pregnancies in population.
Wald 1994a Review article.
Wald 1996a No Down’s pregnancies.
Wald 1996b Dated by LMP.
Wald 1996c No Down’s syndrome pregnancies in population.
Wald 1996d Gestational age greater than 24 weeks.
Wald 1997 Data modelled on 3 separate populations of women.
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(Continued)
Wald 1998 Unable to extract useful data.
Wald 1999a Unable to extract useful data.
Wald 1999b Gestational age not confirmed by USS.
Wald 1999c No Down’s syndrome pregnancies.
Wald 1999d Modelled on several studies, some of which have no USS dating
Wald 2003b No cases.
Wald 2003c Less than 80% had gestational age confirmed by USS.
Wald 2006 Modelled on SURRUS data.
Wallace 1994 Unable to extract useful data.
Wallace 1997 No Down’s syndrome pregnancies in study population.
Wang 2010 Second trimester ultrasound.
Ward 2005 Review article.
Watt 1996a No Down’s syndrome pregnancies in study population.
Watt 1996b No Down’s syndrome pregnancies in study population.
Wax 2007 No diagnostic data.
Weinans 2001 Unable to extract useful data.
Weinans 2004 Study of women’s views on screening.
Weisz 2007 Cohort split into people having different tests and non-representative samples of women assessed for
each test
Welborn 1994 Abnormal results only (cystic hygroma).
Wenstrom 1993 Less than 80% of pregnancies had gestational age confirmed by USS
Wenstrom 1995a Adjustment factors.
Wenstrom 1995b Less than 80% of pregnancies had gestational age confirmed by USS
Wetta 2011 No diagnostic data.
Whitlow 1998a Unable to extract useful data.
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(Continued)
Whitlow 1998b Unable to extract useful data.
Whitlow 1999 Unable to extract useful data.
Williamson 1994 Likely fewer than 80% USS dated.
Wilson 2000 Review.
Wojdemann 2001 No Down’s syndrome pregnancies in study population.
Wong 2003 Less than 5 Down’s syndrome pregnancies in population.
Wright 2006 Mathematical model.
Wright 2007 Simulation study, no new data.
Xie 2010 Only cases of false negatives and true negatives included.
Yagel 1998 Second trimester USS.
Yamamoto 2001a Unable to extract useful data.
Yamamoto 2001b Method of determination of gestational age unclear.
Yamamoto 2001c Unable to extract useful data.
Yaron 2001 Male versus female fetuses.
Ye 1995 Unable to obtain translation.
Yoshida 2000 Fewer than 80% pregnancies had gestational age estimated by USS
Zalel 2008 No diagnostic data.
Zeitune 1991 Only aneuploid pregnancies included in study.
Zelop 2005 No Down’s cases in population.
Zhang 2011 No diagnostic data.
Zhao 1998 Unable to obtain translation.
Zhong 2011 Second trimester ultrasound.
Zoppi 2003 Inappropriate study design.
CME: continuing medical education
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CVS: chorionic villus sampling
DTA: diagnostic test accuracy
FISH technique: fluorescence in situhybridization
LMP: last menstrual period
NT: nuchal translucency
USS: ultrasound scan
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D A T A
Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 1T PAPP-A, 5% FPR 4 2837
2 1T PAPP-A, ≤5th percentile 1 22280
3 1T PAPP-A, mixed cut-points 6 25510
4 1T free ßhCG, 5% FPR 4 4280
5 1T total hCG, 5FPR 2 2482
6 1T AFP, 5% FPR 2 2248
10 1T AFP, mixed cut-points 3 2724
11 1T Inhibin, 5FPR 3 2098
12 1T ADAM 12, 5FPR 1 579
13 1T SP1, 5% FPR 3 1080
17 ba˙hcg˙ratio, 0.25MoM 1 476
18 1T uE3, 5% FPR 1 1110
19 1T PlGF, 5FPR 1 699
20 1T PAPP-A and 1T free ßhCG,
5% FPR
2 795
21 1T PAPP-A and 1T free ßhCG,
mixed cut-points
2 795
22 1T PAPP-A and 1T AFP, 5%
FPR
1 96
23 1T PAPP-A and 1T ITA, 3%
FPR
1 344
24 1T PAPP-A and 1T ITA, 5%
FPR
1 344
25 1T free ßhCG and 1T Inhibin,
5% FPR
1 876
26 1T free ßhCG and 1T AFP, 5%
FPR
1 1138
27 1T PAPP-A and 1T ITA, 10%
FPR
1 344
28 1T PAPP-A, 1T free ßhCG
and 1T ITA, 5% FPR
1 344
29 1T PAPP-A, 1T free ßhCG
and 1T ITA,3% FPR
1 344
30 1T PAPP-A, 1T free ßhCG
and 1T ITA, 10% FPR
1 344
31 1T total hCG, 1T free αhCG
and 1T progesterone, 0.34
MoM
1 129
32 Age, 1T Inhibin, risk 1:100 1 40
33 Age, 1T Inhibin, risk 1:250 1 40
34 Age, 1T Inhibin, risk 1:400 1 40
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35 Age, 1T Inhibin, 5FPR 1 1110
36 Age, 1T Inhibin, mixed
cut-points
2 1150
37 Age, 1T PAPP-A, 5FPR 5 3491
38 Age, 1T PAPP-A, mixed
cut-points
6 13742
39 Age, 1T free ßhCG, 5FPR 7 5893
40 Age, 1T free ßhCG, risk 1:384 1 512
41 Age, 1T free ßhCG, mixed
cut-points
9 16656
42 Age, 1T total hCG,risk 1:384 1 512
43 Age, 1T total hCG, mixed
cut-points
2 1622
44 Age, 1T AFP, 5FPR 2 1397
45 Age, 1T AFP, risk1:384 1 512
46 Age, 1T AFP,mixed cut-points 3 1909
47 Age, 1T uE3, risk 1:384 1 512
48 Age, 1T uE3, mixed cut-points 2 799
49 Age, 1T free αhCG, risk 1:384 1 512
50 Age, 1T SP1, 5FPR 2 804
51 Age, 1T ProMBP, risk 1:250 1 181
52 Age, 1T ITA, 5FPR 1 278
53 Age, 1T ADAM 12, risk 1:400 2 703
54 Age, 1T PAPP-A and 1T free
ßhCG, risk 1:250
11 60484
55 Age, 1T PAPP-A and 1T free
ßhCG, 5FPR
17 49827
56 Age, 1T PAPP-A and 1T free
ßhCG, mixed cut-points
31 158878
57 Age, 1T PAPP-A and 1T
free ßhCG, mixed cut-points
without 5FPR
20 138731
58 Age, 1T total hCG and 1T
PAPP-A, 5FPR
2 4327
59 Age, 1T PAPP-A and 1T
Inhibin, risk 1:100
1 41
60 Age, 1T PAPP-A and 1T
Inhibin, risk 1:250
1 40
61 Age, 1T PAPP-A and 1T
Inhibin, risk 1:400
1 40
62 Age, 1T PAPP-A and 1T
Inhibin, 5FPR
1 1110
63 Age, 1T PAPP-A and 1T
Inhibin, mixed cut-points
2 1150
64 Age, 1T PAPP-A and 1T ITA,
5FPR
2 622
65 Age, 1T PAPP-A and 1T AFP,
5FPR
2 2705
66 Age, 1T free ßhCG and 1T
Inhibin, risk 1:100
1 40
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67 Age, 1T free ßhCG and 1T
Inhibin, risk 1:250
1 40
68 Age, 1T free ßhCG and 1T
Inhibin, risk 1:400
1 40
69 Age, 1T free ßhCG and 1T
Inhibin, 5FPR
1 1110
70 Age, 1T free ßhCG and 1T
Inhibin, mixed cut-points
2 1150
71 Age, 1T free ßhCG and 1T
AFP, 5FPR
3 2992
72 Age, 1T free ßhCG and 1T
AFP, risk 1:250
1 1656
73 Age, 1T free ßhCG and 1T
AFP, risk 1:384
1 512
74 Age, 1T free ßhCG and 1T
AFP, mixed cut-points
5 5160
75 Age, 1T AFP and 1T uE3, risk
1:384
1 512
76 Age, 1T AFP and 1T free
αhCG, risk 1:384
1 512
77 Age, 1T free ßhCG and 1T
total hCG, risk 1:384
1 512
78 Age, 1T free ßhCG and 1T
uE3, risk 1:384
1 512
79 Age, 1T free ßhCG and 1T
uE3, 5FPR
1 287
80 Age, 1T free ßhCG and 1T
uE3, mixed cut-points
2 799
81 Age, 1T free ßhCG and 1T
SP1, 5FPR
1 60
82 Age, 1T free ßhCG and 1T
SP1 risk 1:250
1 60
83 Age, 1T AFP and 1T total
hCG, 1:384
1 512
84 Age, 1T free ßhCG and 1T free
αhCG, risk 1:384
1 512
85 Age, 1T total hCG and 1T
uE3, risk 1:384
1 512
86 Age, 1T total hCG and 1T
Inhibin, 5FPR
1 1110
87 Age, 1T total hCG and 1T free
αhCG, risk 1:384
1 512
88 Age, 1T uE3 and 1T free
αhCG, risk 1:384
1 512
89 Age, 1T PAPP-A, 1T free
ßhCG and 1T AFP, 5FPR
2 2705
90 Age, 1T PAPP-A, 1T free
ßhCG and 1T AFP, mixed
cut-points
3 8188
91 Age, 1T free ßhCG, 1T AFP
and 1T uE3, 5FPR
1 287
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92 Age, 1T free ßhCG, 1T AFP
and 1T uE3, risk 1:384
1 512
93 Age, 1T free ßhCG, 1T AFP
and 1T uE3, mixed cut-points
2 799
94 Age, 1T total hCG, 1T AFP
and 1T uE3, risk 1:384
1 512
95 Age, 1T total hCG, 1T AFP
and 1T uE3, mixed cut-points
2 1505
96 Age, 1T AFP, free αhCG and
1T uE3, risk 1:384
1 512
97 Age, 1T PAPP-A, 1T free
ßhCG and 1T Inhibin, 5FPR
1 1110
98 Age, 1T PAPP-A, 1T total
hCG and 1T Inhibin, 5FPR
1 1110
99 Age, 1T PAPP-A, sp1 and 1T
ProMBP, 5FPR
1 192
100 Age, 1T PAPP-A, sp1 and 1T
ProMBP, risk 1:250
1 192
101 Age, 1T free ßhCG, 1T total
hCG, 1T AFP and 1T uE3,
risk 1:384
1 512
102 Age, 1T total hCG, 1T AFP,
1T uE3 and 1T free αhCG,
risk 1:384
1 512
103 Age, 1T PAPP-A, 1T free
ßhCG, 1T AFP, 1T uE3 and
1T Inhibin, 5FPR
1 1110
104 Age, 1T PAPP-A, 1T total
hCG, 1T AFP, 1T uE3 and 1T
Inhibin, 5FPR
1 1110
105 Age, 1T free ßhCG, 1T total
hCG, 1T AFP, 1T uE3 and 1T
free αhCG, risk 1:384
1 512
106 Age, 1T hPL, risk 1:250 1 183
107 Age, 1T hPL, 1T PAPP-A,
risk 1:250
1 183
108 Age, 1T hPL, 1T free ßhCG,
risk 1:250
1 183
109 Age, 1T hPL, 1T PAPP-A, 1T
free ßhCG, risk 1:250
1 183
110 Age, 1T PGH, risk 1:250 1 335
111 Age, 1T PGH, 1T PAPP-A ,
risk 1:250
1 335
112 Age, 1T PGH, 1T free ßhCG
, risk 1:250
1 335
113 Age, 1T PGH, 1T PAPP-A,
1T free ßhCG , risk 1:250
1 335
114 Age, 1T GHBP, risk 1:250 1 335
115 Age, 1T GHBP, 1T PAPP-A,
risk 1:250
1 335
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116 Age, 1T GHBP, 1T free
ßhCG, risk 1:250
1 335
117 Age, 1T GHBP, 1T PGH,
risk 1:250
1 335
118 Age, 1T GHBP, 1T PAPP-A,
1T free ßhCG , risk 1:250
1 335
119 Age, 1T GHBP, 1T PGH, 1T
PAPP-A, 1T free ßhCG , risk
1:250
1 335
120 Age, 1T ADAM 12, risk
1:250
1 531
121 Age, 1T ADAM 12, 1T
PAPP-A, 1T free ßhCG, risk
1:250
3 1501
122 Age, PlGF, 1T PAPP-A, 1T
free ßhCG, 5FPR
2 1144
123 Age, 1T PAPP-A and 1T free
ßhCG, risk 1:300
4 41172
124 Age, 1T PAPP-A, 1T
Hyperglycosylated hCG, 5FPR
1 10775
128 Age, ADAM 12, 1T PAPP-A,
5FPR
1 691
129 Age, ADAM 12, 1T PAPP-A,
1T free ßhCG, 5FPR
2 1222
130 Age, 1T PlGF, 5FPR 1 699
131 1T PlGF, 1T PAPP-A, 1T free
ßhCG, 5FPR
1 699
132 Age, 1T ADAM 12, 1T
PAPP-A, 1T free ßhCG, mixed
cut-points
3 1501
133 Age, 1T PAPP-A, 1T free
ßhCG and 1T Inhibin, risk
1:250
1 40
134 Age, 1T PAPP-A, 1T free
ßhCG, and 1T Inhibin, mixed
cut-points
2 1150
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Test 1. 1T PAPP-A, 5% FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 1 1T PAPP-A, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brambati 1993 8 23 6 438 0.57 [ 0.29, 0.82 ] 0.95 [ 0.93, 0.97 ]
Casals 1996 11 4 5 76 0.69 [ 0.41, 0.89 ] 0.95 [ 0.88, 0.99 ]
Spencer 1999a 80 47 130 899 0.38 [ 0.31, 0.45 ] 0.95 [ 0.93, 0.96 ]
Wald 2003a 49 51 36 974 0.58 [ 0.46, 0.68 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 2. 1T PAPP-A, ≤5th percentile.
Review: First trimester serum tests for Down’s syndrome screening
Test: 2 1T PAPP-A, ≤5
th
percentile
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brameld 2008 16 922 44 21298 0.27 [ 0.16, 0.40 ] 0.96 [ 0.96, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 3. 1T PAPP-A, mixed cut-points.
Review: First trimester serum tests for Down’s syndrome screening
Test: 3 1T PAPP-A, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brambati 1993 8 23 6 438 0.57 [ 0.29, 0.82 ] 0.95 [ 0.93, 0.97 ]
Brameld 2008 16 922 44 21298 0.27 [ 0.16, 0.40 ] 0.96 [ 0.96, 0.96 ]
Brizot 1994 20 17 25 331 0.44 [ 0.30, 0.60 ] 0.95 [ 0.92, 0.97 ]
Casals 1996 11 4 5 76 0.69 [ 0.41, 0.89 ] 0.95 [ 0.88, 0.99 ]
Spencer 1999a 80 47 130 899 0.38 [ 0.31, 0.45 ] 0.95 [ 0.93, 0.96 ]
Wald 2003a 49 51 36 974 0.58 [ 0.46, 0.68 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 4. 1T free ßhCG, 5% FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 4 1T free hCG, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Casals 1996 2 56 17 1063 0.11 [ 0.01, 0.33 ] 0.95 [ 0.94, 0.96 ]
Noble 1997 22 40 54 760 0.29 [ 0.19, 0.40 ] 0.95 [ 0.93, 0.96 ]
Spencer 1999a 69 47 141 899 0.33 [ 0.27, 0.40 ] 0.95 [ 0.93, 0.96 ]
Wald 2003a 16 51 69 974 0.19 [ 0.11, 0.29 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 5. 1T total hCG, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 5 1T total hCG, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Van Lith 1992 3 67 21 1281 0.13 [ 0.03, 0.32 ] 0.95 [ 0.94, 0.96 ]
Wald 2003a 4 51 81 974 0.05 [ 0.01, 0.12 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 6. 1T AFP, 5% FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 6 1T AFP, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Casals 1996 3 56 16 1063 0.16 [ 0.03, 0.40 ] 0.95 [ 0.94, 0.96 ]
Wald 2003a 7 51 78 974 0.08 [ 0.03, 0.16 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 10. 1T AFP, mixed cut-points.
Review: First trimester serum tests for Down’s syndrome screening
Test: 10 1T AFP, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Casals 1996 3 56 16 1063 0.16 [ 0.03, 0.40 ] 0.95 [ 0.94, 0.96 ]
Nebiolo 1990 2 31 7 436 0.22 [ 0.03, 0.60 ] 0.93 [ 0.91, 0.95 ]
Wald 2003a 7 51 78 974 0.08 [ 0.03, 0.16 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 11. 1T Inhibin, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 11 1T Inhibin, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Noble 1997 10 40 66 760 0.13 [ 0.06, 0.23 ] 0.95 [ 0.93, 0.96 ]
Wald 2003a 4 51 81 974 0.05 [ 0.01, 0.12 ] 0.95 [ 0.94, 0.96 ]
Wallace 1995 15 4 8 85 0.65 [ 0.43, 0.84 ] 0.96 [ 0.89, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
169First trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Test 12. 1T ADAM 12, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 12 1T ADAM 12, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Baviera 2010 7 28 10 534 0.41 [ 0.18, 0.67 ] 0.95 [ 0.93, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 13. 1T SP1, 5% FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 13 1T SP1, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kornman 1998 2 5 13 92 0.13 [ 0.02, 0.40 ] 0.95 [ 0.88, 0.98 ]
Macintosh 1993 6 34 8 644 0.43 [ 0.18, 0.71 ] 0.95 [ 0.93, 0.97 ]
Qin 1997 9 13 15 239 0.38 [ 0.19, 0.59 ] 0.95 [ 0.91, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
170First trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Test 17. ba˙hcg˙ratio, 0.25MoM.
Review: First trimester serum tests for Down’s syndrome screening
Test: 17 ba˙hcg˙ratio, 0.25MoM
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Nebiolo 1990 1 10 8 457 0.11 [ 0.00, 0.48 ] 0.98 [ 0.96, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 18. 1T uE3, 5% FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 18 1T uE3, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003a 11 51 74 974 0.13 [ 0.07, 0.22 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 19. 1T PlGF, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 19 1T PlGF, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Zaragoza 2009 25 30 65 579 0.28 [ 0.19, 0.38 ] 0.95 [ 0.93, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
171First trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Test 20. 1T PAPP-A and 1T free ßhCG, 5% FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 20 1T PAPP-A and 1T free hCG, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Casals 1996 7 4 9 76 0.44 [ 0.20, 0.70 ] 0.95 [ 0.88, 0.99 ]
Zaragoza 2009 61 30 29 579 0.68 [ 0.57, 0.77 ] 0.95 [ 0.93, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 21. 1T PAPP-A and 1T free ßhCG, mixed cut-points.
Review: First trimester serum tests for Down’s syndrome screening
Test: 21 1T PAPP-A and 1T free hCG, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Casals 1996 7 4 9 76 0.44 [ 0.20, 0.70 ] 0.95 [ 0.88, 0.99 ]
Zaragoza 2009 61 30 29 579 0.68 [ 0.57, 0.77 ] 0.95 [ 0.93, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 22. 1T PAPP-A and 1T AFP, 5% FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 22 1T PAPP-A and 1T AFP, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Casals 1996 13 4 3 76 0.81 [ 0.54, 0.96 ] 0.95 [ 0.88, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 23. 1T PAPP-A and 1T ITA, 3% FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 23 1T PAPP-A and 1T ITA, 3% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Weinans 2005 15 10 9 310 0.63 [ 0.41, 0.81 ] 0.97 [ 0.94, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 24. 1T PAPP-A and 1T ITA, 5% FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 24 1T PAPP-A and 1T ITA, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Weinans 2005 17 16 7 304 0.71 [ 0.49, 0.87 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 25. 1T free ßhCG and 1T Inhibin, 5% FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 25 1T free hCG and 1T Inhibin, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Noble 1997 23 40 53 760 0.30 [ 0.20, 0.42 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 26. 1T free ßhCG and 1T AFP, 5% FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 26 1T free hCG and 1T AFP, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Casals 1996 3 56 16 1063 0.16 [ 0.03, 0.40 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 27. 1T PAPP-A and 1T ITA, 10% FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 27 1T PAPP-A and 1T ITA, 10% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Weinans 2005 20 32 4 288 0.83 [ 0.63, 0.95 ] 0.90 [ 0.86, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 28. 1T PAPP-A, 1T free ßhCG and 1T ITA, 5% FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 28 1T PAPP-A, 1T free hCG and 1T ITA, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Weinans 2005 18 16 6 304 0.75 [ 0.53, 0.90 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 29. 1T PAPP-A, 1T free ßhCG and 1T ITA,3% FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 29 1T PAPP-A, 1T free hCG and 1T ITA,3% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Weinans 2005 14 10 10 310 0.58 [ 0.37, 0.78 ] 0.97 [ 0.94, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 30. 1T PAPP-A, 1T free ßhCG and 1T ITA, 10% FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 30 1T PAPP-A, 1T free hCG and 1T ITA, 10% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Weinans 2005 19 32 5 288 0.79 [ 0.58, 0.93 ] 0.90 [ 0.86, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 31. 1T total hCG, 1T free αhCG and 1T progesterone, 0.34 MoM.
Review: First trimester serum tests for Down’s syndrome screening
Test: 31 1T total hCG, 1T free hCG and 1T progesterone, 0.34 MoM
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kratzer 1991 9 5 8 107 0.53 [ 0.28, 0.77 ] 0.96 [ 0.90, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 32. Age, 1T Inhibin, risk 1:100.
Review: First trimester serum tests for Down’s syndrome screening
Test: 32 Age, 1T Inhibin, risk 1:100
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2005 2 0 10 28 0.17 [ 0.02, 0.48 ] 1.00 [ 0.88, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 33. Age, 1T Inhibin, risk 1:250.
Review: First trimester serum tests for Down’s syndrome screening
Test: 33 Age, 1T Inhibin, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2005 4 2 8 26 0.33 [ 0.10, 0.65 ] 0.93 [ 0.76, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 34. Age, 1T Inhibin, risk 1:400.
Review: First trimester serum tests for Down’s syndrome screening
Test: 34 Age, 1T Inhibin, risk 1:400
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2005 6 3 6 25 0.50 [ 0.21, 0.79 ] 0.89 [ 0.72, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 35. Age, 1T Inhibin, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 35 Age, 1T Inhibin, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003a 27 51 58 974 0.32 [ 0.22, 0.43 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 36. Age, 1T Inhibin, mixed cut-points.
Review: First trimester serum tests for Down’s syndrome screening
Test: 36 Age, 1T Inhibin, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2005 4 2 8 26 0.33 [ 0.10, 0.65 ] 0.93 [ 0.76, 0.99 ]
Wald 2003a 27 51 58 974 0.32 [ 0.22, 0.43 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 37. Age, 1T PAPP-A, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 37 Age, 1T PAPP-A, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Biagiotti 1998 16 10 16 190 0.50 [ 0.32, 0.68 ] 0.95 [ 0.91, 0.98 ]
Brambati 1993 9 23 5 438 0.64 [ 0.35, 0.87 ] 0.95 [ 0.93, 0.97 ]
Forest 1997 8 25 10 475 0.44 [ 0.22, 0.69 ] 0.95 [ 0.93, 0.97 ]
Spencer 1999a 101 47 109 899 0.48 [ 0.41, 0.55 ] 0.95 [ 0.93, 0.96 ]
Wald 2003a 57 51 28 974 0.67 [ 0.56, 0.77 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 38. Age, 1T PAPP-A, mixed cut-points.
Review: First trimester serum tests for Down’s syndrome screening
Test: 38 Age, 1T PAPP-A, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Biagiotti 1998 16 10 16 190 0.50 [ 0.32, 0.68 ] 0.95 [ 0.91, 0.98 ]
Brambati 1993 9 23 5 438 0.64 [ 0.35, 0.87 ] 0.95 [ 0.93, 0.97 ]
Forest 1997 8 25 10 475 0.44 [ 0.22, 0.69 ] 0.95 [ 0.93, 0.97 ]
Krantz 2000 19 510 31 9691 0.38 [ 0.25, 0.53 ] 0.95 [ 0.95, 0.95 ]
Spencer 1999a 101 47 109 899 0.48 [ 0.41, 0.55 ] 0.95 [ 0.93, 0.96 ]
Wald 2003a 57 51 28 974 0.67 [ 0.56, 0.77 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 39. Age, 1T free ßhCG, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 39 Age, 1T free hCG, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Biagiotti 1995 21 12 20 234 0.51 [ 0.35, 0.67 ] 0.95 [ 0.92, 0.97 ]
Biagiotti 1998 11 10 21 190 0.34 [ 0.19, 0.53 ] 0.95 [ 0.91, 0.98 ]
Brambati 1994 4 4 9 85 0.31 [ 0.09, 0.61 ] 0.96 [ 0.89, 0.99 ]
Forest 1997 6 25 12 475 0.33 [ 0.13, 0.59 ] 0.95 [ 0.93, 0.97 ]
Noble 1995 22 121 39 2306 0.36 [ 0.24, 0.49 ] 0.95 [ 0.94, 0.96 ]
Spencer 1999a 97 47 113 899 0.46 [ 0.39, 0.53 ] 0.95 [ 0.93, 0.96 ]
Wald 2003a 33 51 52 974 0.39 [ 0.28, 0.50 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 40. Age, 1T free ßhCG, risk 1:384.
Review: First trimester serum tests for Down’s syndrome screening
Test: 40 Age, 1T free hCG, risk 1:384
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 3 32 9 468 0.25 [ 0.05, 0.57 ] 0.94 [ 0.91, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 41. Age, 1T free ßhCG, mixed cut-points.
Review: First trimester serum tests for Down’s syndrome screening
Test: 41 Age, 1T free hCG, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Biagiotti 1995 21 12 20 234 0.51 [ 0.35, 0.67 ] 0.95 [ 0.92, 0.97 ]
Biagiotti 1998 11 10 21 190 0.34 [ 0.19, 0.53 ] 0.95 [ 0.91, 0.98 ]
Brambati 1994 4 4 9 85 0.31 [ 0.09, 0.61 ] 0.96 [ 0.89, 0.99 ]
Forest 1995 3 32 9 468 0.25 [ 0.05, 0.57 ] 0.94 [ 0.91, 0.96 ]
Forest 1997 6 25 12 475 0.33 [ 0.13, 0.59 ] 0.95 [ 0.93, 0.97 ]
Krantz 2000 23 510 27 9691 0.46 [ 0.32, 0.61 ] 0.95 [ 0.95, 0.95 ]
Noble 1995 22 121 39 2306 0.36 [ 0.24, 0.49 ] 0.95 [ 0.94, 0.96 ]
Spencer 1999a 97 47 113 899 0.46 [ 0.39, 0.53 ] 0.95 [ 0.93, 0.96 ]
Wald 2003a 33 51 52 974 0.39 [ 0.28, 0.50 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 42. Age, 1T total hCG,risk 1:384.
Review: First trimester serum tests for Down’s syndrome screening
Test: 42 Age, 1T total hCG,risk 1:384
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 4 30 8 470 0.33 [ 0.10, 0.65 ] 0.94 [ 0.92, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 43. Age, 1T total hCG, mixed cut-points.
Review: First trimester serum tests for Down’s syndrome screening
Test: 43 Age, 1T total hCG, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 4 30 8 470 0.33 [ 0.10, 0.65 ] 0.94 [ 0.92, 0.96 ]
Wald 2003a 27 51 58 974 0.32 [ 0.22, 0.43 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 44. Age, 1T AFP, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 44 Age, 1T AFP, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Biagiotti 1995 14 12 27 234 0.34 [ 0.20, 0.51 ] 0.95 [ 0.92, 0.97 ]
Wald 2003a 28 51 57 974 0.33 [ 0.23, 0.44 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 45. Age, 1T AFP, risk1:384.
Review: First trimester serum tests for Down’s syndrome screening
Test: 45 Age, 1T AFP, risk1:384
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 3 39 9 461 0.25 [ 0.05, 0.57 ] 0.92 [ 0.89, 0.94 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 46. Age, 1T AFP,mixed cut-points.
Review: First trimester serum tests for Down’s syndrome screening
Test: 46 Age, 1T AFP,mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Biagiotti 1995 14 12 27 234 0.34 [ 0.20, 0.51 ] 0.95 [ 0.92, 0.97 ]
Forest 1995 3 39 9 461 0.25 [ 0.05, 0.57 ] 0.92 [ 0.89, 0.94 ]
Wald 2003a 28 51 57 974 0.33 [ 0.23, 0.44 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 47. Age, 1T uE3, risk 1:384.
Review: First trimester serum tests for Down’s syndrome screening
Test: 47 Age, 1T uE3, risk 1:384
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 4 70 8 430 0.33 [ 0.10, 0.65 ] 0.86 [ 0.83, 0.89 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 48. Age, 1T uE3, mixed cut-points.
Review: First trimester serum tests for Down’s syndrome screening
Test: 48 Age, 1T uE3, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Biagiotti 1995 17 12 24 234 0.41 [ 0.26, 0.58 ] 0.95 [ 0.92, 0.97 ]
Forest 1995 4 70 8 430 0.33 [ 0.10, 0.65 ] 0.86 [ 0.83, 0.89 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 49. Age, 1T free αhCG, risk 1:384.
Review: First trimester serum tests for Down’s syndrome screening
Test: 49 Age, 1T free hCG, risk 1:384
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 3 56 9 444 0.25 [ 0.05, 0.57 ] 0.89 [ 0.86, 0.91 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 50. Age, 1T SP1, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 50 Age, 1T SP1, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kornman 1998 4 5 11 92 0.27 [ 0.08, 0.55 ] 0.95 [ 0.88, 0.98 ]
Macintosh 1993 7 34 7 644 0.50 [ 0.23, 0.77 ] 0.95 [ 0.93, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 51. Age, 1T ProMBP, risk 1:250.
Review: First trimester serum tests for Down’s syndrome screening
Test: 51 Age, 1T ProMBP, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 1999 9 9 16 147 0.36 [ 0.18, 0.57 ] 0.94 [ 0.89, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 52. Age, 1T ITA, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 52 Age, 1T ITA, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Spencer 2002a 26 11 28 213 0.48 [ 0.34, 0.62 ] 0.95 [ 0.91, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 53. Age, 1T ADAM 12, risk 1:400.
Review: First trimester serum tests for Down’s syndrome screening
Test: 53 Age, 1T ADAM 12, risk 1:400
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2010 16 55 12 448 0.57 [ 0.37, 0.76 ] 0.89 [ 0.86, 0.92 ]
Laigaard 2003 15 5 3 149 0.83 [ 0.59, 0.96 ] 0.97 [ 0.93, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 54. Age, 1T PAPP-A and 1T free ßhCG, risk 1:250.
Review: First trimester serum tests for Down’s syndrome screening
Test: 54 Age, 1T PAPP-A and 1T free hCG, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2005 8 2 4 26 0.67 [ 0.35, 0.90 ] 0.93 [ 0.76, 0.99 ]
Christiansen 2007a 33 8 14 128 0.70 [ 0.55, 0.83 ] 0.94 [ 0.89, 0.97 ]
Christiansen 2009 55 15 19 246 0.74 [ 0.63, 0.84 ] 0.94 [ 0.91, 0.97 ]
Christiansen 2010 19 27 9 476 0.68 [ 0.48, 0.84 ] 0.95 [ 0.92, 0.96 ]
Crossley 2002a 23 848 19 16105 0.55 [ 0.39, 0.70 ] 0.95 [ 0.95, 0.95 ]
Kagan 2009 96 2079 26 17535 0.79 [ 0.70, 0.86 ] 0.89 [ 0.89, 0.90 ]
Muller 2003a 18 437 8 5020 0.69 [ 0.48, 0.86 ] 0.92 [ 0.91, 0.93 ]
Niemimaa 2001a 6 243 2 2264 0.75 [ 0.35, 0.97 ] 0.90 [ 0.89, 0.91 ]
Torring 2010 40 61 6 584 0.87 [ 0.74, 0.95 ] 0.91 [ 0.88, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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(. . . Continued)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Valinen 2007 23 360 7 7144 0.77 [ 0.58, 0.90 ] 0.95 [ 0.95, 0.96 ]
Wojdemann 2005 8 564 3 5866 0.73 [ 0.39, 0.94 ] 0.91 [ 0.91, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 55. Age, 1T PAPP-A and 1T free ßhCG, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 55 Age, 1T PAPP-A and 1T free hCG, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Biagiotti 1998 19 10 13 190 0.59 [ 0.41, 0.76 ] 0.95 [ 0.91, 0.98 ]
Brambati 1994 10 4 3 85 0.77 [ 0.46, 0.95 ] 0.96 [ 0.89, 0.99 ]
Christiansen 2007a 31 7 16 129 0.66 [ 0.51, 0.79 ] 0.95 [ 0.90, 0.98 ]
Christiansen 2009 53 13 21 248 0.72 [ 0.60, 0.81 ] 0.95 [ 0.92, 0.97 ]
Christiansen 2010 18 25 10 478 0.64 [ 0.44, 0.81 ] 0.95 [ 0.93, 0.97 ]
Cowans 2010 49 19 21 356 0.70 [ 0.58, 0.80 ] 0.95 [ 0.92, 0.97 ]
De Graaf 1999a 17 9 13 168 0.57 [ 0.37, 0.75 ] 0.95 [ 0.91, 0.98 ]
Forest 1997 10 25 8 475 0.56 [ 0.31, 0.78 ] 0.95 [ 0.93, 0.97 ]
Haddow 1998 29 158 19 3011 0.60 [ 0.45, 0.74 ] 0.95 [ 0.94, 0.96 ]
Kagan 2009 82 981 40 18633 0.67 [ 0.58, 0.75 ] 0.95 [ 0.95, 0.95 ]
Sahota 2010 20 541 12 10281 0.63 [ 0.44, 0.79 ] 0.95 [ 0.95, 0.95 ]
Spencer 1999a 141 47 69 899 0.67 [ 0.60, 0.73 ] 0.95 [ 0.93, 0.96 ]
Torring 2010 35 32 11 613 0.76 [ 0.61, 0.87 ] 0.95 [ 0.93, 0.97 ]
Tsukerman 1999 21 78 10 1486 0.68 [ 0.49, 0.83 ] 0.95 [ 0.94, 0.96 ]
Wald 2003a 63 51 22 974 0.74 [ 0.63, 0.83 ] 0.95 [ 0.94, 0.96 ]
Wapner 2003 41 408 20 7747 0.67 [ 0.54, 0.79 ] 0.95 [ 0.95, 0.95 ]
Zaragoza 2009 69 30 21 579 0.77 [ 0.67, 0.85 ] 0.95 [ 0.93, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 56. Age, 1T PAPP-A and 1T free ßhCG, mixed cut-points.
Review: First trimester serum tests for Down’s syndrome screening
Test: 56 Age, 1T PAPP-A and 1T free hCG, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Biagiotti 1998 19 10 13 190 0.59 [ 0.41, 0.76 ] 0.95 [ 0.91, 0.98 ]
Brambati 1994 10 4 3 85 0.77 [ 0.46, 0.95 ] 0.96 [ 0.89, 0.99 ]
Christiansen 2005 8 2 4 26 0.67 [ 0.35, 0.90 ] 0.93 [ 0.76, 0.99 ]
Christiansen 2007a 33 8 26 128 0.56 [ 0.42, 0.69 ] 0.94 [ 0.89, 0.97 ]
Christiansen 2009 55 15 19 246 0.74 [ 0.63, 0.84 ] 0.94 [ 0.91, 0.97 ]
Christiansen 2010 19 27 9 476 0.68 [ 0.48, 0.84 ] 0.95 [ 0.92, 0.96 ]
Cowans 2010 49 19 21 356 0.70 [ 0.58, 0.80 ] 0.95 [ 0.92, 0.97 ]
Crossley 2002a 23 848 19 16105 0.55 [ 0.39, 0.70 ] 0.95 [ 0.95, 0.95 ]
De Graaf 1999a 17 9 13 168 0.57 [ 0.37, 0.75 ] 0.95 [ 0.91, 0.98 ]
Forest 1997 10 25 8 475 0.56 [ 0.31, 0.78 ] 0.95 [ 0.93, 0.97 ]
Gyselaers 2005 21 2212 5 10969 0.81 [ 0.61, 0.93 ] 0.83 [ 0.83, 0.84 ]
Haddow 1998 29 158 19 3011 0.60 [ 0.45, 0.74 ] 0.95 [ 0.94, 0.96 ]
Kagan 2009 96 2079 26 17535 0.79 [ 0.70, 0.86 ] 0.89 [ 0.89, 0.90 ]
Kozlowski 2007 GC 17 1081 2 5806 0.89 [ 0.67, 0.99 ] 0.84 [ 0.83, 0.85 ]
Kozlowski 2007 PC 26 802 0 3034 1.00 [ 0.87, 1.00 ] 0.79 [ 0.78, 0.80 ]
Krantz 2000 31 510 19 9691 0.62 [ 0.47, 0.75 ] 0.95 [ 0.95, 0.95 ]
Muller 2003a 18 437 8 5020 0.69 [ 0.48, 0.86 ] 0.92 [ 0.91, 0.93 ]
Niemimaa 2001a 6 243 2 2264 0.75 [ 0.35, 0.97 ] 0.90 [ 0.89, 0.91 ]
O’Leary 2006 51 2560 9 19720 0.85 [ 0.73, 0.93 ] 0.89 [ 0.88, 0.89 ]
Orlandi 1997 7 68 0 669 1.00 [ 0.59, 1.00 ] 0.91 [ 0.88, 0.93 ]
Sahota 2010 20 541 12 10281 0.63 [ 0.44, 0.79 ] 0.95 [ 0.95, 0.95 ]
Schaelike 2009 48 1730 11 8879 0.81 [ 0.69, 0.90 ] 0.84 [ 0.83, 0.84 ]
Scott 2004 4 390 1 1658 0.80 [ 0.28, 0.99 ] 0.81 [ 0.79, 0.83 ]
Spencer 1999a 141 47 69 899 0.67 [ 0.60, 0.73 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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(. . . Continued)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Torring 2010 40 61 6 584 0.87 [ 0.74, 0.95 ] 0.91 [ 0.88, 0.93 ]
Tsukerman 1999 21 78 10 1486 0.68 [ 0.49, 0.83 ] 0.95 [ 0.94, 0.96 ]
Valinen 2007 23 360 7 7144 0.77 [ 0.58, 0.90 ] 0.95 [ 0.95, 0.96 ]
Wald 2003a 63 51 22 974 0.74 [ 0.63, 0.83 ] 0.95 [ 0.94, 0.96 ]
Wapner 2003 52 1892 9 6263 0.85 [ 0.74, 0.93 ] 0.77 [ 0.76, 0.78 ]
Wojdemann 2005 8 564 3 5866 0.73 [ 0.39, 0.94 ] 0.91 [ 0.91, 0.92 ]
Zaragoza 2009 69 30 21 579 0.77 [ 0.67, 0.85 ] 0.95 [ 0.93, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 57. Age, 1T PAPP-A and 1T free ßhCG, mixed cut-points without 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 57 Age, 1T PAPP-A and 1T free hCG, mixed cut-points without 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2005 8 2 4 26 0.67 [ 0.35, 0.90 ] 0.93 [ 0.76, 0.99 ]
Christiansen 2007a 33 8 14 128 0.70 [ 0.55, 0.83 ] 0.94 [ 0.89, 0.97 ]
Christiansen 2009 55 15 19 246 0.74 [ 0.63, 0.84 ] 0.94 [ 0.91, 0.97 ]
Christiansen 2010 19 27 9 476 0.68 [ 0.48, 0.84 ] 0.95 [ 0.92, 0.96 ]
Crossley 2002a 23 848 19 16105 0.55 [ 0.39, 0.70 ] 0.95 [ 0.95, 0.95 ]
Gyselaers 2005 21 2212 5 10969 0.81 [ 0.61, 0.93 ] 0.83 [ 0.83, 0.84 ]
Kagan 2009 96 2079 26 17535 0.79 [ 0.70, 0.86 ] 0.89 [ 0.89, 0.90 ]
Kozlowski 2007 GC 17 1081 2 5806 0.89 [ 0.67, 0.99 ] 0.84 [ 0.83, 0.85 ]
Kozlowski 2007 PC 26 802 0 3034 1.00 [ 0.87, 1.00 ] 0.79 [ 0.78, 0.80 ]
Krantz 2000 31 510 19 9691 0.62 [ 0.47, 0.75 ] 0.95 [ 0.95, 0.95 ]
Muller 2003a 18 437 8 5020 0.69 [ 0.48, 0.86 ] 0.92 [ 0.91, 0.93 ]
Niemimaa 2001a 6 243 2 2264 0.75 [ 0.35, 0.97 ] 0.90 [ 0.89, 0.91 ]
O’Leary 2006 51 2560 9 19720 0.85 [ 0.73, 0.93 ] 0.89 [ 0.88, 0.89 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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(. . . Continued)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Orlandi 1997 7 68 0 669 1.00 [ 0.59, 1.00 ] 0.91 [ 0.88, 0.93 ]
Schaelike 2009 48 1730 11 8879 0.81 [ 0.69, 0.90 ] 0.84 [ 0.83, 0.84 ]
Scott 2004 4 390 1 1658 0.80 [ 0.28, 0.99 ] 0.81 [ 0.79, 0.83 ]
Torring 2010 40 61 6 584 0.87 [ 0.74, 0.95 ] 0.91 [ 0.88, 0.93 ]
Valinen 2007 23 360 7 7144 0.77 [ 0.58, 0.90 ] 0.95 [ 0.95, 0.96 ]
Wapner 2003 52 1892 9 6263 0.85 [ 0.74, 0.93 ] 0.77 [ 0.76, 0.78 ]
Wojdemann 2005 8 564 3 5866 0.73 [ 0.39, 0.94 ] 0.91 [ 0.91, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 58. Age, 1T total hCG and 1T PAPP-A, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 58 Age, 1T total hCG and 1T PAPP-A, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Haddow 1998 30 158 18 3011 0.63 [ 0.47, 0.76 ] 0.95 [ 0.94, 0.96 ]
Wald 2003a 58 51 27 974 0.68 [ 0.57, 0.78 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 59. Age, 1T PAPP-A and 1T Inhibin, risk 1:100.
Review: First trimester serum tests for Down’s syndrome screening
Test: 59 Age, 1T PAPP-A and 1T Inhibin, risk 1:100
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2005 8 1 4 28 0.67 [ 0.35, 0.90 ] 0.97 [ 0.82, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 60. Age, 1T PAPP-A and 1T Inhibin, risk 1:250.
Review: First trimester serum tests for Down’s syndrome screening
Test: 60 Age, 1T PAPP-A and 1T Inhibin, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2005 9 1 3 27 0.75 [ 0.43, 0.95 ] 0.96 [ 0.82, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 61. Age, 1T PAPP-A and 1T Inhibin, risk 1:400.
Review: First trimester serum tests for Down’s syndrome screening
Test: 61 Age, 1T PAPP-A and 1T Inhibin, risk 1:400
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2005 10 2 2 26 0.83 [ 0.52, 0.98 ] 0.93 [ 0.76, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 62. Age, 1T PAPP-A and 1T Inhibin, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 62 Age, 1T PAPP-A and 1T Inhibin, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003a 58 51 27 974 0.68 [ 0.57, 0.78 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 63. Age, 1T PAPP-A and 1T Inhibin, mixed cut-points.
Review: First trimester serum tests for Down’s syndrome screening
Test: 63 Age, 1T PAPP-A and 1T Inhibin, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2005 9 1 3 27 0.75 [ 0.43, 0.95 ] 0.96 [ 0.82, 1.00 ]
Wald 2003a 58 51 27 974 0.68 [ 0.57, 0.78 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 64. Age, 1T PAPP-A and 1T ITA, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 64 Age, 1T PAPP-A and 1T ITA, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Spencer 2002a 33 11 21 213 0.61 [ 0.47, 0.74 ] 0.95 [ 0.91, 0.98 ]
Weinans 2005 15 16 9 304 0.63 [ 0.41, 0.81 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 65. Age, 1T PAPP-A and 1T AFP, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 65 Age, 1T PAPP-A and 1T AFP, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tsukerman 1999 15 78 16 1486 0.48 [ 0.30, 0.67 ] 0.95 [ 0.94, 0.96 ]
Wald 2003a 58 51 27 974 0.68 [ 0.57, 0.78 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 66. Age, 1T free ßhCG and 1T Inhibin, risk 1:100.
Review: First trimester serum tests for Down’s syndrome screening
Test: 66 Age, 1T free hCG and 1T Inhibin, risk 1:100
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2005 4 1 8 27 0.33 [ 0.10, 0.65 ] 0.96 [ 0.82, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 67. Age, 1T free ßhCG and 1T Inhibin, risk 1:250.
Review: First trimester serum tests for Down’s syndrome screening
Test: 67 Age, 1T free hCG and 1T Inhibin, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2005 6 2 6 26 0.50 [ 0.21, 0.79 ] 0.93 [ 0.76, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 68. Age, 1T free ßhCG and 1T Inhibin, risk 1:400.
Review: First trimester serum tests for Down’s syndrome screening
Test: 68 Age, 1T free hCG and 1T Inhibin, risk 1:400
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2005 8 4 4 24 0.67 [ 0.35, 0.90 ] 0.86 [ 0.67, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 69. Age, 1T free ßhCG and 1T Inhibin, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 69 Age, 1T free hCG and 1T Inhibin, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003a 37 51 48 974 0.44 [ 0.33, 0.55 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 70. Age, 1T free ßhCG and 1T Inhibin, mixed cut-points.
Review: First trimester serum tests for Down’s syndrome screening
Test: 70 Age, 1T free hCG and 1T Inhibin, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2005 6 2 6 26 0.50 [ 0.21, 0.79 ] 0.93 [ 0.76, 0.99 ]
Wald 2003a 37 51 48 974 0.44 [ 0.33, 0.55 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 71. Age, 1T free ßhCG and 1T AFP, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 71 Age, 1T free hCG and 1T AFP, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Biagiotti 1995 23 12 18 234 0.56 [ 0.40, 0.72 ] 0.95 [ 0.92, 0.97 ]
Tsukerman 1999 18 78 13 1486 0.58 [ 0.39, 0.75 ] 0.95 [ 0.94, 0.96 ]
Wald 2003a 35 51 50 974 0.41 [ 0.31, 0.52 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 72. Age, 1T free ßhCG and 1T AFP, risk 1:250.
Review: First trimester serum tests for Down’s syndrome screening
Test: 72 Age, 1T free hCG and 1T AFP, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Benattar 1999 4 137 1 1514 0.80 [ 0.28, 0.99 ] 0.92 [ 0.90, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 73. Age, 1T free ßhCG and 1T AFP, risk 1:384.
Review: First trimester serum tests for Down’s syndrome screening
Test: 73 Age, 1T free hCG and 1T AFP, risk 1:384
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 5 25 7 475 0.42 [ 0.15, 0.72 ] 0.95 [ 0.93, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 74. Age, 1T free ßhCG and 1T AFP, mixed cut-points.
Review: First trimester serum tests for Down’s syndrome screening
Test: 74 Age, 1T free hCG and 1T AFP, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Benattar 1999 4 137 1 1514 0.80 [ 0.28, 0.99 ] 0.92 [ 0.90, 0.93 ]
Biagiotti 1995 23 12 18 234 0.56 [ 0.40, 0.72 ] 0.95 [ 0.92, 0.97 ]
Forest 1995 5 25 7 475 0.42 [ 0.15, 0.72 ] 0.95 [ 0.93, 0.97 ]
Tsukerman 1999 18 78 13 1486 0.58 [ 0.39, 0.75 ] 0.95 [ 0.94, 0.96 ]
Wald 2003a 35 51 50 974 0.41 [ 0.31, 0.52 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 75. Age, 1T AFP and 1T uE3, risk 1:384.
Review: First trimester serum tests for Down’s syndrome screening
Test: 75 Age, 1T AFP and 1T uE3, risk 1:384
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 5 66 7 434 0.42 [ 0.15, 0.72 ] 0.87 [ 0.84, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 76. Age, 1T AFP and 1T free αhCG, risk 1:384.
Review: First trimester serum tests for Down’s syndrome screening
Test: 76 Age, 1T AFP and 1T free hCG, risk 1:384
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 4 67 8 433 0.33 [ 0.10, 0.65 ] 0.87 [ 0.83, 0.89 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 77. Age, 1T free ßhCG and 1T total hCG, risk 1:384.
Review: First trimester serum tests for Down’s syndrome screening
Test: 77 Age, 1T free hCG and 1T total hCG, risk 1:384
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 3 37 9 463 0.25 [ 0.05, 0.57 ] 0.93 [ 0.90, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 78. Age, 1T free ßhCG and 1T uE3, risk 1:384.
Review: First trimester serum tests for Down’s syndrome screening
Test: 78 Age, 1T free hCG and 1T uE3, risk 1:384
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 6 45 6 455 0.50 [ 0.21, 0.79 ] 0.91 [ 0.88, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 79. Age, 1T free ßhCG and 1T uE3, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 79 Age, 1T free hCG and 1T uE3, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Biagiotti 1995 25 12 16 234 0.61 [ 0.45, 0.76 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 80. Age, 1T free ßhCG and 1T uE3, mixed cut-points.
Review: First trimester serum tests for Down’s syndrome screening
Test: 80 Age, 1T free hCG and 1T uE3, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Biagiotti 1995 25 12 16 234 0.61 [ 0.45, 0.76 ] 0.95 [ 0.92, 0.97 ]
Forest 1995 6 45 6 455 0.50 [ 0.21, 0.79 ] 0.91 [ 0.88, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 81. Age, 1T free ßhCG and 1T SP1, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 81 Age, 1T free hCG and 1T SP1, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2004 10 2 4 44 0.71 [ 0.42, 0.92 ] 0.96 [ 0.85, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 82. Age, 1T free ßhCG and 1T SP1 risk 1:250.
Review: First trimester serum tests for Down’s syndrome screening
Test: 82 Age, 1T free hCG and 1T SP1 risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2004 9 1 5 45 0.64 [ 0.35, 0.87 ] 0.98 [ 0.88, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 83. Age, 1T AFP and 1T total hCG, 1:384.
Review: First trimester serum tests for Down’s syndrome screening
Test: 83 Age, 1T AFP and 1T total hCG, 1:384
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 4 36 8 464 0.33 [ 0.10, 0.65 ] 0.93 [ 0.90, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 84. Age, 1T free ßhCG and 1T free αhCG, risk 1:384.
Review: First trimester serum tests for Down’s syndrome screening
Test: 84 Age, 1T free hCG and 1T free hCG, risk 1:384
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 5 31 7 469 0.42 [ 0.15, 0.72 ] 0.94 [ 0.91, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 85. Age, 1T total hCG and 1T uE3, risk 1:384.
Review: First trimester serum tests for Down’s syndrome screening
Test: 85 Age, 1T total hCG and 1T uE3, risk 1:384
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 5 41 7 459 0.42 [ 0.15, 0.72 ] 0.92 [ 0.89, 0.94 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 86. Age, 1T total hCG and 1T Inhibin, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 86 Age, 1T total hCG and 1T Inhibin, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003a 29 51 56 974 0.34 [ 0.24, 0.45 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 87. Age, 1T total hCG and 1T free αhCG, risk 1:384.
Review: First trimester serum tests for Down’s syndrome screening
Test: 87 Age, 1T total hCG and 1T free hCG, risk 1:384
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 5 39 7 461 0.42 [ 0.15, 0.72 ] 0.92 [ 0.89, 0.94 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 88. Age, 1T uE3 and 1T free αhCG, risk 1:384.
Review: First trimester serum tests for Down’s syndrome screening
Test: 88 Age, 1T uE3 and 1T free hCG, risk 1:384
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 4 56 8 444 0.33 [ 0.10, 0.65 ] 0.89 [ 0.86, 0.91 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 89. Age, 1T PAPP-A, 1T free ßhCG and 1T AFP, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 89 Age, 1T PAPP-A, 1T free hCG and 1T AFP, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tsukerman 1999 23 78 8 1486 0.74 [ 0.55, 0.88 ] 0.95 [ 0.94, 0.96 ]
Wald 2003a 63 51 22 974 0.74 [ 0.63, 0.83 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 90. Age, 1T PAPP-A, 1T free ßhCG and 1T AFP, mixed cut-points.
Review: First trimester serum tests for Down’s syndrome screening
Test: 90 Age, 1T PAPP-A, 1T free hCG and 1T AFP, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Muller 2003a 18 437 8 5020 0.69 [ 0.48, 0.86 ] 0.92 [ 0.91, 0.93 ]
Tsukerman 1999 23 78 8 1486 0.74 [ 0.55, 0.88 ] 0.95 [ 0.94, 0.96 ]
Wald 2003a 63 51 22 974 0.74 [ 0.63, 0.83 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 91. Age, 1T free ßhCG, 1T AFP and 1T uE3, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 91 Age, 1T free hCG, 1T AFP and 1T uE3, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Biagiotti 1995 27 12 14 234 0.66 [ 0.49, 0.80 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 92. Age, 1T free ßhCG, 1T AFP and 1T uE3, risk 1:384.
Review: First trimester serum tests for Down’s syndrome screening
Test: 92 Age, 1T free hCG, 1T AFP and 1T uE3, risk 1:384
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 5 40 7 460 0.42 [ 0.15, 0.72 ] 0.92 [ 0.89, 0.94 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 93. Age, 1T free ßhCG, 1T AFP and 1T uE3, mixed cut-points.
Review: First trimester serum tests for Down’s syndrome screening
Test: 93 Age, 1T free hCG, 1T AFP and 1T uE3, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Biagiotti 1995 27 12 14 234 0.66 [ 0.49, 0.80 ] 0.95 [ 0.92, 0.97 ]
Forest 1995 5 40 7 460 0.42 [ 0.15, 0.72 ] 0.92 [ 0.89, 0.94 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 94. Age, 1T total hCG, 1T AFP and 1T uE3, risk 1:384.
Review: First trimester serum tests for Down’s syndrome screening
Test: 94 Age, 1T total hCG, 1T AFP and 1T uE3, risk 1:384
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 5 44 7 456 0.42 [ 0.15, 0.72 ] 0.91 [ 0.88, 0.94 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 95. Age, 1T total hCG, 1T AFP and 1T uE3, mixed cut-points.
Review: First trimester serum tests for Down’s syndrome screening
Test: 95 Age, 1T total hCG, 1T AFP and 1T uE3, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Crandall 1993 9 208 2 774 0.82 [ 0.48, 0.98 ] 0.79 [ 0.76, 0.81 ]
Forest 1995 5 44 7 456 0.42 [ 0.15, 0.72 ] 0.91 [ 0.88, 0.94 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 96. Age, 1T AFP, free αhCG and 1T uE3, risk 1:384.
Review: First trimester serum tests for Down’s syndrome screening
Test: 96 Age, 1T AFP, free hCG and 1T uE3, risk 1:384
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 7 89 5 411 0.58 [ 0.28, 0.85 ] 0.82 [ 0.79, 0.85 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 97. Age, 1T PAPP-A, 1T free ßhCG and 1T Inhibin, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 97 Age, 1T PAPP-A, 1T free hCG and 1T Inhibin, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003a 63 51 22 974 0.74 [ 0.63, 0.83 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 98. Age, 1T PAPP-A, 1T total hCG and 1T Inhibin, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 98 Age, 1T PAPP-A, 1T total hCG and 1T Inhibin, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003a 59 51 26 974 0.69 [ 0.58, 0.79 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 99. Age, 1T PAPP-A, sp1 and 1T ProMBP, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 99 Age, 1T PAPP-A, sp1 and 1T ProMBP, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2004 11 9 4 168 0.73 [ 0.45, 0.92 ] 0.95 [ 0.91, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 100. Age, 1T PAPP-A, sp1 and 1T ProMBP, risk 1:250.
Review: First trimester serum tests for Down’s syndrome screening
Test: 100 Age, 1T PAPP-A, sp1 and 1T ProMBP, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2004 11 7 4 170 0.73 [ 0.45, 0.92 ] 0.96 [ 0.92, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 101. Age, 1T free ßhCG, 1T total hCG, 1T AFP and 1T uE3, risk 1:384.
Review: First trimester serum tests for Down’s syndrome screening
Test: 101 Age, 1T free hCG, 1T total hCG, 1T AFP and 1T uE3, risk 1:384
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 6 41 6 459 0.50 [ 0.21, 0.79 ] 0.92 [ 0.89, 0.94 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 102. Age, 1T total hCG, 1T AFP, 1T uE3 and 1T free αhCG, risk 1:384.
Review: First trimester serum tests for Down’s syndrome screening
Test: 102 Age, 1T total hCG, 1T AFP, 1T uE3 and 1T free hCG, risk 1:384
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 6 51 6 449 0.50 [ 0.21, 0.79 ] 0.90 [ 0.87, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 103. Age, 1T PAPP-A, 1T free ßhCG, 1T AFP, 1T uE3 and 1T Inhibin, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 103 Age, 1T PAPP-A, 1T free hCG, 1T AFP, 1T uE3 and 1T Inhibin, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003a 66 51 19 974 0.78 [ 0.67, 0.86 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 104. Age, 1T PAPP-A, 1T total hCG, 1T AFP, 1T uE3 and 1T Inhibin, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 104 Age, 1T PAPP-A, 1T total hCG, 1T AFP, 1T uE3 and 1T Inhibin, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003a 62 51 23 974 0.73 [ 0.62, 0.82 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 105. Age, 1T free ßhCG, 1T total hCG, 1T AFP, 1T uE3 and 1T free αhCG, risk 1:384.
Review: First trimester serum tests for Down’s syndrome screening
Test: 105 Age, 1T free hCG, 1T total hCG, 1T AFP, 1T uE3 and 1T free hCG, risk 1:384
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 4 51 8 449 0.33 [ 0.10, 0.65 ] 0.90 [ 0.87, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 106. Age, 1T hPL, risk 1:250.
Review: First trimester serum tests for Down’s syndrome screening
Test: 106 Age, 1T hPL, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2007a 21 9 26 127 0.45 [ 0.30, 0.60 ] 0.93 [ 0.88, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 107. Age, 1T hPL, 1T PAPP-A, risk 1:250.
Review: First trimester serum tests for Down’s syndrome screening
Test: 107 Age, 1T hPL, 1T PAPP-A, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2007a 26 8 21 128 0.55 [ 0.40, 0.70 ] 0.94 [ 0.89, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 108. Age, 1T hPL, 1T free ßhCG, risk 1:250.
Review: First trimester serum tests for Down’s syndrome screening
Test: 108 Age, 1T hPL, 1T free hCG, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2007a 32 8 15 128 0.68 [ 0.53, 0.81 ] 0.94 [ 0.89, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 109. Age, 1T hPL, 1T PAPP-A, 1T free ßhCG, risk 1:250.
Review: First trimester serum tests for Down’s syndrome screening
Test: 109 Age, 1T hPL, 1T PAPP-A, 1T free hCG, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2007a 36 7 11 129 0.77 [ 0.62, 0.88 ] 0.95 [ 0.90, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
211First trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Test 110. Age, 1T PGH, risk 1:250.
Review: First trimester serum tests for Down’s syndrome screening
Test: 110 Age, 1T PGH, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2009 30 15 44 246 0.41 [ 0.29, 0.53 ] 0.94 [ 0.91, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 111. Age, 1T PGH, 1T PAPP-A , risk 1:250.
Review: First trimester serum tests for Down’s syndrome screening
Test: 111 Age, 1T PGH, 1T PAPP-A , risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2009 48 18 26 243 0.65 [ 0.53, 0.76 ] 0.93 [ 0.89, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 112. Age, 1T PGH, 1T free ßhCG , risk 1:250.
Review: First trimester serum tests for Down’s syndrome screening
Test: 112 Age, 1T PGH, 1T free hCG , risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2009 47 19 27 242 0.64 [ 0.52, 0.74 ] 0.93 [ 0.89, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 113. Age, 1T PGH, 1T PAPP-A, 1T free ßhCG , risk 1:250.
Review: First trimester serum tests for Down’s syndrome screening
Test: 113 Age, 1T PGH, 1T PAPP-A, 1T free hCG , risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2009 56 15 18 246 0.76 [ 0.64, 0.85 ] 0.94 [ 0.91, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 114. Age, 1T GHBP, risk 1:250.
Review: First trimester serum tests for Down’s syndrome screening
Test: 114 Age, 1T GHBP, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2009 20 14 54 247 0.27 [ 0.17, 0.39 ] 0.95 [ 0.91, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 115. Age, 1T GHBP, 1T PAPP-A, risk 1:250.
Review: First trimester serum tests for Down’s syndrome screening
Test: 115 Age, 1T GHBP, 1T PAPP-A, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2009 49 18 25 243 0.66 [ 0.54, 0.77 ] 0.93 [ 0.89, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 116. Age, 1T GHBP, 1T free ßhCG, risk 1:250.
Review: First trimester serum tests for Down’s syndrome screening
Test: 116 Age, 1T GHBP, 1T free hCG, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2009 45 22 29 239 0.61 [ 0.49, 0.72 ] 0.92 [ 0.88, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
214First trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Test 117. Age, 1T GHBP, 1T PGH, risk 1:250.
Review: First trimester serum tests for Down’s syndrome screening
Test: 117 Age, 1T GHBP, 1T PGH, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2009 35 17 39 244 0.47 [ 0.36, 0.59 ] 0.93 [ 0.90, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 118. Age, 1T GHBP, 1T PAPP-A, 1T free ßhCG , risk 1:250.
Review: First trimester serum tests for Down’s syndrome screening
Test: 118 Age, 1T GHBP, 1T PAPP-A, 1T free hCG , risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2009 56 15 18 246 0.76 [ 0.64, 0.85 ] 0.94 [ 0.91, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 119. Age, 1T GHBP, 1T PGH, 1T PAPP-A, 1T free ßhCG , risk 1:250.
Review: First trimester serum tests for Down’s syndrome screening
Test: 119 Age, 1T GHBP, 1T PGH, 1T PAPP-A, 1T free hCG , risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2009 56 14 18 247 0.76 [ 0.64, 0.85 ] 0.95 [ 0.91, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 120. Age, 1T ADAM 12, risk 1:250.
Review: First trimester serum tests for Down’s syndrome screening
Test: 120 Age, 1T ADAM 12, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2010 13 30 15 473 0.46 [ 0.28, 0.66 ] 0.94 [ 0.92, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 121. Age, 1T ADAM 12, 1T PAPP-A, 1T free ßhCG, risk 1:250.
Review: First trimester serum tests for Down’s syndrome screening
Test: 121 Age, 1T ADAM 12, 1T PAPP-A, 1T free hCG, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2010 20 24 8 479 0.71 [ 0.51, 0.87 ] 0.95 [ 0.93, 0.97 ]
Torring 2010 40 60 6 585 0.87 [ 0.74, 0.95 ] 0.91 [ 0.88, 0.93 ]
Valinen 2009 34 10 19 216 0.64 [ 0.50, 0.77 ] 0.96 [ 0.92, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 122. Age, PlGF, 1T PAPP-A, 1T free ßhCG, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 122 Age, PlGF, 1T PAPP-A, 1T free hCG, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cowans 2010 50 19 20 356 0.71 [ 0.59, 0.82 ] 0.95 [ 0.92, 0.97 ]
Zaragoza 2009 72 30 18 579 0.80 [ 0.70, 0.88 ] 0.95 [ 0.93, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 123. Age, 1T PAPP-A and 1T free ßhCG, risk 1:300.
Review: First trimester serum tests for Down’s syndrome screening
Test: 123 Age, 1T PAPP-A and 1T free hCG, risk 1:300
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kagan 2009 101 2373 21 17241 0.83 [ 0.75, 0.89 ] 0.88 [ 0.87, 0.88 ]
Kozlowski 2007 GC 17 1081 2 5806 0.89 [ 0.67, 0.99 ] 0.84 [ 0.83, 0.85 ]
Kozlowski 2007 PC 26 802 0 3034 1.00 [ 0.87, 1.00 ] 0.79 [ 0.78, 0.80 ]
Schaelike 2009 48 1730 11 8879 0.81 [ 0.69, 0.90 ] 0.84 [ 0.83, 0.84 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 124. Age, 1T PAPP-A, 1T Hyperglycosylated hCG, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 124 Age, 1T PAPP-A, 1T Hyperglycosylated hCG, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Palomaki 2007 17 538 6 10214 0.74 [ 0.52, 0.90 ] 0.95 [ 0.95, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 128. Age, ADAM 12, 1T PAPP-A, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 128 Age, ADAM 12, 1T PAPP-A, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Torring 2010 28 32 18 613 0.61 [ 0.45, 0.75 ] 0.95 [ 0.93, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 129. Age, ADAM 12, 1T PAPP-A, 1T free ßhCG, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 129 Age, ADAM 12, 1T PAPP-A, 1T free hCG, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2010 21 25 7 478 0.75 [ 0.55, 0.89 ] 0.95 [ 0.93, 0.97 ]
Torring 2010 34 32 12 613 0.74 [ 0.59, 0.86 ] 0.95 [ 0.93, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 130. Age, 1T PlGF, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 130 Age, 1T PlGF, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Zaragoza 2009 39 30 51 579 0.43 [ 0.33, 0.54 ] 0.95 [ 0.93, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 131. 1T PlGF, 1T PAPP-A, 1T free ßhCG, 5FPR.
Review: First trimester serum tests for Down’s syndrome screening
Test: 131 1T PlGF, 1T PAPP-A, 1T free hCG, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Zaragoza 2009 65 30 25 579 0.72 [ 0.62, 0.81 ] 0.95 [ 0.93, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 132. Age, 1T ADAM 12, 1T PAPP-A, 1T free ßhCG, mixed cut-points.
Review: First trimester serum tests for Down’s syndrome screening
Test: 132 Age, 1T ADAM 12, 1T PAPP-A, 1T free hCG, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2010 20 24 8 479 0.71 [ 0.51, 0.87 ] 0.95 [ 0.93, 0.97 ]
Torring 2010 40 60 6 585 0.87 [ 0.74, 0.95 ] 0.91 [ 0.88, 0.93 ]
Valinen 2009 34 10 19 216 0.64 [ 0.50, 0.77 ] 0.96 [ 0.92, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 133. Age, 1T PAPP-A, 1T free ßhCG and 1T Inhibin, risk 1:250.
Review: First trimester serum tests for Down’s syndrome screening
Test: 133 Age, 1T PAPP-A, 1T free hCG and 1T Inhibin, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2005 9 1 3 27 0.75 [ 0.43, 0.95 ] 0.96 [ 0.82, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 134. Age, 1T PAPP-A, 1T free ßhCG, and 1T Inhibin, mixed cut-points.
Review: First trimester serum tests for Down’s syndrome screening
Test: 134 Age, 1T PAPP-A, 1T free hCG, and 1T Inhibin, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2005 9 1 3 27 0.75 [ 0.43, 0.95 ] 0.96 [ 0.82, 1.00 ]
Wald 2003a 63 51 22 974 0.74 [ 0.63, 0.83 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. Direct comparisons of the sensitivity of nine test strategies at the 5% false positive rate
Ratio of
sensitivity
(95%
CI), P value
for compar-
ison (stud-
ies)
Free ßhCG PAPP-A Age, free
ßhCG
Age, PAPP-
A
Age, PAPP-
A , free
ßhCG
Age, free
ßhCG, AFP
Age,
ADAM 12,
PAPP-A,
free ßhCG
Age, PAPP-
A, free
ßhCG, AFP
PAPP-A 1.78 (1.10
to 2.88), P =
0.02
(2)
Age, free
ßhCG
1.67 (1.11
to 2.50). P =
0.013
(2)
0.94 (0.68
to 1.29), P =
0.70
(2)
Age, PAPP-
A
2.15 (1.37
to 3.38), P =
0.001
(2)
1.20 (0.86
to 1.67), P =
0.29
(3)
1.26 (1.02
to 1.57), P =
0.034
(4)
Age, PAPP-
A , free
ßhCG
2.62 (1.77
to 3.87), P <
0.001
(2)
1.47 (1.09
to 2.00), P =
0.012
(2)
1.61 (1.31
tp 1.98), P <
0.001
(5)
1.26 (1.04
to 1.52), P =
0.02
(4)
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Table 1. Direct comparisons of the sensitivity of nine test strategies at the 5% false positive rate (Continued)
Age, free
ßhCG, AFP
2.19 (1.31
to 3.64), P =
0.002
(1)
0.71 (0.52
to 0.98), P =
0.03
(1)
1.08 (0.80
to 1.46), P =
0.62
(2)
0.61 (0.46
to 0.82), P <
0.001
(1)
0.63 (0.47
to 0.86), P =
0.004
(2)
Age,
ADAM 12,
PAPP-A,
free ßhCG
- - - - 1.04 (0.85
to 1.26), P =
0.71
(2)
-
Age, PAPP-
A, free
ßhCG, AFP
3.94 (2.49
to 6.23), P <
0.001
(1)
1.29 (1.03
to 1.60), P =
0.024
(1)
1.91 (1.42
to 2.56), P <
0.001
(1)
1.11 (0.91
to 1.34), P =
0.31
(1)
1.02 (0.88
to 1.20), P =
0.77
(2)
1.62 (1.19
to 2.19), P =
0.002
(2)
-
Age, PlGF,
PAPP-A,
free ßhCG
- - - - 1.03 (0.91
to 1.17), P =
0.61
(2)
- - -
- indicates that no comparative study was available for the pair of tests.
Direct comparisons were made only using data from studies which compared each pair of tests on the same women. Where there were
at least two studies, meta-analysis was performed to summarise and compare the sensitivities. The ratio of sensitivities was computed by
division of the sensitivity for the column by the sensitivity for the row. If the ratio of sensitivity is greater than one then the sensitivity of
the test for the column is higher than that for the row, if less than one the sensitivity of the test in the row is higher than in the column.
All test comparisons that were evaluated by only one study were from Wald 2003. The ratio of the sensitivities for test comparisons
from a single study were calculated as a ratio of two proportions.
ADAM12: a disintegrin and metalloprotease; AFP: alpha-fetoprotein; ßhCG: beta human chorionic gonadotrophin; CI: confidence
interval; PAPP-A: pregnancy-associated plasma protein A; PIGF: placental growth factor; PROMBP: proform of eosinophil major
basic protein
Table 2. Indirect comparisons of the sensitivity of nine test strategies at the 5% false positive rate
Ratio
of sensi-
tivity
(95%CI)
, P value
for com-
parison
Free
ßhCG
PAPP-A Age, free
ßhCG
Age,
PAPP-A
Age,
PAPP-A,
free
ßhCG
Age, free
ßhCG,
AFP
Age,
ADAM
12,
PAPP-A,
free
ßhCG
Age,
PAPP-A,
free
ßhCG,
AFP
Studies
(cases/
women)
4
(390/
4280)
4
(325/
2837)
7
(460/
5893)
5
(359/
3491)
17
(1037/
49827)
3
(157/
2992)
2
(74/
1222)
2
(116/
2705)
Studies
(cases/
Sensi-
tivity %
25 (18 to
34)
52 (39 to
65)
42 (36 to
48)
55 (46 to
63)
68 (65 to
71)
49 (39 to
60)
74 (63 to
83)
74 (65 to
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Table 2. Indirect comparisons of the sensitivity of nine test strategies at the 5% false positive rate (Continued)
women) (95%CI) 81)
PAPP-A 4
(325/
2837)
52 (39 to
65)
2.05
(1.37 to
3.09), P =
0.001
Age, free
ßhCG
7
(460/
5893)
42 (36 to
48)
1.66
(1.17 to
2.36), P =
0.004
0.81
(0.61 to
1.08), P =
0.15
Age,
PAPP-A
5
(359/
3491)
55 (46 to
63)
2.16
(1.51 to
3.10), P <
0.001
1.05
(0.78 to
1.42), P =
0.73
1.30
(1.05 to
1.61), P =
0.015
Age,
PAPP-A,
free
ßhCG
17
(1037/
49827)
68 (65 to
71)
2.70
(1.95 to
3.73), P <
0.001
1.31
(1.02 to
1.70), P =
0.037
1.62
(1.40 to
1.88), P <
0.001
1.25
(1.05 to
1.47), P =
0.01
Age, free
ßhCG,
AFP
3
(157/
2992)
49 (39 to
60)
1.95
(1.33 to
2.86), P =
0.001
0.95
(0.69 to
1.32), P =
0.76
1.18
(0.92 to
1.51), P =
0.20
0.90
(0.69 to
1.17), P =
0.45
0.72
(0.59 to
0.89), P =
0.003
Age,
ADAM
12,
PAPP-A,
free
ßhCG
2
(74/
1222)
74 (63 to
83)
2.94
(2.07 to
4.16), P <
0.001
1.43
(1.07 to
1.90), P =
0.014
1.77
(1.46 to
2.14), P <
0.001
1.36
(1.10 to
1.67), P =
0.004
1.09
(0.95 to
1.25), P =
0.24
1.50
(1.17 to
1.92), P =
0.001
Age,
PAPP-A,
free
ßhCG,
AFP
2
(116/
2705)
74 (65 to
81)
2.93
(2.09 to
4.11), P <
0.001
1.43
(1.08 to
1.88), P =
0.011
1.76
(1.48 to
2.10), P <
0.001
1.35
(1.11 to
1.64), P =
0.002
1.09
(0.97 to
1.22), P =
0.16
1.50
(1.19, to
1.89).
P = 0.001
1.00
(0.84 to
1.18), P =
0.98
Age,
PlGF,
PAPP-A,
free
ßhCG
2
(160/
1144)
76 (69 to
82)
3.01
(2.16 to
4.20), P <
0.001
1.47
(1.12 to
1.91), P =
0.005
1.81
(1.54 to
2.14), P <
0.001
1.39
(1.16 to
1.67), P <
0.001
1.12
(1.01 to
1.23), P =
0.024
1.54
(1.23 to
1.93), P <
0.001
1.03
(0.87 to
1.20), P =
0.75
1.03
(0.90 to
1.18), P =
0.7
Ratio of sensitivities were computed by division of the sensitivity for the column by the sensitivity for the row. If the ratio of sensitivity
is greater than one then the sensitivity of the test for the column is higher than that for the row, if less than one the sensitivity of the
test in the row is higher than in the column.
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AFP: alpha-fetoprotein; αhCG: alpha human chorionic gonadotrophin; ßhCG: beta human chorionic gonadotrophin; CI: confidence
interval; PAPP-A: Pregnancy-associated plasma protein A
Table 3. Summary of study characteristics
Study PAPP-A, free
ßhCG and age*
Maternal age
(years)
Reference stan-
dard
Population Study design Study location
Baviera 2010 Mean 35.3 for
Down’s cases, 30.
4 for control
Amniocen-
tesis or follow-up
to birth
Routine screen-
ing
Case-control Italy
Benattar 1999 Mean32 (16-46)
, 8.3% > 35
Amniocentesis
due to maternal
age > 38 years (6.
1% or women).
Karyotyping en-
couraged
for women with
positive result on
one or more in-
dex test. No de-
tails of reference
standard for in-
dex test negative
women
Routine screen-
ing
Prospective co-
hort
France
Biagiotti 1995 Not reported Amniocentesis
or CVS
High-risk refer-
ral for invasive
testing
Case-control Italy
Biagiotti 1998 X Unclear (maybe
all ≥ 38)
Amniocentesis
or CVS
High-risk refer-
ral for invasive
testing
Retrospective
case-control
Italy
Brambati 1993 Median 38 (20-
47)
CVS High-risk refer-
ral for invasive
testing
Retrospective
cohort
Italy
Brambati 1994 X Not reported CVS High-risk refer-
ral for invasive
testing
Case-control Italy
Brameld 2008 Median 31 (14-
47), 20% ≥ 35
Karyotyp-
ing or follow-up
to birth
Routine screen-
ing
Retrospective
cohort
Australia
Brizot 1994 Median 38 (22-
45)
Fetal karyotyp-
ing
High-risk refer-
ral for invasive
testing
Retrospective
case-control
UK
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Table 3. Summary of study characteristics (Continued)
Casals 1996 94.4% > 35 CVS High-risk refer-
ral for invasive
testing
Retrospective
case-control
Spain
Christiansen
1999
Not reported Karyotyping High-risk refer-
ral for invasive
testing
Case-control Denmark
Christiansen
2004
Not reported CVS (for 120 of
cases of Down’s)
or follow-up to
birth (for 36 of
cases of Down’s)
Routine screen-
ing
Case-control Denmark
Christiansen
2005
Not reported Karyotyping Screen-
ing programmes
for syphilis
and Down’s syn-
drome
Case-control Denmark
Christiansen
2007a
X Me-
dian 37.7 (24-
48) for Down’s
cases, 36.4 (22-
44) for controls
Karyotyp-
ing or follow-up
to birth
Routine screen-
ing
Case-control Denmark
Christiansen
2009
X Median 37.5 for
Down’s cases, 36.
4 for controls
Karyotyp-
ing or follow-up
to birth
Routine screen-
ing
Case-control Denmark
Christiansen
2010
X Median 36 (25-
44) for Down’s
cases, 29 (17-45)
for controls
Karyotyp-
ing or follow-up
to birth
Routine screen-
ing
Case-control Denmark
Cowans 2010 X Mean 37.0 (IQR
32.9-40.5) for
Down’s cases, 32.
4 (IQR 29.0-35.
9) for controls
Karyotyp-
ing or follow-up
to birth
Routine screen-
ing
Case-control UK
Crandall 1993 90% > 35 Amniocentesis High-risk refer-
ral for invasive
testing
Retrospective
cohort
USA
Crossley 2002a Median 29.9,
15.4% ≥ 35
CVS offered
where women
had high NT
measurements.
Routine screen-
ing
Prospective co-
hort
UK
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Table 3. Summary of study characteristics (Continued)
Also amniocen-
tesis or follow-up
to birth
De Graaf 1999a X Not reported Amniocentesis
or CVS
High-risk refer-
ral for invasive
testing
Case-control The Netherlands
Forest 1995 Mean 29.1 (SD
4.7), 10.7% ≥
35
Follow-up to
birth
Routine screen-
ing
Case-control Canada
Forest 1997 X Mean 27.9, 10.
7% ≥ 35
Follow-up to
birth
Routine screen-
ing
Case-control Canada
Gyselaers 2005 Not reported Amniocentesis,
CVS and postna-
tal karyotyping
Routine screen-
ing
Prospective co-
hort
Belgium
Haddow 1998 X Median 37 (15-
51)
Amniocentesis
or CVS
High-risk refer-
ral for invasive
testing
Prospective co-
hort
USA
Kagan 2009 X Mean 35.4 (14.
1-52.2)
Karyotyp-
ing or follow-up
to birth
Routine screen-
ing
Prospective co-
hort
UK
Kornman 1998 Not reported CVS High-risk refer-
ral for invasive
testing
Case-control The Netherlands
Kozlowski 2007
GC
Median 32 (15-
48), 26.4% ≥ 35
Karyotyp-
ing or follow-up
to birth
Routine screen-
ing
Cohort Germany
Kozlowski 2007
PC
Median 34 (14-
46), 43.2% ≥ 35
Karyotyp-
ing or follow-up
to birth
Routine screen-
ing
Cohort Germany
Krantz 2000 34.7% ≥ 35 Not reported Routine screen-
ing
Prospective co-
hort
USA
Kratzer 1991 Missing CVS High-risk refer-
ral for invasive
testing
Case-control USA
Laigaard 2003 Not reported Karyotyping,
unclear reference
standard for con-
Routine screen-
ing
Case-control Denmark
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Table 3. Summary of study characteristics (Continued)
trols
Macintosh 1993 Median 38 (27-
40)
CVS High-risk refer-
ral for invasive
testing
Retrospective
cohort
UK and Italy
Muller 2003a Not reported Invasive testing
(offered
to women with
high NT mea-
surement) or fol-
low-up to birth
Routine screen-
ing
Retrospective
cohort
France
Nebiolo 1990 Approximately
75% ≥ 35
CVS High-risk refer-
ral for invasive
testing
Retrospective
cohort
Italy
Niemimaa
2001a
17.5% ≥35 Invasive
testing (patients
considered high-
risk based onNT
screening) or fol-
low-up to birth
Routine screen-
ing
Prospective co-
hort
Finland
Noble 1995 Median 34 (15-
47), 47% ≥ 35
Karyotyping
performed
(27%), ultra-
sound examina-
tion at 20 weeks
(65%), or fol-
low-up to birth
(9%)
Routine screen-
ing in a high-risk
population
Prospective co-
hort
UK
Noble 1997 Median 34 (15-
47)
CVS, follow-up
to birth not re-
ported
Routine screen-
ing
Case-control UK
O’Leary 2006 Median 31 (14-
47), 20% ≥ 35
years
CVS
or amniocentesis
(women assessed
to be high risk on
screening) or fol-
low-up to birth
Routine screen-
ing
Prospective co-
hort
Australia
Orlandi 1997 Range 15-46,
35% ≥ 35
Not reported Routine screen-
ing
Prospective co-
hort
Italy
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Table 3. Summary of study characteristics (Continued)
Palomaki 2007 Mean maternal
age 32.3 years
(SD 4.6 years)
Karyotyp-
ing or follow-up
to birth
Routine screen-
ing
Prospective co-
hort
Canada
Qin 1997 Not reported CVS, amniocen-
tesis, kary-
otyping at birth,
unclear reference
standard for con-
trol
Routine screen-
ing
Case-control Denmark
Sahota 2010 X Median 33.1,
30.1% ≥ 35
Karyotyp-
ing or follow-up
to birth
Routine screen-
ing
Prospective co-
hort
China
Schaelike 2009 31.0% ≥35 Karyotyp-
ing or follow-up
to birth
Routine screen-
ing
Prospective co-
hort
Germany
Scott 2004 Median 32 (15-
44), 29% ≥ 35
Invasive testing
or follow-up to
birth
Routine screen-
ing
Prospective co-
hort
Australia
Spencer 1999a X Median cases 38
(19-46), controls
36 (15-47)
Invasive
testing (high-risk
women) or fol-
low-up to birth
Referred for in-
vasive testing or
self-referred for
screening
Case-control UK
Spencer 2002a Median cases 36
(20-44), controls
30 (16-41)
Not reported Routine screen-
ing
Case-control UK
Torring 2010 X Mean 35 for
Down’s, 31 for
controls
Karyotyp-
ing or follow-up
to birth
Routine screen-
ing
Case-control Denmark
Tsukerman 1999 X Not reported Karyotyp-
ing, karyotyping
at birth, follow-
up to birth not
reported
Routine screen-
ing
Case-control Belarus
Valinen 2007 Mean 29.6, 18.
6% ≥ 35
Karyotyp-
ing or follow-up
to birth
Routine screen-
ing
Retrospective
cohort
Finland
Valinen 2009 Not reported Karyotyp-
ing or follow-up
to birth
Routine screen-
ing
Case-control Finland
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Table 3. Summary of study characteristics (Continued)
Van Lith 1992 Not reported CVS High-risk refer-
ral for invasive
testing
Case-control The Netherlands
Wald 2003a X Missing Invasive testing
(following
second trimester
screening) or fol-
low-up to birth
Routine screen-
ing
Case-control UK and Austria
Wallace 1995 Mean32 (22-44)
for Down’s cases,
28 (19-38) for
controls
Not reported Routine screen-
ing
Case-control UK
Wapner 2003 X Mean 35 (SD 4.
6), 50% ≥ 35
Invasive testing,
miscarriage with
cytogenetic test-
ing, follow-up to
birth
Routine screen-
ing
Prospective co-
hort
USA
Weinans 2005 Mean 38 (SD
2.7) for Down’s
cases, 37 (SD 3.
0) for controls
CVS High-risk refer-
ral for invasive
testing
Case-control The Netherlands
Wojdemann
2005
Mean 29, 10.8%
≥ 35
Invasive
testing (in cases
of increased risk)
or follow-up to
birth
Routine screen-
ing
Prospective co-
hort
Denmark
Zaragoza 2009 X Median
37.9 (19.1-46.5)
for Down’s cases,
32.7 (16.1-45.2)
for controls
Karyotyp-
ing or follow-up
to birth
Routine screen-
ing
Case-control UK
*The PAPP-A, free ßhCG and age test combination was the only test evaluated by at least 10 studies. X indicates that the test was
evaluated in the study.
CVS: chorionic villus sampling; IQR: interquartile range; SD: standard deviation.
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A P P E N D I C E S
Appendix 1. Search Strategy
Database: Ovid MEDLINE
--------------------------------------------------------------------------------
1 exp Prenatal Diagnosis/
2 nuchal translucency.mp.
3 exp Pregnancy-Associated Plasma Protein-A/
4 pregnancy associated plasma protein a.mp.
5 papp-a.mp.
6 exp Chorionic Gonadotropin, beta Subunit, Human/
7 (b-hcg or bhcg).mp.
8 human chorionic gonadotropin.mp.
9 exp alpha-Fetoproteins/
10 alphafetoprotein$.mp.
11 alpha-fetoprotein$.mp.
12 afp.mp.
13 (unconjugated estriol or unconjugated oestriol).mp.
14 ue3.mp.
15 exp INHIBINS/
16 inhibin a.mp.
17 ultrasound.mp.
18 amniocentesis/
19 chorion$ vill$ sampling.mp.
20 Chorionic Villi-Sampling/
21 nasal bone.mp.
22 tricuspid regurgitation.mp.
23 ductus venosus.mp
24 marker$.mp.
25 screen$.mp.
26 detect$.mp.
27 accura$.mp.
28 predict$.mp.
29 ROC.mp.
30 ROC curve/
31 AUC.mp.
32 Area under curve/
33 exp false negative reactions/ or exp false positive reactions/
34 (false positive$ or false negative$).mp.
35 likelihood ratio$.mp.
36 sensitiv$.mp.
37 specific$.mp.
38 diagnos$.ti,ab.
39 “reproducibility of results”.mp.
40 reference value$.mp.
41 reference standard$.mp.
42 exp Down Syndrome/
43 downs syndrome.mp.
44 down syndrome.mp.
45 trisomy 21.mp.
46 Aneuploidy/
47 aneuploidy.mp.
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48 Mosaicism/
49 mosaicism.mp.
50 or/1-41
51 or/42-49
52 50 and 51
53 (antenatal$ or prenatal$ or trimester$ or pregnan$ or fetus or foetus or fetal or foetal).mp.
54 52 and 53
55 animal/ not (humans/ and animal/)
56 54 not 55
*******************************************************
Embase via Dialog Datastar
1. PRENATAL-DIAGNOSIS#.DE.
2. FETUS-ECHOGRAPHY#.DE.
3. PREGNANCY-ASSOCIATED-PLASMA-PROTEIN-A#.DE.
4. CHORIONIC-GONADOTROPIN-BETA-SUBUNIT#.DE.
5. HCG.AB.
6. PAPP.AB.
7. ALPHA-FETOPROTEIN#.DE.
8. AFP.AB.
9. ALPHA ADJ FETOPROTEIN$
10. ALPHAFETOPROTEIN$
11. BETA ADJ HUMAN ADJ CHORIONIC ADJ GONADOTROPIN
12. PREGNANCY ADJ ASSOCIATED ADJ PLASMA ADJ PROTEIN
13. (UNCONJUGATED ADJ ESTRIOL OR UNCONJUGATED ADJ OESTRIOL).TI.
14. (UNCONJUGATED ADJ ESTRIOL OR UNCONJUGATED ADJ OESTRIOL).AB.
15. UE3
16. INHIBIN-A#.DE.
17. INHIBIN ADJ A
18. ULTRASOUND
19. AMNIOCENTESIS
20. CHORION-VILLUS-SAMPLING.DE.
21. NASAL ADJ BONE
22. TRICUSPID ADJ REGURGITATION
23. DUCTUS ADJ VENOSUS
24. MARKER OR MARKERS
25. SCREEN OR SCREENING
26. DETECT OR DETECTING OR DETECTION
27. FALSE ADJ POSITIVE$
28. FALSE ADJ NEGATIVE$
29. SENSITIVITY OR SENSITIVE OR SENSITIVITIES
30. SPECIFICITY OR SPECIFICITIES
31. (DIAGNOSE OR DIAGNOSIS OR DIAGNOSTIC OR DIAGNOSTICS OR DIAGNOSES
OR DIAGNOSED).TI.
32. (DIAGNOSE OR DIAGNOSIS OR DIAGNOSTIC OR DIAGNOSTICS OR DIAGNOSES
OR DIAGNOSED).AB.
33. ROC.AB.
34. AUC.AB.
35. AREA-UNDER-THE-CURVE.DE.
36. ROC-CURVE.DE.
37. ACCURA$
38. PREDICT$
39. REPRODUCIBILITY.DE.
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40. REFERENCE ADJ VALUE$
41. REFERENCE-VALUE.DE.
42. REFERENCE ADJ STANDARD$
43. DOWN-SYNDROME#.DE.
44. DOWN ADJ SYNDROME OR DOWNS ADJ SYNDROME
45. TRISOMY ADJ ’21’
46. MOSAICISM
47. ANEUPLOIDY
48. ANTENATAL$ OR PRENATAL$ OR PREGNANCYOR PREGNANTOR TRIMESTER$ ORMATERNAL OR FETUS
OR FOETUS OR FOETAL OR FETAL
49. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR
19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 35 OR 36
OR 37 OR 38 OR 39 OR 40 OR 41 OR 42
50. 43 OR 44 OR 45 OR 46 OR 47
51. 48 AND 49 AND 50
52. HUMAN=YES
53. 51 AND 52
ADJ = adjacent AB = abstract
TI = title $ = truncation symbol DE = descriptor (similar to MeSH)
*******************************************************
CINAHL via OVID
--------------------------------------------------------------------------------
1 exp Prenatal Diagnosis/
2 nuchal translucency.mp.
3 pregnancy associated plasma protein.mp.
4 papp$.ti,ab.
5 exp Gonadotropins, chorionic/
6 (b-hcg or bhcg).mp.
7 human chorionic gonadotropin.mp.
8 exp alpha-Fetoproteins/
9 alphafetoprotein$.mp.
10 alpha-fetoprotein$.mp.
11 afp.mp.
12 (unconjugated estriol or unconjugated oestriol).mp.
13 ue3.mp.
14 inhibin$.mp.
15 ultrasound.mp.
16 amniocentesis/
17 chorion$ vill$ sampling.mp.
18 Chorionic Villi-Sampling/
19 nasal bone.mp.
20 tricuspid regurgitation.mp.
21 ductus venosus.mp.
22 marker$.mp.
23 screen$.mp.
24 detect$.mp.
25 accura$.mp.
26 predict$.mp.
27 ROC.mp.
28 ROC curve/
29 AUC.mp.
30 “area under curve”.mp.
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31 exp false negative reactions/ or exp false positive reactions/
32 (false positive$ or false negative$).mp.
33 likelihood ratio$.mp.
34 sensitiv$.mp.
35 specific$.mp.
36 diagnos$.ti,ab.
37 “reproducibility of results”.mp.
38 reference value$.mp.
39 reference standard$.mp.
40 exp Down Syndrome/
41 downs syndrome.mp.
42 down syndrome.mp.
43 trisomy 21.mp.
44 aneuploidy.mp.
45 mosaicism.mp.
46 (antenatal$ or prenatal$ or trimester$ or pregnan$ or fetus or foetus or fetal or foetal).mp.
47 or/1-39
48 or/40-45
49 47 and 48 and 46
*******************************************************
Search terms and instructions for Biosis
The following search terms were entered separately in standard search box (select ‘Titles/subject/abstract’ from the drop-down box on
the right of the search box).
1. “reference standard*”
2. “reference value*”
3. “reproducibility of results”
4. diagnos*
5. sensitiv*
6. specific*
7. “likelihood ratio*”
8. “false negative*
9. “false positive”
10. “area under curve”
11. ROC
12. AUC
13. predict*
14. detect*
15. marker*
16. screen*
17. accura*
18. “ductus venosus”
19. “nasal bone”
20. “tricuspid regurgitation”
21. “chorion* vill* sampling”
22. amniocentesis
23. ultrasound
24. inhibin*
25. “unconjugaed oestriol”
26. “unconjugated estriol”
27. afp
28. “alpha fetoprotein*”
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29. alphafetoprotein*
30. “ bhcg”
31. “human chorionic gonadotrophin”
32. “papp a”
33. “pregnancy associated plasma protein”
34. “nuchal translucency”
35. foetal
36. fetal
37. foetus
38. foetal
39. prenatal*
40. antenatal*
41. pregnan*
42. maternal*
43. “trisomy 21”
44. mosaicism
45. “down* syndrome”
The search then used the history function to combine terms:
1-34 - combine using OR
35 - 42 - combine using OR
43 - 45 - combine using OR
The three sets were combined using AND
The combined search strategy had the form
(((((((al: “trisomy 21”) or (al: (mosaicism))) or (al: “down* syndrome”))) and (((((((((((((((((((((((((((((((((((al: “reference stan-
dard*”) or (al: “reference value*”)) or (al: “reproducibility of results”)) or (al: (diagnos*))) or (al: (specific*))) or (al: (sensitiv*)))
or (al: “likelihood ratio*”)) or (al: “false negative*”)) or (al: “false positive*”)) or (al: “area under curve”)) or (al: (auc))) or (al:
(roc))) or (al: (predict*))) or (al: (accura*))) or (al: (detect*))) or (al: (screen*))) or (al: (marker*))) or (al: “ductus venosus”))
or (al: “tricuspid regurgitation”)) or (al: “nasal bone”)) or (al: “chorion* vill* sampling”)) or (al: (amniocentesis))) or (al:
(ultrasound))) or (al: (inhibin*))) or (al: “unconjugated oestriol”)) or (al: “unconjugated estriol”)) or (al: (afp))) or (al: “alpha
feto protein*”)) or (al: “alpha fetoprotein*”)) or (al: “b hcg”)) or (al: “human chorionic gonadotropin”)) or (al: “papp a”))
or (al: “pregnancy associated plasma protein”)) or (al: “nuchal translucency”)))) and (((((((((al: (foetal)) or (al: (fetal))) or (al:
(foetus))) or (al: (fetus))) or (al: (pregnan*))) or (al: (trimester*))) or (al: (prenatal*))) or (al: (antenatal*))))))
*******************************************************
The Database of Abstracts of Reviews of Effectiveness (DARE), National Research Register and Health Services Research Projects in
Progress database
:
1. Down syndrome (MeSH)
2. down* next syndrome
3. trisomy
4. aneuploidy
5. mosaicism
6. OR/ 1-5
*******************************************************
MEDION (http://www.mediondatabase.nl/)
ICPC code for pregnancy - ‘W’.
*******************************************************
The Database of Systematic Reviews and Meta-Analyses in Laboratory Medicine - download the database to a .pdf file and search for
the following terms separately:
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Down
Trisomy
Aneuploidy
Pregnant
Pregnancy
Pregnancies
Mosaicism
*******************************************************
Appendix 2. Glossary of terms (adapted in part from the UK National Screening Committee
Glossary)
Abnormal ductus venosus flow velocity The ductus venosus is a vessel in the fetus which allows oxygenated blood from the placenta
to bypass the fetal liver andflow straight to the heart. In conditions such asDown’s syndrome
the pressure in this vessel can be abnormally high
Absent nasal bone Absence of the bone that forms the bridge of the nose, which may be detected at ultrasound
scan during early pregnancy
Affected individuals Those individuals who are affected by the disorder for which they are being screened
Amniocentesis Amniocentesis is an invasive procedure which involves taking a small sample of the amniotic
fluid (liquor) surrounding the baby, using a needle which goes through the abdominal wall
into the uterus, and is usually performed after 15 weeks’ gestation
Chorionic villus sampling (CVS) Chorionic villus sampling involves taking a sample of the placental tissue using a needle
which goes through the abdominal wall and uterus or a cannula through the cervix. It is
usually performed between 10 and 13 weeks’ gestation
Combined test First trimester test (up to 13 + 6 weeks of pregnancy) based on combining nuchal translu-
cency (NT) measurement with free beta-hCG, pregnancy-associated plasma protein A
(PAPP-A) and the woman’s age
Diagnostic accuracy The amount of agreement between the information from the index test and the reference
standard (see below)
Diagnostic test A definitive test, performed after a positive screening test result that gives a diagnosis (i.e.
yes or no)?
Double test Second trimester test (from 13 + 6 up to 24 weeks of pregnancy) based on themeasurement
of alpha-fetoprotein (AFP), human chorionic gonadotrophin (hCG ß either free beta-hCG
or total hCG), together with the woman’s age
First trimester Pregnancy from conception up to 13 weeks and 6 days.
Iatrogenic A disease or condition in a patient occurring as a result of treatment
Index test A test or group of tests being evaluated in a systematic review
235First trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Integrated test Measurements performed at different times of pregnancy combined into a single test result.
Unless otherwise specified, ’integrated test’ refers to the combination of nuchal translucency
measurement and PAPP-A in the first trimester, with the quadruple test (see below) in the
second
Mosaicism This is a condition in which person has some cells containing a normal number of chro-
mosomes, and some containing an abnormal number. The more abnormal cells there are,
the greater the effect
Multiple of the median (MOM) The serum test concentration for a pregnant woman divided by the average (median) for
unaffected pregnancies in a defined population at the same stage of pregnancy
Quadruple test Second trimester test (from 13 + 6 up to 24 weeks of pregnancy) based on themeasurement
of AFP, uE3, free beta-hCG (or total hCG), and inhibin-A together with the woman’s age
Reference Standard The best available method for establishing the presence or absence of the target disease or
condition
Second trimester Pregnancy from14weeks to 28weeks’ gestation.Note that for the purposes of this Cochrane
review, second trimester testing refers to the period of 14 to 24 weeks’ gestation
Tricuspid regurgitation Leakiness of or backflow of blood through the tricuspid valve of the heart. The tricuspid
valve separates the upper and lower chambers of the right side of the heart
Triple test Second trimester test (from 14 up to 24 weeks of pregnancy) based on the measurement of
AFP, unconjugated oestriol (uE3), and hCG (either total hCG or free beta-hCG) together
with the woman’s age
Trisomy The presence of an extra chromosome resulting in three copies of a particular chromosome
instead of the normal two
Translocation Part of one chromosome is broken off and attached to another chromosome. This does not
usually cause the individual any problems as they have a normal amount of chromosomes,
but in an abnormal arrangement. It can be passed on as an extra chromosome to offspring,
resulting in conditions such as Down’s syndrome
Appendix 3. QUADAS questionnaire
QUADAS criteria included the following 10 questions.
1. Was the spectrum of women representative of the women who will receive the test in practice? (criteria met if the sample was
selected from a wide range of childbearing ages, or selected from a specified ‘high risk’ group such as over 35s, family history of
Down’s Syndrome, multiple pregnancy or diabetes mellitus, provided all affected and unaffected fetuses included that could be tested
at the time point when the screening test would be applied; criteria not met if the sample taken from a select or unrepresentative
group of women (i.e. private practice), was an atypical screening population or recruited at a later time point when selection could be
affected by selective fetal loss)
2. Is the reference standard likely to correctly classify the target condition? (amniocentesis, chorionic villus sampling, postnatal
karyotyping, miscarriage with cytogenetic testing of the fetus, a phenotypically normal baby or birth registers are all regarded as
meeting this criteria)
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3. Did the whole sample or a random selection of the sample receive verification using a reference standard of diagnosis?
4. Did women receive the same reference standard regardless of the index test result?
5. Was the reference standard independent of the index test result (i.e. the index test did not form part of the reference standard)?
6. Were the index test results interpreted without knowledge of the results of the reference standard?
7. Were the reference standard results interpreted without knowledge of the results of the index test?
8. Were the same clinical data (i.e. maternal age and weight, ethnic origin, gestational age) available when test results were
interpreted as would be available when the test is used in practice?
9. Were uninterpretable/intermediate test results reported?
10. Were withdrawals from the study explained?
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The protocol intended to investigate several additional outcomes downstream from test accuracy, should they be reported in the test
accuracy studies. When we attempted to extract this information however, it was found to be available in very few studies, and where
such information was found it was difficult to extract meaningful data to allow for comparison between studies, as data were not
reported in a universal manner. In several studies such outcomes were estimated rather than measured. Often they were not reported
at all. The outcomes stated in the protocol which have not been included are: harms of testing; need for further testing; side effects
of test; interventions and side effects; other abnormalities detected by testing; spontaneous miscarriage; miscarriage subsequent to
invasive procedure, with or without normal karyotype; fetal karyotype; termination of pregnancy (prior to definitive testing or in
a karyotypically normal pregnancy and following confirmation of Down’s syndrome or following detection of other chromosomal
abnormalities); stillbirth; livebirth of affected and unaffected fetus; uptake of definitive testing by women.
The following refinements to the eligibility criteria were imposed to ensure that the quality of the included literature remained high.
We excluded studies that identified fewer than five Down’s syndrome pregnancies in their study population. We excluded studies that
had less than 80% follow-up of participants.
In addition, the analytical strategy was informed by the volume of tests and studies included, and developed so that we focused on key
tests and test combinations by a) only meta-analysed tests that were included in four or more studies or b) showed more than 70%
sensitivity for more than 95% specificity. In addition, a requirement that a minimum of 10 studies for a single test was required before
subgroup analysis was undertaken. Consequently several possible sources of heterogeneity were not investigated due to lack of data.
N O T E S
This is one of a suite of planned systematic diagnostic test reviews planned for prenatal testing for fetal Down’s syndrome. The plans for
these reviews were described in a generic protocol (Alldred 2010) published in the Cochrane Library in 2010. The five reviews were to
be of: first trimester serum tests only; first trimester ultrasound tests alone, and in combination with first trimester serum tests; second
trimester serum tests only; first and second trimester serum tests with and without first trimester ultrasound tests; and urine tests. One
of these reviews has been published already (Alldred 2012). Diagnostic test reviews are relatively new, and this project has proven much
larger, more complex and difficult to complete than had been anticipated. Whilst not fulfilling the usual Cochrane up-to-date criteria
(the electronic search was done in 2011), this review is published because it provides historical context in what is a rapidly-changing
field, and because it is unlikely to ever be repeated.
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